var title_f21_41_22160="Reconstruction with an implant PI";
var content_f21_41_22160=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F69825&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F69825&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 564px\">",
"   <div class=\"ttl\">",
"    Reconstruction with an implant",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 544px; height: 331px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Women who have reconstruction using an implant usually have a device that is similar to a balloon - called an expander - inserted under a layer of muscle. At the same time, they have a piece of mesh called a graft sewn into the muscle. The graft keeps the muscle from being stretched too tightly. Over time, doctors add more and more fluid to the expander. That helps the muscle and skin on the chest stretch, so that it can hold an implant the same size as the other breast. The graft gets absorbed with time.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_41_22160=[""].join("\n");
var outline_f21_41_22160=null;
var title_f21_41_22161="Pericarditis mediastinal mass";
var content_f21_41_22161=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F70734&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F70734&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Unusual presentation of purulent pericarditis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 338px; height: 321px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest CT scan shows an anterior mediastinal mass compressing and displacing the heart. This was a case of Staphylococcus aureus purulent pericarditis in a patient on hemodialysis who had been treated twice over a six-month period for S. aureus bacteremia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from Nwiloh, JO, Egbe, PA, Tagoe, AT, Weaver, LW. Chest 2000; 118:1832.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_41_22161=[""].join("\n");
var outline_f21_41_22161=null;
var title_f21_41_22162="Dx chronic diarrhea I";
var content_f21_41_22162=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F75832&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F75832&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 621px\">",
"   <div class=\"ttl\">",
"    Diagnostic approach to chronic diarrhea - part I",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 601px; height: 635px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from: Fine KD, Schiller LR. AGA technical review on the evaluation and management of chronic diarrhea. Gastroenterology 1999; 116:1464.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_41_22162=[""].join("\n");
var outline_f21_41_22162=null;
var title_f21_41_22163="Echocardiogram apical long axis view of calcific aortic stenosis";
var content_f21_41_22163=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/59538/aorstapl_conv.mp4?title=Echocardiogram+apical+long+axis+view+of+calcific+aortic+stenosis+\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Echocardiogram apical long axis view of calcific aortic stenosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 250px; height: 392px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The apical long axis view from a 2-D echocardiogram shows significant calcification of the aortic valve and aortic root with limited leaflet mobility. There is also significant concentric hypertrophy of the left ventricular myocardium.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Binder, MD. University of Vienna.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_41_22163=[""].join("\n");
var outline_f21_41_22163=null;
var title_f21_41_22164="Ankle fracture ring";
var content_f21_41_22164=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F55837&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F55837&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 569px\">",
"   <div class=\"ttl\">",
"    Ring scheme for ankle fractures",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 549px; height: 417px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The ankle can be conceived of as a ring of supporting structures surrounding the talus (picture A). If the ring is broken at one site (picture B), the injury is stable and can generally be managed nonoperatively. If the ring is broken at two or more sites (picture C), the injury is unstable and is managed operatively. Fractures or ligament ruptures constitute breaks in the ring.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_41_22164=[""].join("\n");
var outline_f21_41_22164=null;
var title_f21_41_22165="Docusate: Drug information";
var content_f21_41_22165=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Docusate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?8/14/8420?source=see_link\">",
"    see \"Docusate: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/50/33571?source=see_link\">",
"    see \"Docusate: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F162174\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Colace&reg; [OTC];",
"     </li>",
"     <li>",
"      Correctol&reg; [OTC];",
"     </li>",
"     <li>",
"      Diocto [OTC];",
"     </li>",
"     <li>",
"      Doc-Q-Lace [OTC];",
"     </li>",
"     <li>",
"      Docu-Soft [OTC];",
"     </li>",
"     <li>",
"      DocuSoft S&trade; [OTC];",
"     </li>",
"     <li>",
"      Dok&trade; [OTC];",
"     </li>",
"     <li>",
"      DSS&reg; [OTC];",
"     </li>",
"     <li>",
"      Dulcolax&reg; Stool Softener [OTC];",
"     </li>",
"     <li>",
"      Dulcolax&reg; [OTC];",
"     </li>",
"     <li>",
"      Enemeez&reg; Plus [OTC];",
"     </li>",
"     <li>",
"      Enemeez&reg; [OTC];",
"     </li>",
"     <li>",
"      Fleet&reg; Pedia-Lax&trade; Liquid Stool Softener [OTC];",
"     </li>",
"     <li>",
"      Fleet&reg; Sof-Lax&reg; [OTC];",
"     </li>",
"     <li>",
"      Kao-Tin [OTC];",
"     </li>",
"     <li>",
"      Kaopectate&reg; Stool Softener [OTC];",
"     </li>",
"     <li>",
"      Phillips'&reg; Liquid-Gels&reg; [OTC];",
"     </li>",
"     <li>",
"      Phillips'&reg; Stool Softener Laxative [OTC];",
"     </li>",
"     <li>",
"      Silace [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F162175\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Docusate-Sodium&reg;;",
"     </li>",
"     <li>",
"      Colace&reg;;",
"     </li>",
"     <li>",
"      Colax-C&reg;;",
"     </li>",
"     <li>",
"      Novo-Docusate Calcium;",
"     </li>",
"     <li>",
"      Novo-Docusate Sodium;",
"     </li>",
"     <li>",
"      PMS-Docusate Calcium;",
"     </li>",
"     <li>",
"      PMS-Docusate Sodium;",
"     </li>",
"     <li>",
"      Regulex&reg;;",
"     </li>",
"     <li>",
"      Selax&reg;;",
"     </li>",
"     <li>",
"      Soflax&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F162207\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Stool Softener",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F162176\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Docusate salts are interchangeable; the amount of sodium, calcium, or potassium per dosage unit is clinically insignificant.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Stool softener:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Oral:",
"     </i>",
"     50-500 mg/day in 1-4 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Rectal:",
"     </i>",
"     Add 50-100 mg of docusate liquid to enema fluid (saline or water); give as retention or flushing enema",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F162193\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/50/33571?source=see_link\">",
"      see \"Docusate: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Docusate salts are interchangeable; the amount of sodium, calcium, or potassium per dosage unit is clinically insignificant.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Stool softener:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Oral:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants and Children &lt;3 years: 10-40 mg/day in 1-4 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     3-6 years: 20-60 mg/day in 1-4 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     6-12 years: 40-150 mg/day in 1-4 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adolescents: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Rectal:",
"     </i>",
"     Older Children: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F162177\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F162159\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral, as sodium:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Colace&reg;: 50 mg [contains sodium 3 mg/capsule]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Colace&reg;: 100 mg [contains sodium 5 mg/capsule]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Doc-Q-Lace: 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, liquid, oral, as sodium:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     DocuSoft S&trade;: 100 mg [contains sodium 5 mg/capsule]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, softgel, oral, as calcium: 240 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Kao-Tin: 240 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Kaopectate&reg; Stool Softener: 240 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, softgel, oral, as sodium: 50 mg, 100 mg, 250 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Correctol&reg;: 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Docu-Soft: 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dok&trade;: 100 mg, 250 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     DSS&reg;: 100 mg, 250 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dulcolax&reg;: 100 mg [contains sodium 5 mg/capsule]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dulcolax&reg; Stool Softener: 100 mg [contains sodium 5 mg/capsule]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fleet&reg; Sof-Lax&reg;: 100 mg [contains sodium 5 mg/capsule]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Phillips'&reg; Liquid-Gels&reg;: 100 mg [contains sodium 5.2 mg/capsule]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Phillips'&reg; Stool Softener Laxative: 100 mg [contains sodium 5.2 mg/capsule]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, oral, as sodium: 50 mg/5 mL (10 mL, 25 mL, 473 mL [DSC]); 150 mg/15 mL (480 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Diocto: 150 mg/15 mL (480 mL [DSC])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Diocto: 150 mg/15 mL (473 mL) [contains propylene glycol, sodium 15 mg/15 mL; vanilla flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fleet&reg; Pedia-Lax&trade; Liquid Stool Softener: 50 mg/15 mL (118 mL) [contains propylene glycol, sodium 13 mg/15 mL; fruit-punch flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Silace: 150 mg/15 mL (473 mL) [lemon-vanilla flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, rectal, as sodium [enema]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Enemeez&reg;: 283 mg/5 mL (5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Enemeez&reg; Plus: 283 mg/5 mL (5 mL) [contains benzocaine]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Syrup, oral, as sodium: 20 mg/5 mL (25 mL, 473 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Colace&reg;: 60 mg/15 mL (473 mL) [ethanol free, sugar free; contains propylene glycol, sodium 34 mg/15 mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Diocto: 60 mg/15 mL (473 mL) [contains menthol, sodium 12 mg/15 mL, sodium benzoate; mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Doc-Q-Lace: 60 mg/15 mL (480 mL) [contains propylene glycol; peppermint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Silace: 60 mg/15 mL (480 mL) [peppermint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as sodium: 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dok&trade;: 100 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F162145\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes enema",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F803127\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ensure adequate fluid intake. Docusate syrup should be administered with 6-8 ounces of milk, juice, or infant formula to mask the bitter taste.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F162162\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stool softener in patients who should avoid straining during defecation and constipation associated with hard, dry stools; prophylaxis for straining (Valsalva) following myocardial infarction. A safe agent to be used in elderly; some evidence that doses &lt;200 mg are ineffective; stool softeners are unnecessary if stool is well hydrated or &ldquo;mushy&rdquo; and soft; shown to be ineffective used long-term.",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F162204\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ceruminolytic",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F162214\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Colace&reg; may be confused with Calan&reg;, Cozaar&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Dulcolax&reg; (docusate) may be confused with Dulcolax&reg; (bisacodyl)",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Docusate may be confused with Doxinate brand name for doxylamine and pyridoxine [India]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F162205\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Intestinal obstruction, diarrhea, abdominal cramping",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Throat irritation",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F162165\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to docusate or any component of the formulation; concomitant use of mineral oil; intestinal obstruction, acute abdominal pain, nausea, or vomiting",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F162149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dependence: Prolonged, frequent, or excessive use may result in dependence.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Electrolyte imbalance: Prolonged, frequent or excessive use may result in electrolyte imbalance.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299225\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6219958\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13888218\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Short-term use of docusate is generally considered safe during pregnancy (Mahadevan, 2006). Hypomagnesemia was reported in a newborn following chronic maternal overuse throughout pregnancy (Schindler, 1984).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F162180\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/compatible (Mahadevan, 2006)",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F162167\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ensure adequate fluid intake. Some products may contain sodium.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Syrup: Should be taken with 6-8 ounces of milk, juice, or infant formula.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F4370591\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Colace Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (30): $8.22",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (30): $9.96",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Correctol Extra Gentle Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (30): $4.49",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Docusate Calcium Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     240 mg (100): $8.98",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Docusate Sodium Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $5.15",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (100): $6.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Docusil Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (1000): $44.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (DSS Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (100): $5.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Dulcolax Stool Softener Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (50): $9.08",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Phillips Stool Softener Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (30): $3.89",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Sof-Lax Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (60): $6.92",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Surfak Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     240 mg (30): $7.58",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Enema",
"     </b>",
"     (Enemeez Mini Rectal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     283 mg (5 mL): $2.24",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Enema",
"     </b>",
"     (Enemeez Plus Rectal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20-283 mg (5 mL): $2.24",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Pedia-Lax Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg/15 mL (118 mL): $5.28",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Syrup",
"     </b>",
"     (Colace Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     60 mg/15 mL (473 mL): $21.65",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Docusate Sodium Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $4.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Promolaxin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $98.94",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038603\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Coloxyl (AU, NZ);",
"     </li>",
"     <li>",
"      Cusate (TH);",
"     </li>",
"     <li>",
"      Dama-Lax (ES);",
"     </li>",
"     <li>",
"      Dioctyl (GB);",
"     </li>",
"     <li>",
"      Docusaat FNA (NL);",
"     </li>",
"     <li>",
"      Docusoft (IL);",
"     </li>",
"     <li>",
"      Docusol (GB);",
"     </li>",
"     <li>",
"      Doslax (IN);",
"     </li>",
"     <li>",
"      Emtix (FI);",
"     </li>",
"     <li>",
"      Irwax (PH);",
"     </li>",
"     <li>",
"      Jamylene (FR);",
"     </li>",
"     <li>",
"      Klyx (FI, NL, NO, SE);",
"     </li>",
"     <li>",
"      Lambanol (IT);",
"     </li>",
"     <li>",
"      Laxadine (ID);",
"     </li>",
"     <li>",
"      Laxol (PL);",
"     </li>",
"     <li>",
"      Molcer (GB);",
"     </li>",
"     <li>",
"      Norgalax (AE, BE, BH, CH, CY, DE, EG, GB, IE, IQ, IR, JO, KW, LB, LU, LY, NL, OM, QA, RU, SA, SY, YE);",
"     </li>",
"     <li>",
"      Norgalax Micro-enema (GB);",
"     </li>",
"     <li>",
"      Otowax (PH);",
"     </li>",
"     <li>",
"      Pedia-lax Liquid Stool Softener (HK);",
"     </li>",
"     <li>",
"      Purgeron (JP);",
"     </li>",
"     <li>",
"      Regutol (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Soliwax (GB);",
"     </li>",
"     <li>",
"      Soluwax Ear Drops (MY, SG);",
"     </li>",
"     <li>",
"      Tirolaxo (ES);",
"     </li>",
"     <li>",
"      Wasserlax (ES);",
"     </li>",
"     <li>",
"      Waxsol (AU, GB, IE, NZ);",
"     </li>",
"     <li>",
"      Yal (CZ);",
"     </li>",
"     <li>",
"      Yi Ke Long (CL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F162148\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reduces surface tension of the oil-water interface of the stool resulting in enhanced incorporation of water and fat allowing for stool softening",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F162164\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: 12-72 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Chen DA and Caparosa RJ, &ldquo;A Nonprescription Cerumenolytic,&rdquo;",
"      <i>",
"       Am J Otol",
"      </i>",
"      , 1991, 12(6):475-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/41/22165/abstract-text/1725243/pubmed\" id=\"1725243\" target=\"_blank\">",
"        1725243",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mahadevan U and Kane S, \"American Gastroenterological Association Institute Medical Position Statement on the Use of Gastrointestinal Medications in Pregnancy,\"",
"      <i>",
"       Gastroenterology",
"      </i>",
"      , 2006, 131(1):278-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/41/22165/abstract-text/16831610/pubmed\" id=\"16831610\" target=\"_blank\">",
"        16831610",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pietrusko RG, &ldquo;Use and Abuse of Laxatives,&rdquo;",
"      <i>",
"       Am J Hosp Pharm",
"      </i>",
"      , 1977, 34:291-300.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/41/22165/abstract-text/324272/pubmed\" id=\"324272\" target=\"_blank\">",
"        324272",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schindler AM, &ldquo;Isolated Neonatal Hypomagnesaemia Associated With Maternal Overuse of Stool Softener,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1984, 2(8406):822.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Singer AJ, Sauris E, and Viccellio AS, &ldquo;Ceruminolytic Effects of Docusate Sodium: A Randomized, Controlled Trial,&rdquo;",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 2000, 36(3):228-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/41/22165/abstract-text/10969225/pubmed\" id=\"10969225\" target=\"_blank\">",
"        10969225",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9382 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-11633CD92E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_41_22165=[""].join("\n");
var outline_f21_41_22165=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162174\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162175\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162207\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162176\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162193\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162177\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162159\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162145\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F803127\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162162\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162204\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162214\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162205\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162165\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162149\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299225\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6219958\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13888218\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162180\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162167\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4370591\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038603\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162148\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162164\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9382\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9382|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?8/14/8420?source=related_link\">",
"      Docusate: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/50/33571?source=related_link\">",
"      Docusate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_41_22166="EEG focal epilepsy";
var content_f21_41_22166=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F56977&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F56977&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 599px\">",
"   <div class=\"ttl\">",
"    Focal epileptic discharges",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 579px; height: 384px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The electroencephalogram records the spike and wave activity that is occurring in the right parietal region.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Shahram Khoshbin, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_41_22166=[""].join("\n");
var outline_f21_41_22166=null;
var title_f21_41_22167="Causes of hyperprolactinemia";
var content_f21_41_22167=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Causes of hyperprolactinemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/41/22167/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/41/22167/contributors\">",
"     Peter J Snyder, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/41/22167/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/41/22167/contributors\">",
"     David S Cooper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/41/22167/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/41/22167/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/41/22167/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prolactin is secreted solely by the lactotroph cells of the pituitary gland. As a result, hyperprolactinemia results almost exclusively from diseases that cause hypersecretion of prolactin by lactotroph cells. Some of these causes are physiologic and others pathologic.",
"   </p>",
"   <p>",
"    This topic will review the major causes of hyperprolactinemia. The clinical manifestations, diagnosis, and treatment are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19254?source=see_link\">",
"     \"Clinical manifestations and diagnosis of hyperprolactinemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/52/31561?source=see_link\">",
"     \"Treatment of hyperprolactinemia due to lactotroph adenoma and other causes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PHYSIOLOGIC CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum prolactin concentrations normally increase substantially during pregnancy and to a lesser degree in response to nipple stimulation and stress. The upper normal value for serum prolactin in most laboratories is about 20",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (20",
"    <span class=\"nowrap\">",
"     mcg/L",
"    </span>",
"    SI units).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum prolactin increases throughout pregnancy, reaching a peak at delivery (",
"    <a class=\"graphic graphic_figure graphicRef82454 \" href=\"UTD.htm?5/46/5869\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22167/abstract/1\">",
"     1",
"    </a>",
"    ]. The magnitude of the increase, however, is quite variable; in one study the mean value at term was 207",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    but the range was from 35 to 600",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (35 to 600",
"    <span class=\"nowrap\">",
"     mcg/L",
"    </span>",
"    SI units) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22167/abstract/1\">",
"     1",
"    </a>",
"    ]. The probable cause of the hyperprolactinemia is the increasing serum estradiol concentrations during pregnancy. By six weeks after delivery, estradiol secretion has decreased and the basal serum prolactin concentration is usually normal even when the mother is breastfeeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Nipple stimulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nipple stimulation increases serum prolactin concentrations, presumably via a neural pathway. The magnitude of the increase is directly proportional to the degree of preexisting lactotroph hyperplasia due to estrogen. In the first weeks postpartum, as an example, the serum prolactin concentration increases up to a few hundred",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    above baseline in response to suckling; in contrast, several months after delivery the increase in prolactin in response to suckling in the breastfeeding woman is usually less than 10",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (10",
"    <span class=\"nowrap\">",
"     mcg/L",
"    </span>",
"    SI units) above baseline (",
"    <a class=\"graphic graphic_figure graphicRef59612 \" href=\"UTD.htm?34/57/35742\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22167/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In nonlactating women, nipple stimulation or breast examination usually does not increase prolactin secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22167/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Stress",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stress of any kind, physical or psychological, can cause an increase in the serum prolactin concentration. As with all stimuli of prolactin secretion, women have greater increases than men, presumably due to the effect of their higher serum estradiol concentrations on the lactotroph cells. The magnitude of the increase in prolactin in response to stress is small, the values rarely exceeding 40",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (40",
"    <span class=\"nowrap\">",
"     mcg/L",
"    </span>",
"    SI units).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PATHOLOGIC CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pathologic hyperprolactinemia can be caused by the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lactotroph adenomas (prolactinomas), which are benign tumors of the lactotroph cell.",
"     </li>",
"     <li>",
"      Decreased dopaminergic inhibition of prolactin secretion.",
"     </li>",
"     <li>",
"      Other conditions, including decreased clearance of prolactin.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Serum prolactin concentrations in patients who have lactotroph adenomas can range from minimally elevated to 50,000",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (50,000",
"    <span class=\"nowrap\">",
"     mcg/L",
"    </span>",
"    SI units); in comparison, in hyperprolactinemia due to other causes, the concentrations rarely exceed 200",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (200",
"    <span class=\"nowrap\">",
"     mcg/L",
"    </span>",
"    SI units)&nbsp;(",
"    <a class=\"graphic graphic_figure graphicRef72540 \" href=\"UTD.htm?23/28/24014\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22167/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Lactotroph adenomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lactotroph adenomas, like other pituitary adenomas, arise from monoclonal expansion of a single cell that has presumably undergone somatic mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22167/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. The pituitary tumor transforming gene is overexpressed in most lactotroph adenomas [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22167/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. It also appears to play a role in tumor invasiveness since expression is increased in tumors that invade the sphenoid bone.",
"   </p>",
"   <p>",
"    Most adenomas that secrete prolactin and cause hyperprolactinemia are comprised solely of lactotroph cells; however, about 10 percent are comprised of both lactotroph and either somatotroph or somatomammotroph cells and therefore secrete growth hormone as well as prolactin [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22167/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lactotroph adenomas are relatively common; they account for approximately 30 to 40 percent of all clinically recognized pituitary adenomas. The diagnosis is made more frequently in women than in men, especially between the ages of 20 and 40 years [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22167/abstract/9\">",
"     9",
"    </a>",
"    ], presumably because of the sensitivity of menses to disruption by hyperprolactinemia. However, the adenomas that occur in men are usually larger, in part due to the lack of symptoms or delay in seeking medical attention for symptoms such as erectile dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22167/abstract/10\">",
"     10",
"    </a>",
"    ]. In addition, the tumors in men may have an inherently greater rate of growth [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22167/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most lactotroph adenomas are sporadic, but they can rarely occur as part of the multiple endocrine neoplasia type 1 syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22167/abstract/11\">",
"     11",
"    </a>",
"    ]. Almost all lactotroph tumors are benign but a rare tumor can be malignant and metastasize [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22167/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/14/43240?source=see_link\">",
"     \"Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prolactin secretion by lactotroph adenomas is generally characterized by both efficiency and proportionality.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As a result of their efficiency, even microadenomas (&lt;1 cm in diameter) typically secrete sufficient prolactin to cause hyperprolactinemia.",
"     </li>",
"     <li>",
"      As a result of their proportionality, serum prolactin concentrations tend to vary with adenoma size. Adenomas &lt;1 cm in diameter are typically associated with serum prolactin values below 200",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      (200",
"      <span class=\"nowrap\">",
"       mcg/L",
"      </span>",
"      SI units); those approximately 1.0 to 2.0 cm in diameter with values between 200 and 1000",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      (1000",
"      <span class=\"nowrap\">",
"       mcg/L",
"      </span>",
"      SI units); and those greater than 2.0 cm in diameter with values above 1000",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      (1000",
"      <span class=\"nowrap\">",
"       mcg/L",
"      </span>",
"      SI units) (",
"      <a class=\"graphic graphic_figure graphicRef72540 \" href=\"UTD.htm?23/28/24014\">",
"       figure 3",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are exceptions to both generalizations. As an example, occasional patients have a large lactotroph adenoma but only modest hyperprolactinemia. Such adenomas are generally less well differentiated and respond less well to dopamine agonists than the more typical tumors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/52/31561?source=see_link\">",
"     \"Treatment of hyperprolactinemia due to lactotroph adenoma and other causes\"",
"    </a>",
"    .) Another example is a lactotroph adenoma that is largely cystic, so only a small portion of the mass is cellular and producing prolactin. In yet other patients who have lactotroph macroadenomas but only modest elevation of the reported serum prolactin concentration, the reason for the discrepancy between the large size of the adenoma and modest elevation of the prolactin concentration is due to an artifact in the immunoradiometric assay for prolactin. This artifact, called the \"hook effect,\" can be obviated by dilution of the sera, which will allow a true assessment of the prolactin concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22167/abstract/13-15\">",
"     13-15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Decreased dopaminergic inhibition of prolactin secretion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several conditions interfere with normal dopamine inhibition of prolactin secretion. These include damage to the dopaminergic neurons of the hypothalamus, pituitary stalk section, or drugs that block dopamine receptors on lactotroph cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Hypothalamic and pituitary disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any disease in or near the hypothalamus or pituitary that interferes with the secretion of dopamine or its delivery to the hypothalamus can cause hyperprolactinemia [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22167/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/18/29992?source=see_link\">",
"     \"Causes, presentation, and evaluation of sellar masses\"",
"    </a>",
"    .) These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tumors of the hypothalamus, both benign (eg, craniopharyngiomas) and malignant (eg, metastatic breast carcinoma)",
"     </li>",
"     <li>",
"      Infiltrative diseases of the hypothalamus (eg, sarcoidosis)",
"     </li>",
"     <li>",
"      Section of the hypothalamic-pituitary stalk (eg, due to head trauma or surgery)",
"     </li>",
"     <li>",
"      Adenomas of the pituitary other than lactotroph adenomas",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Drug use",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of drugs may cause hyperprolactinemia (",
"    <a class=\"graphic graphic_table graphicRef75914 \" href=\"UTD.htm?2/58/2988\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22167/abstract/16\">",
"     16",
"    </a>",
"    ]. Although drugs can cause hyperprolactinemia, they do not cause prolactinomas. Several drugs are known dopamine D2 receptor antagonists and raise serum prolactin by that mechanism. These include antipsychotic drugs such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    , phenothiazines,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22167/abstract/17\">",
"     17",
"    </a>",
"    ], and butyrophenones [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22167/abstract/18\">",
"     18",
"    </a>",
"    ], and the gastric motility drugs",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22167/abstract/19\">",
"     19",
"    </a>",
"    ] and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/43/1717?source=see_link\">",
"     domperidone",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22167/abstract/20\">",
"     20",
"    </a>",
"    ]. Serum prolactin concentrations increase within hours after acute administration of these drugs and return to normal within two to four days after cessation of chronic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22167/abstract/18\">",
"     18",
"    </a>",
"    ]. The magnitude of the elevation varies with the drug. As an example, haloperidol raises the serum prolactin concentration by an average of 17",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (17",
"    <span class=\"nowrap\">",
"     mcg/L",
"    </span>",
"    SI units), whereas risperidone may raise it by 45 to 80",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (45 to 80",
"    <span class=\"nowrap\">",
"     mcg/L",
"    </span>",
"    SI units) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22167/abstract/17\">",
"     17",
"    </a>",
"    ]. Among newer antipsychotics, the highest prevalence of hyperprolactinemia has been observed with amisulpride (89 percent); it has not been observed with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22167/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The antihypertensive drugs",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/15/28918?source=see_link\">",
"     methyldopa",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/35/16950?source=see_link\">",
"     reserpine",
"    </a>",
"    , neither of which is commonly used now, increase prolactin secretion by a similar mechanism. Methyldopa inhibits dopamine synthesis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22167/abstract/22\">",
"     22",
"    </a>",
"    ], while reserpine inhibits dopamine storage [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22167/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     Verapamil",
"    </a>",
"    may raise serum prolactin concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22167/abstract/24\">",
"     24",
"    </a>",
"    ], but other calcium channel blockers do not [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22167/abstract/25\">",
"     25",
"    </a>",
"    ]. The mechanism of this verapamil-induced increase is not known. Hyperprolactinemia occurred in 8.6 percent of 449 men taking verapamil in one report, as compared with only 3 percent of control men [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22167/abstract/26\">",
"     26",
"    </a>",
"    ]. The elevated serum prolactin concentration persisted during continued drug administration in 14 of 15 men and returned to normal in all nine after the drug was stopped.",
"   </p>",
"   <p>",
"    Selective serotonin reuptake inhibitors (SSRIs) cause little if any increase in the serum prolactin concentration. In one study [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22167/abstract/27\">",
"     27",
"    </a>",
"    ], 20 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    a day caused no increase in the serum prolactin concentration after one week but did cause a slight increase, although still to only high-normal to slightly high values, after three weeks. In another study in patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    chronically [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22167/abstract/28\">",
"     28",
"    </a>",
"    ], the mean basal serum prolactin concentration was no different from that in untreated patients with similar diseases. These drugs, in short, do not appear to cause clinically significant hyperprolactinemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     OTHER CAUSES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Estrogen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estrogen increases prolactin secretion proportionate to the degree of estrogenization. Amounts of estrogen that are physiologic for a woman increase the basal serum prolactin concentration minimally, but explain the greater prolactin response of women (compared with men) to almost all physiologic stimuli [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22167/abstract/29\">",
"     29",
"    </a>",
"    ]. Greater amounts of estrogen, such as occur in pregnancy, increase basal serum prolactin concentrations, as described above. The amount of estrogen in hormonal contraceptives generally does not cause hyperprolactinemia.",
"   </p>",
"   <p>",
"    The mechanism by which estrogen stimulates prolactin secretion appears to involve binding of estrogen to the estrogen receptor, which then binds to an estrogen response element on the prolactin gene, in the lactotroph cell of the pituitary [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22167/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Hypothyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypothyroidism predisposes to hyperprolactinemia. However, basal serum prolactin concentrations are normal in most hypothyroid patients [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22167/abstract/32\">",
"     32",
"    </a>",
"    ], and only the serum prolactin response to stimuli, such as TRH (thyrotropin-releasing hormone), is increased [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22167/abstract/33\">",
"     33",
"    </a>",
"    ]. In the few hypothyroid patients who have elevated basal serum prolactin concentrations, the values return to normal when the hypothyroidism is corrected [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22167/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. It is important to recognize hypothyroidism as a potential cause of an enlarged pituitary gland (due to thyrotroph hyperplasia, lactotroph hyperplasia, or both) and hyperprolactinemia, and not to confuse this entity with a lactotroph adenoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/18/29992?source=see_link\">",
"     \"Causes, presentation, and evaluation of sellar masses\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The mechanism of hyperprolactinemia in hypothyroidism is not known. Both enhanced hypothalamic synthesis of TRH and increased pituitary responsiveness to TRH have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22167/abstract/33\">",
"     33",
"    </a>",
"    ]. The management of hyperprolactinemia due to hypothyroidism is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/52/31561?source=see_link&amp;anchor=H20#H20\">",
"     \"Treatment of hyperprolactinemia due to lactotroph adenoma and other causes\", section on 'Hypothyroidism'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Chest wall injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chest wall injuries, such as severe burns, increase prolactin secretion, presumably due to a neural mechanism similar to that of suckling [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22167/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Chronic renal failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The serum prolactin concentration is high in patients who have chronic renal failure and returns to normal after renal transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22167/abstract/37\">",
"     37",
"    </a>",
"    ]. The major mechanism is a threefold increase in prolactin secretion and there is a one-third decrease in metabolic clearance rate [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22167/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Idiopathic hyperprolactinemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a substantial number of patients whose serum prolactin concentration is between 20 and 100",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (100",
"    <span class=\"nowrap\">",
"     mcg/L",
"    </span>",
"    SI units), no cause can be found. Although many of these patients may have microadenomas not visible on imaging studies, in most of them the serum prolactin concentrations change little during follow-up for several years [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22167/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. In one report, as an example, only 1 of 59 patients who were followed for an average of 6.5 years developed a detectable pituitary adenoma and about 20 percent had a normal serum prolactin concentration when it was last measured [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22167/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Macroprolactinemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two causes of hyperprolactinemia due to decreased clearance of prolactin include chronic renal failure (discussed above) and big prolactin. The most common form of prolactin in serum is 23 kD in size and is not glycosylated, but a small amount of a 25 kD glycosylated form can also be detected. In rare cases, glycosylated prolactin, which appears to circulate in aggregates, accounts for most of the prolactin [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22167/abstract/42\">",
"     42",
"    </a>",
"    ]. In this situation the prolactin has been called \"big prolactin\" and the condition referred to as \"macroprolactinemia.\" The elevated serum prolactin concentration in these patients can be distinguished from hyperprolactinemia of other causes by gel filtration or polyethylene glycol precipitation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22167/abstract/43\">",
"     43",
"    </a>",
"    ]. In one series of 1106 patients with hyperprolactinemia, approximately 10 percent had macroprolactinemia [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22167/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical manifestations of macroprolactinemia were described in a series of 55 women ages 18 to 55. None had a history of amenorrhea, eight had oligomenorrhea before age 40, and one had galactorrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22167/abstract/45\">",
"     45",
"    </a>",
"    ]. All subjects had pituitary imaging; no macroadenomas and four microadenomas were seen (consistent with the prevalence of incidentalomas in the normal population). Similar results were seen in a second study of 51 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22167/abstract/46\">",
"     46",
"    </a>",
"    ]. Thus, macroprolactinemia appears to be a benign clinical condition [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22167/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Equally rare is a raised serum prolactin level due to complexing of normal-sized prolactin with circulating prolactin antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22167/abstract/47\">",
"     47",
"    </a>",
"    ]. In this situation, the free prolactin concentration is normal and causes no biologic abnormalities.",
"   </p>",
"   <p>",
"    These entities are not of clinical significance directly, but are of clinical significance in an indirect way because they can be misdiagnosed and treated as ordinary hyperprolactinemia [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22167/abstract/48\">",
"     48",
"    </a>",
"    ]. Misdiagnosis can be avoided by asking the laboratory to pretreat the serum with polyethylene glycol to precipitate the macroprolactin before the immunoassay for prolactin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/6/25698?source=see_link\">",
"       \"Patient information: Prolactinoma (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?25/0/25603?source=see_link\">",
"       \"Patient information: High prolactin levels and prolactinomas (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperprolactinemia results almost exclusively from diseases that cause hypersecretion of prolactin by lactotroph cells. Some of these causes are physiologic and others pathologic.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Physiologic causes include pregnancy, nipple stimulation, and stress.",
"     </li>",
"     <li>",
"      Pathologic causes include lactotroph adenomas, other hypothalamic and pituitary disorders, estrogen (pregnancy), medication use, hypothyroidism, chest wall injury, and chronic renal failure.",
"     </li>",
"     <li>",
"      Other causes include idiopathic hyperprolactinemia and macroprolactinemia due to \"big prolactin.\"",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical manifestations, diagnosis, and treatment of hyperprolactinemia are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19254?source=see_link\">",
"     \"Clinical manifestations and diagnosis of hyperprolactinemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/52/31561?source=see_link\">",
"     \"Treatment of hyperprolactinemia due to lactotroph adenoma and other causes\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22167/abstract/1\">",
"      Tyson JE, Hwang P, Guyda H, Friesen HG. Studies of prolactin secretion in human pregnancy. Am J Obstet Gynecol 1972; 113:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22167/abstract/2\">",
"      Jarrell J, Franks S, McInnes R, et al. Breast examination does not elevate serum prolactin. Fertil Steril 1980; 33:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22167/abstract/3\">",
"      Kleinberg DL, Noel GL, Frantz AG. Galactorrhea: a study of 235 cases, including 48 with pituitary tumors. N Engl J Med 1977; 296:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22167/abstract/4\">",
"      Alexander JM, Biller BM, Bikkal H, et al. Clinically nonfunctioning pituitary tumors are monoclonal in origin. J Clin Invest 1990; 86:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22167/abstract/5\">",
"      Herman V, Fagin J, Gonsky R, et al. Clonal origin of pituitary adenomas. J Clin Endocrinol Metab 1990; 71:1427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22167/abstract/6\">",
"      Zhang X, Horwitz GA, Heaney AP, et al. Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. J Clin Endocrinol Metab 1999; 84:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22167/abstract/7\">",
"      Vlotides G, Eigler T, Melmed S. Pituitary tumor-transforming gene: physiology and implications for tumorigenesis. Endocr Rev 2007; 28:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22167/abstract/8\">",
"      Corenblum B, Sirek AM, Horvath E, et al. Human mixed somatotrophic and lactotrophic pituitary adenomas. J Clin Endocrinol Metab 1976; 42:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22167/abstract/9\">",
"      Mindermann T, Wilson CB. Age-related and gender-related occurrence of pituitary adenomas. Clin Endocrinol (Oxf) 1994; 41:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22167/abstract/10\">",
"      Delgrange E, Trouillas J, Maiter D, et al. Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. J Clin Endocrinol Metab 1997; 82:2102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22167/abstract/11\">",
"      Prosser PR, Karam JH, Townsend JJ, Forsham PH. Prolactin-secreting pituitary adenomas in multiple endocrine adenomatosis, type I. Ann Intern Med 1979; 91:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22167/abstract/12\">",
"      Walker JD, Grossman A, Anderson JV, et al. Malignant prolactinoma with extracranial metastases: a report of three cases. Clin Endocrinol (Oxf) 1993; 38:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22167/abstract/13\">",
"      Petakov MS, Damjanovi�� SS, Nikoli��-Durovi�� MM, et al. Pituitary adenomas secreting large amounts of prolactin may give false low values in immunoradiometric assays. The hook effect. J Endocrinol Invest 1998; 21:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22167/abstract/14\">",
"      St-Jean E, Blain F, Comtois R. High prolactin levels may be missed by immunoradiometric assay in patients with macroprolactinomas. Clin Endocrinol (Oxf) 1996; 44:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22167/abstract/15\">",
"      Barkan AL, Chandler WF. Giant pituitary prolactinoma with falsely low serum prolactin: the pitfall of the \"high-dose hook effect\": case report. Neurosurgery 1998; 42:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22167/abstract/16\">",
"      Molitch ME. Drugs and prolactin. Pituitary 2008; 11:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22167/abstract/17\">",
"      David SR, Taylor CC, Kinon BJ, Breier A. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin Ther 2000; 22:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22167/abstract/18\">",
"      Rivera JL, Lal S, Ettigi P, et al. Effect of acute and chronic neuroleptic therapy on serum prolactin levels in men and women of different age groups. Clin Endocrinol (Oxf) 1976; 5:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22167/abstract/19\">",
"      McCallum RW, Sowers JR, Hershman JM, Sturdevant RA. Metoclopramide stimulates prolactin secretion in man. J Clin Endocrinol Metab 1976; 42:1148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22167/abstract/20\">",
"      Sowers JR, Sharp B, McCallum RW. Effect of domperidone, an extracerebral inhibitor of dopamine receptors, on thyrotropin, prolactin, renin, aldosterone, and 18-hydroxycorticosterone secretion in man. J Clin Endocrinol Metab 1982; 54:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22167/abstract/21\">",
"      Bushe C, Yeomans D, Floyd T, Smith SM. Categorical prevalence and severity of hyperprolactinaemia in two UK cohorts of patients with severe mental illness during treatment with antipsychotics. J Psychopharmacol 2008; 22:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22167/abstract/22\">",
"      Steiner J, Cassar J, Mashiter K, et al. Effects of methyldopa on prolactin and growth hormone. Br Med J 1976; 1:1186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22167/abstract/23\">",
"      Lee PA, Kelly MR, Wallin JD. Increased prolactin levels during reserpine treatment of hypertensive patients. JAMA 1976; 235:2316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22167/abstract/24\">",
"      Fearrington EL, Rand CH Jr, Rose JD. Hyperprolactinemia-galactorrhea induced by verapamil. Am J Cardiol 1983; 51:1466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22167/abstract/25\">",
"      Veldhuis JD, Borges JL, Drake CR, et al. Divergent influences of the structurally dissimilar calcium entry blockers, diltiazem and verapamil, on thyrotropin- and gonadotropin-releasing hormone-stimulated anterior pituitary hormone secretion in man. J Clin Endocrinol Metab 1985; 60:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22167/abstract/26\">",
"      Romeo JH, Dombrowski R, Kwak YS, et al. Hyperprolactinaemia and verapamil: prevalence and potential association with hypogonadism in men. Clin Endocrinol (Oxf) 1996; 45:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22167/abstract/27\">",
"      Cowen PJ, Sargent PA. Changes in plasma prolactin during SSRI treatment: evidence for a delayed increase in 5-HT neurotransmission. J Psychopharmacol 1997; 11:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22167/abstract/28\">",
"      Meltzer H, Bastani B, Jayathilake K, Maes M. Fluoxetine, but not tricyclic antidepressants, potentiates the 5-hydroxytryptophan-mediated increase in plasma cortisol and prolactin secretion in subjects with major depression or with obsessive compulsive disorder. Neuropsychopharmacology 1997; 17:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22167/abstract/29\">",
"      Frantz AG. Prolactin. N Engl J Med 1978; 298:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22167/abstract/30\">",
"      Murdoch FE, Byrne LM, Ariazi EA, et al. Estrogen receptor binding to DNA: affinity for nonpalindromic elements from the rat prolactin gene. Biochemistry 1995; 34:9144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22167/abstract/31\">",
"      Malayer JR, Gorski J. The role of estrogen receptor in modulation of chromatin conformation in the 5' flanking region of the rat prolactin gene. Mol Cell Endocrinol 1995; 113:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22167/abstract/32\">",
"      Honbo KS, van Herle AJ, Kellett KA. Serum prolactin levels in untreated primary hypothyroidism. Am J Med 1978; 64:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22167/abstract/33\">",
"      Snyder PJ, Jacobs LS, Utiger RD, Daughaday WH. Thyroid hormone inhibition of the prolactin response to thyrotropin-releasing hormone. J Clin Invest 1973; 52:2324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22167/abstract/34\">",
"      Groff TR, Shulkin BL, Utiger RD, Talbert LM. Amenorrhea-galactorrhea, hyperprolactinemia, and suprasellar pituitary enlargement as presenting features of primary hypothyroidism. Obstet Gynecol 1984; 63:86S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22167/abstract/35\">",
"      Grubb MR, Chakeres D, Malarkey WB. Patients with primary hypothyroidism presenting as prolactinomas. Am J Med 1987; 83:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22167/abstract/36\">",
"      Morley JE, Dawson M, Hodgkinson H, Kalk WJ. Galactorrhea and hyperprolactinemia associated with chest wall injury. J Clin Endocrinol Metab 1977; 45:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22167/abstract/37\">",
"      Lim VS, Kathpalia SC, Frohman LA. Hyperprolactinemia and impaired pituitary response to suppression and stimulation in chronic renal failure: reversal after transplantation. J Clin Endocrinol Metab 1979; 48:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22167/abstract/38\">",
"      Sievertsen GD, Lim VS, Nakawatase C, Frohman LA. Metabolic clearance and secretion rates of human prolactin in normal subjects and in patients with chronic renal failure. J Clin Endocrinol Metab 1980; 50:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22167/abstract/39\">",
"      Schlechte J, Dolan K, Sherman B, et al. The natural history of untreated hyperprolactinemia: a prospective analysis. J Clin Endocrinol Metab 1989; 68:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22167/abstract/40\">",
"      Martin TL, Kim M, Malarkey WB. The natural history of idiopathic hyperprolactinemia. J Clin Endocrinol Metab 1985; 60:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22167/abstract/41\">",
"      Sluijmer AV, Lapp&ouml;hn RE. Clinical history and outcome of 59 patients with idiopathic hyperprolactinemia. Fertil Steril 1992; 58:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22167/abstract/42\">",
"      Carlson HE, Markoff E, Lee DW. On the nature of serum prolactin in two patients with macroprolactinemia. Fertil Steril 1992; 58:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22167/abstract/43\">",
"      Olukoga AO, Kane JW. Macroprolactinaemia: validation and application of the polyethylene glycol precipitation test and clinical characterization of the condition. Clin Endocrinol (Oxf) 1999; 51:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22167/abstract/44\">",
"      Vallette-Kasic S, Morange-Ramos I, Selim A, et al. Macroprolactinemia revisited: a study on 106 patients. J Clin Endocrinol Metab 2002; 87:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22167/abstract/45\">",
"      Leslie H, Courtney CH, Bell PM, et al. Laboratory and clinical experience in 55 patients with macroprolactinemia identified by a simple polyethylene glycol precipitation method. J Clin Endocrinol Metab 2001; 86:2743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22167/abstract/46\">",
"      Strachan MW, Teoh WL, Don-Wauchope AC, et al. Clinical and radiological features of patients with macroprolactinaemia. Clin Endocrinol (Oxf) 2003; 59:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22167/abstract/47\">",
"      Hattori N, Inagaki C. Anti-prolactin (PRL) autoantibodies cause asymptomatic hyperprolactinemia: bioassay and clearance studies of PRL-immunoglobulin G complex. J Clin Endocrinol Metab 1997; 82:3107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22167/abstract/48\">",
"      Gibney J, Smith TP, McKenna TJ. Clinical relevance of macroprolactin. Clin Endocrinol (Oxf) 2005; 62:633.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6626 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-210.101.131.232-C3EBFED581-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_41_22167=[""].join("\n");
var outline_f21_41_22167=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PHYSIOLOGIC CAUSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Nipple stimulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Stress",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PATHOLOGIC CAUSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Lactotroph adenomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Decreased dopaminergic inhibition of prolactin secretion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Hypothalamic and pituitary disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Drug use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      OTHER CAUSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Estrogen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Chest wall injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Chronic renal failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Idiopathic hyperprolactinemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Macroprolactinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/6626\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/6626|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/46/5869\" title=\"figure 1\">",
"      Serum prolactin in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/57/35742\" title=\"figure 2\">",
"      Serum prolactin and suckling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/28/24014\" title=\"figure 3\">",
"      Serum prolactin by dx",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/6626|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/58/2988\" title=\"table 1\">",
"      Drugs cause hyperprolactinemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/18/29992?source=related_link\">",
"      Causes, presentation, and evaluation of sellar masses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19254?source=related_link\">",
"      Clinical manifestations and diagnosis of hyperprolactinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/14/43240?source=related_link\">",
"      Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/0/25603?source=related_link\">",
"      Patient information: High prolactin levels and prolactinomas (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/6/25698?source=related_link\">",
"      Patient information: Prolactinoma (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/52/31561?source=related_link\">",
"      Treatment of hyperprolactinemia due to lactotroph adenoma and other causes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_41_22168="Clinical manifestations and diagnosis of gastroesophageal reflux in adults";
var content_f21_41_22168=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of gastroesophageal reflux in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/41/22168/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/41/22168/contributors\">",
"     Peter J Kahrilas, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/41/22168/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/41/22168/contributors\">",
"     Nicholas J Talley, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/41/22168/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/41/22168/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/41/22168/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastroesophageal reflux disease (GERD) is notable for its prevalence, variety of clinical presentations, under-recognized morbidity, and substantial economic consequences.",
"   </p>",
"   <p>",
"    This topic review will discuss the clinical features and diagnostic approach to patients with this disorder. The pathophysiology and medical and surgical management of GERD are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13928?source=see_link\">",
"     \"Pathophysiology of reflux esophagitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42840?source=see_link\">",
"     \"Medical management of gastroesophageal reflux disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/57/42905?source=see_link\">",
"     \"Surgical management of gastroesophageal reflux in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some degree of reflux is physiologic [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22168/abstract/1\">",
"     1",
"    </a>",
"    ]. Physiologic reflux episodes typically occur postprandially, are short-lived, asymptomatic, and rarely occur during sleep. Pathologic reflux is associated with symptoms or mucosal injury, often including nocturnal episodes. In general terms, gastroesophageal reflux disease (GERD) is applied to patients with symptoms suggestive of reflux or complications thereof, but not necessarily with esophageal inflammation. Reflux esophagitis describes a subset of patients with symptoms of GERD who also have endoscopic or histopathologic evidence of esophageal inflammation.",
"   </p>",
"   <p>",
"    Due to the broad spectrum of conditions attributable to reflux, there is little agreement as to what constitutes typical reflux disease. A consensus statement (the Montreal Classification) defines GERD as a condition that develops when the reflux of stomach contents causes troublesome symptoms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    complications [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22168/abstract/2\">",
"     2",
"    </a>",
"    ]. According to the Montreal Working Group, heartburn is considered troublesome if mild symptoms occur two or more days a week, or moderate to severe symptoms occur more than one day a week [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22168/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are limitations in the epidemiologic estimates of the prevalence of gastroesophageal reflux disease (GERD) as they are based upon the assumption that heartburn",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    regurgitation are the only indicators of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22168/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. However, patients with objective evidence of GERD (such as esophagitis or Barrett's esophagus) do not always have heartburn and heartburn is not always indicative of GERD [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22168/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A systematic review identified 15 epidemiological studies of GERD that fulfilled strict quality criteria (at least weekly heartburn",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    acid regurgitation and studies also met criteria concerning sample size, response rate, and recall period) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22168/abstract/4\">",
"     4",
"    </a>",
"    ]. GERD prevalence was found to be 10 to 20 percent in the Western world and less than 5 percent in Asia. The incidence in the Western world was approximately 5 per 1000 person-years.",
"   </p>",
"   <p>",
"    In a subsequent population-based survey in the United States, 22 percent of respondents reported that they had heartburn or regurgitation within the last month while 16 percent reported regurgitation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22168/abstract/5\">",
"     5",
"    </a>",
"    ]. Heartburn or regurgitation was \"clinically significant\" (&ge;twice weekly) in 6 and 3 percent, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13576047\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common symptoms of gastroesophageal reflux disease (GERD) are heartburn (pyrosis), regurgitation, and dysphagia. A variety of extraesophageal manifestations have been described including bronchospasm, laryngitis, and chronic cough. Complications from GERD can arise even in patients who lack typical symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19253?source=see_link\">",
"     \"Complications of gastroesophageal reflux in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Heartburn is typically described as a burning sensation in the retrosternal area [",
"      <a class=\"abstract\" href=\"UTD.htm?21/41/22168/abstract/2\">",
"       2",
"      </a>",
"      ], most commonly experienced in the postprandial period.",
"     </li>",
"     <li>",
"      Regurgitation is defined as the perception of flow of refluxed gastric content into the mouth or hypopharynx [",
"      <a class=\"abstract\" href=\"UTD.htm?21/41/22168/abstract/2\">",
"       2",
"      </a>",
"      ]. Patients typically regurgitate acidic material mixed with small amounts of undigested food.",
"     </li>",
"     <li>",
"      Dysphagia is common in the setting of longstanding heartburn commonly attributable to reflux esophagitis but potentially indicative of a stricture [",
"      <a class=\"abstract\" href=\"UTD.htm?21/41/22168/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other symptoms of GERD include chest pain, water brash, globus sensation, odynophagia, and nausea.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      GERD-related chest pain may mimic angina pectoris, and is typically described as squeezing or burning, located substernally and radiating to the back, neck, jaw, or arms, lasting anywhere from minutes to hours, and resolving either spontaneously or with antacids. It usually occurs after meals, awakens patients from sleep, and may be exacerbated by emotional stress [",
"      <a class=\"abstract\" href=\"UTD.htm?21/41/22168/abstract/1\">",
"       1",
"      </a>",
"      ]. Patients with reflux-induced chest pain may also have typical reflux symptoms. However, heartburn is a poor predictor of whether patients with chest pain have evidence of GERD by objective testing [",
"      <a class=\"abstract\" href=\"UTD.htm?21/41/22168/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Water brash or hypersalivation is a relatively unusual symptom in which patients can foam at the mouth, secreting as much as 10 mL of saliva per minute in response to reflux.",
"     </li>",
"     <li>",
"      Globus sensation is the almost constant perception of a lump in the throat (irrespective of swallowing), which has been related to GERD in some studies. However, the role of esophageal reflux in this disorder is uncertain. One study suggested that globus was associated with a hypertensive upper esophageal sphincter rather than with reflux [",
"      <a class=\"abstract\" href=\"UTD.htm?21/41/22168/abstract/9\">",
"       9",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/19/21814?source=see_link\">",
"       \"Globus sensation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Odynophagia is an unusual symptom of GERD but, when present, usually indicates an esophageal ulcer.",
"     </li>",
"     <li>",
"      Nausea is infrequently reported with GERD, but a diagnosis of GERD should be considered in patients with otherwise unexplained nausea. In one report, nausea resolved after therapy for GERD in 10 patients who previously had intractable symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?21/41/22168/abstract/10\">",
"       10",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42840?source=see_link\">",
"       \"Medical management of gastroesophageal reflux disease in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/57/42905?source=see_link\">",
"       \"Surgical management of gastroesophageal reflux in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13576054\">",
"    <span class=\"h2\">",
"     Upper gastrointestinal endoscopy findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;The findings on upper endoscopy are variable. Upper endoscopy may be normal in patients with GERD, or there may be evidence of esophagitis of varying degrees (see",
"    <a class=\"local\" href=\"#H82189930\">",
"     'Esophagitis on esophagoscopy'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13576062\">",
"    <span class=\"h3\">",
"     Histology",
"    </span>",
"    &nbsp;&mdash;&nbsp;A review of the literature suggested that about two-thirds of patients who have symptoms of GERD, but have no visible endoscopic findings (ie, nonerosive reflux disease) have histologic evidence of esophageal injury that responds to acid suppression [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22168/abstract/11\">",
"     11",
"    </a>",
"    ]. The most consistently observed histologic finding in this study was dilation of the intercellular spaces seen on transmission electron microscopy. This finding is also present in patients with reflux esophagitis.",
"   </p>",
"   <p>",
"    The mild histologic findings noted in GERD represent the reparative capacity of the esophageal epithelium after cell damage due to acid exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22168/abstract/12\">",
"     12",
"    </a>",
"    ]. Cellular injury stimulates cell proliferation, the morphologic equivalent of which is thickening of the basal cell layer and elongation of the papillae of the epithelium (",
"    <a class=\"graphic graphic_picture graphicRef56086 \" href=\"UTD.htm?19/44/20167\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22168/abstract/13\">",
"     13",
"    </a>",
"    ]. Other histologic features include the presence of neutrophils and eosinophils, dilated vascular channels in papillae of the lamina propria, and distended, pale squamous (\"balloon\") cells. However, none of these findings is specific for GERD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13576252\">",
"    <span class=\"h2\">",
"     Radiographic findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Double contrast",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    swallow examination is of limited use because of its low sensitivity in patients with mild GERD. Radiologic evaluation is most useful in the detection of peptic stricture.",
"   </p>",
"   <p>",
"    A number of changes may be seen on double contrast",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    swallow:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Double contrast",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"       barium",
"      </a>",
"      swallow examinations can identify early stages of reflux esophagitis by a granular or nodular appearance of the mucosa of the distal third of the esophagus with numerous ill-defined, 1 to 3 mm lucencies [",
"      <a class=\"abstract\" href=\"UTD.htm?21/41/22168/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Shallow ulcers and erosions are recognized on double contrast radiographs as tiny collections of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"       barium",
"      </a>",
"      in the distal esophagus near the gastroesophageal junction, sometimes surrounded by a radiolucent halo of edematous mucosa.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The appearance of a smooth, tapered area of concentric narrowing in the distal esophagus, 1 to 4 cm in length and 0.2 to 2.0 cm in diameter is virtually pathognomonic of a benign peptic stricture (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef66161 \" href=\"UTD.htm?15/48/16142\">",
"     image 1",
"    </a>",
"    ). However, many peptic strictures have an asymmetric appearance with puckering of one wall of the stricture due to eccentric scarring.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13575781\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of gastroesophageal reflux disease (GERD) can be based upon clinical symptoms alone. In patients presenting with any of the clinical manifestations described above, a presumptive diagnosis of GERD can be made.",
"   </p>",
"   <p>",
"    Response to antisecretory therapy is not a diagnostic criterion for GERD [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22168/abstract/15\">",
"     15",
"    </a>",
"    ]. A meta-analysis of diagnostic test characteristics found that a response to proton pump inhibitors (PPIs) did not correlate well with objective measures of GERD such as ambulatory pH monitoring [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22168/abstract/16\">",
"     16",
"    </a>",
"    ]. Pooled sensitivity was 78 percent while specificity was 54 percent. Thus, a response to PPIs does not correspond to a GERD diagnosis based on reflux testing. However, the observation that 40 to 90 percent of patients with symptoms suggestive of GERD [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22168/abstract/16\">",
"     16",
"    </a>",
"    ] have a symptomatic response to PPIs raises the question of which diagnostic approach is more relevant in practice. Clearly, it is neither necessary nor practical to initiate a diagnostic evaluation in every patient with heartburn [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22168/abstract/2,17\">",
"     2,17",
"    </a>",
"    ].",
"    <br/>",
"   </p>",
"   <p>",
"    However, in a subset of patients, diagnostic testing is required to confirm the diagnosis of GERD and to rule out other diagnoses (see",
"    <a class=\"local\" href=\"#H13576009\">",
"     'Overview'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastroesophageal reflux disease (GERD) needs to be distinguished from infectious esophagitis, pill esophagitis, eosinophilic esophagitis, peptic ulcer disease, non-ulcer dyspepsia, biliary tract disease, coronary artery disease, and esophageal motor disorders. Symptoms alone do not reliably distinguish among these disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22168/abstract/18\">",
"     18",
"    </a>",
"    ]. Similarly, the severity and duration of symptoms correlate poorly with the severity of esophagitis.",
"   </p>",
"   <p>",
"    Dysphagia may be due to GERD, but slowly progressive dysphagia for solids with episodic esophageal obstruction is suggestive of a peptic stricture. Other, more common causes of dysphagia are reflux esophagitis, eosinophilic esophagitis, and impaired peristalsis. Another, fortunately rare, cause of dysphagia is esophageal cancer, either adenocarcinoma arising from Barrett's metaplasia or squamous cell carcinoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     ADDITIONAL EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13576009\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of additional testing is to confirm the diagnosis of GERD in patients refractory to therapy, assess for complications of GERD, or to establish alternative diagnoses [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22168/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    According to a guideline issued by the American Gastroenterological Association (AGA), endoscopy with biopsy should be done at presentation for patients with an esophageal GERD syndrome with troublesome dysphagia and to evaluate patients with a suspected esophageal GERD syndrome who have not responded to an empirical trial of twice daily PPI therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22168/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19253?source=see_link\">",
"     \"Complications of gastroesophageal reflux in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other potentially useful tests are ambulatory pH monitoring and manometry [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22168/abstract/20\">",
"     20",
"    </a>",
"    ]. Ambulatory pH monitoring is useful for confirming gastroesophageal reflux disease in those with persistent symptoms (whether typical or atypical) who do not have evidence for mucosal damage on endoscopy, particularly if a trial of twice daily PPI has failed or to monitor the adequacy of treatment in those with continued symptoms (",
"    <a class=\"graphic graphic_table graphicRef78947 \" href=\"UTD.htm?26/7/26748\">",
"     table 1",
"    </a>",
"    ). In this setting, pH monitoring should be done while withholding PPI therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22168/abstract/21\">",
"     21",
"    </a>",
"    ]. Manometry is useful in ensuring that ambulatory pH probes are placed correctly, to evaluate peristaltic function before antireflux surgery, and to exclude major motor disorders as an alternative diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22168/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Biliary tract ultrasonography should be considered in patients with nausea",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    epigastric pain. Double contrast",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    swallow is used infrequently. When data from barium radiography and endoscopy were compared, the diagnostic accuracy of radiography was 25 percent with mild esophagitis, 82 percent with moderate esophagitis, and 99 percent with severe esophagitis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22168/abstract/22\">",
"     22",
"    </a>",
"    ]. The demonstration of reflux of barium during the study is of dubious significance since it can be provoked in 25 to 71 percent of symptomatic patients compared with 20 percent of normal controls [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22168/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unexplained chest pain should be evaluated with at least an electrocardiogram and exercise stress test prior to a gastrointestinal evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Upper gastrointestinal endoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Upper endoscopy provides a mechanism for detecting, stratifying, and managing the esophageal manifestations of GERD. The indications for upper endoscopy in patients with GERD are controversial and are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42840?source=see_link&amp;anchor=H257926783#H257926783\">",
"     \"Medical management of gastroesophageal reflux disease in adults\", section on 'Indications for upper endoscopy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    On upper endoscopy, biopsies should target any areas of suspected metaplasia, dysplasia, or, in the absence of visual abnormalities, normal mucosa (at least five samples to evaluate for eosinophilic esophagitis) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22168/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H82189930\">",
"    <span class=\"h3\">",
"     Esophagitis on esophagoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The interoperator variability of endoscopy in assessing the severity of peptic esophagitis spawned many endoscopic grading schemes; of the more than 80 proposed schemes, the two most dominant will be described.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h4\">",
"     Los Angeles classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Los Angeles classification is the most thoroughly evaluated classification for esophagitis and is widely used. The Los Angeles classification grades esophagitis severity by the extent of mucosal abnormality, with complications recorded separately. In this grading scheme, a mucosal break refers to an area of slough adjacent to more normal mucosa in the squamous epithelium with or without overlying exudate.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Grade A &ndash; one or more mucosal breaks each &le;5 mm in length (",
"      <a class=\"graphic graphic_picture graphicRef60311 \" href=\"UTD.htm?31/30/32238\">",
"       picture 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Grade B &ndash; at least one mucosal break &gt;5 mm long, but not continuous between the tops of adjacent mucosal folds (",
"      <a class=\"graphic graphic_picture graphicRef74162 \" href=\"UTD.htm?15/60/16335\">",
"       picture 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Grade C &ndash; at least one mucosal break that is continuous between the tops of adjacent mucosal folds, but which is not circumferential (",
"      <a class=\"graphic graphic_picture graphicRef53483 \" href=\"UTD.htm?16/1/16415\">",
"       picture 4",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Grade D &ndash; mucosal break that involves at least three-fourths of the luminal circumference (",
"      <a class=\"graphic graphic_picture graphicRef63178 \" href=\"UTD.htm?30/50/31535\">",
"       picture 5",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H575215834\">",
"    <span class=\"h4\">",
"     Savary-Miller classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historically, the most widely referenced grading of esophagitis is the Savary-Miller classification [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22168/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Grade I exhibits one or more supravestibular, nonconfluent reddish spots, with or without exudate",
"     </li>",
"     <li>",
"      Grade II demonstrates erosive and exudative lesions in the distal esophagus that may be confluent, but not circumferential",
"     </li>",
"     <li>",
"      Grade III is characterized by circumferential erosions in the distal esophagus, covered by hemorrhagic and pseudomembranous exudate",
"     </li>",
"     <li>",
"      Grade IV is defined by the presence of chronic complications such as deep ulcers, stenosis, or scarring with Barrett's metaplasia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite its widespread use, the Savary-Miller grading scheme has its limitations. Because it includes all complications, grade IV esophagitis is ambiguous. This has led to modifications which either offer subdivisions of grade IV or relegate metaplasia to grade V. With so many proposed modifications, grades IV and V no longer have any widely accepted meaning.",
"   </p>",
"   <p>",
"    The findings on endoscopy vary with the etiology of the inflammation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infectious esophagitis is circumferential and tends to involve the proximal esophagus far more frequently than does reflux esophagitis. The ulcerations seen in peptic esophagitis are usually irregularly shaped or linear, multiple, and distal, whereas infectious ulcers are multiple and punctate.",
"     </li>",
"     <li>",
"      Pill-induced ulcerations are usually singular and deep, occurring at points of stasis (especially near the carina), with sparing of the distal esophagus. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/13/37078?source=see_link\">",
"       \"Medication-induced esophagitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Eosinophilic esophagitis has been associated with a variety of morphological features in the esophagus. These include a ringed esophagus, strictures (particularly proximal strictures), attenuation of the subepithelial vascular pattern, linear furrowing that may extend the entire length of the esophagus, whitish papules (representing eosinophil microabscesses), and a small caliber esophagus. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/45/32474?source=see_link&amp;anchor=H1679777#H1679777\">",
"       \"Pathogenesis, clinical manifestations, and diagnosis of eosinophilic esophagitis\", section on 'Endoscopy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Both infectious and pill esophagitis are usually accompanied by odynophagia, which is less common in peptic esophagitis.",
"   </p>",
"   <p>",
"    The absence of endoscopic features of GERD does not exclude the diagnosis. Some patients with initial negative endoscopies will develop mucosal lesions during follow-up examinations [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22168/abstract/26\">",
"     26",
"    </a>",
"    ]. In addition, symptoms may be due to esophageal hypersensitivity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13928?source=see_link\">",
"     \"Pathophysiology of reflux esophagitis\"",
"    </a>",
"    .) It is also important to note that the accuracy of endoscopy for the diagnosis of GERD is subject to observer variability. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17178?source=see_link\">",
"     \"Wireless video capsule endoscopy\"",
"    </a>",
"    .) Finally, even though the esophagus may appear endoscopically normal, it is not necessarily histologically normal (see",
"    <a class=\"local\" href=\"#H13576062\">",
"     'Histology'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Ambulatory esophageal pH monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ambulatory pH monitoring is useful for confirming gastroesophageal reflux disease in those with persistent symptoms (whether typical or atypical) who do not have evidence for mucosal damage on endoscopy, particularly if a trial of twice daily PPI has failed [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22168/abstract/27\">",
"     27",
"    </a>",
"    ]. It can also be used to monitor the adequacy of treatment in those with continued symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22168/abstract/28\">",
"     28",
"    </a>",
"    ]. Suggested clinical indications for ambulatory pH monitoring are listed in the Table (",
"    <a class=\"graphic graphic_table graphicRef78947 \" href=\"UTD.htm?26/7/26748\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22168/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ambulatory pH monitoring can be done with either a transnasally placed catheter or a wireless, capsule-shaped device that is affixed to the distal esophageal mucosa [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22168/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. In each case, the pH sensor is coupled with compact, portable data recorders, and computerized data analysis. The catheter type pH electrode is positioned 5 cm above the manometrically defined upper limit of the lower esophageal sphincter. In the case of the wireless device, the pH capsule is attached 6 cm proximal to the endoscopically defined squamocolumnar junction. Tests are traditionally conducted for a 24-hour period with patients advised to consume an unrestricted diet. However, increasing monitoring to 48 hours in patients undergoing evaluation using a wireless device may increase the yield of the study for detecting reflux episodes and correlating those events with symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22168/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because the validity of pH monitoring studies has only been established when conducted off of antisecretory drugs, studies should be done after withholding PPI therapy for seven days. However, in the case of the wireless device, studies can be conducted for two to four days, varying the dietary",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    therapeutic circumstances between days if desired [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22168/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The current consensus is to consider the percentage time with the intraesophageal pH below 4 as the most useful outcome measure in discriminating between physiologic and pathologic esophageal reflux [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22168/abstract/34\">",
"     34",
"    </a>",
"    ]. Although symptom association is essential when evaluating atypical or sporadic symptoms, a direct one-to-one correlation between reflux events and symptoms rarely exists, leading to several proposed methods for quantifying the reflux-symptom relationship. However, none of the proposed symptom evaluation schemes has been prospectively validated against an independent parameter of diagnostic accuracy such as antireflux therapy with a symptomatic response [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22168/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. Whether ambulatory esophageal pH monitoring should be performed with the patient on acid suppressive therapy is somewhat controversial. The unclear relevance of &ldquo;normative&rdquo; data for studies performed on PPI therapy makes it difficult to interpret the results [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22168/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ambulatory pH monitoring is also used for the detection of pathologic reflux associated with supra-esophageal complications such as reflux laryngitis or cough. However, there has been no consensus on the pH criteria that should be used for defining pathologic reflux in this setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Esophageal manometry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Esophageal manometry should be considered in patients with symptoms of GERD and normal upper endoscopy, especially if there is any associated dysphagia, even though esophageal manometry is of minimal use in the diagnosis of GERD. However, manometry is useful in identifying alternative diagnoses such as achalasia, the symptoms of which sometimes closely mimic those of GERD [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22168/abstract/19\">",
"     19",
"    </a>",
"    ]. The evaluation of peristaltic function to exclude major motor disorders is also important before antireflux surgery (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/57/42905?source=see_link\">",
"     \"Surgical management of gastroesophageal reflux in adults\"",
"    </a>",
"    ), and it can also be used to ensure that ambulatory pH probes are placed correctly [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22168/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/2/24610?source=see_link\">",
"       \"Patient information: Acid reflux (gastroesophageal reflux disease) in adults (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/41/33426?source=see_link\">",
"       \"Patient information: Upper endoscopy (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?37/30/38373?source=see_link\">",
"       \"Patient information: Acid reflux (gastroesophageal reflux disease) in adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/0/21506?source=see_link\">",
"       \"Patient information: Upper endoscopy (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A consensus statement (the Montreal Classification) defines GERD as \"a condition that develops when the reflux of stomach contents causes troublesome symptoms",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      complications\". (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common symptoms of GERD are heartburn (or pyrosis), regurgitation, and dysphagia. In addition, a variety of extraesophageal manifestations have been described including bronchospasm, laryngitis, and chronic coughing. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19253?source=see_link\">",
"       \"Complications of gastroesophageal reflux in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The diagnosis of GERD can be based upon clinical symptoms alone. In patients presenting with any of the clinical manifestations described above, a presumptive diagnosis of GERD can be made. (See",
"      <a class=\"local\" href=\"#H13575781\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Additional evaluation should be performed in patients with dysphagia or who have suspected esophageal GERD symptoms and have not responded to an empiric trial of twice daily proton pump inhibitor (PPI) therapy. The goal of additional testing is to confirm the diagnosis of GERD in patients refractory to therapy, to assess for complications of GERD, or to establish alternative diagnoses. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Additional evaluation'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42840?source=see_link&amp;anchor=H257926783#H257926783\">",
"       \"Medical management of gastroesophageal reflux disease in adults\", section on 'Indications for upper endoscopy'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Endoscopy with biopsy should be done at presentation for patients with an esophageal GERD syndrome with troublesome dysphagia and to evaluate patients with a suspected esophageal GERD syndrome who have not responded to an empirical trial of twice daily PPI therapy. Biopsies should target any areas of suspected metaplasia, dysplasia, or, in the absence of visual abnormalities, normal mucosa (at least five samples to evaluate for eosinophilic esophagitis). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19253?source=see_link\">",
"       \"Complications of gastroesophageal reflux in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/8/1161?source=see_link&amp;anchor=H8#H8\">",
"       \"Epidemiology, clinical manifestations, and diagnosis of Barrett's esophagus\", section on 'Screening patients for Barrett's esophagus'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Ambulatory pH monitoring is useful for confirming gastroesophageal reflux disease in those with persistent symptoms (whether typical or atypical) who do not have evidence for mucosal damage on endoscopy, particularly if a trial of twice daily PPI has failed. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Ambulatory esophageal pH monitoring'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Esophageal manometry is useful to detect esophageal motor disorders, especially achalasia, the symptoms of which can mimic GERD. Manometry is also useful for the evaluation of peristaltic function before antireflux surgery to exclude major motor disorders and to ensure that ambulatory pH probes are placed correctly. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Esophageal manometry'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      GERD needs to be distinguished from infectious esophagitis, pill esophagitis, eosinophilic esophagitis, peptic ulcer disease, non-ulcer dyspepsia, biliary tract disease, coronary artery disease, and esophageal motor disorders. Unexplained chest pain should be evaluated with an electrocardiogram and exercise stress test prior to a gastrointestinal evaluation. The remaining elements of the differential diagnosis can be evaluated by endoscopy or biliary tract ultrasonography. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22168/abstract/1\">",
"      Richter JE. Typical and atypical presentations of gastroesophageal reflux disease. The role of esophageal testing in diagnosis and management. Gastroenterol Clin North Am 1996; 25:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22168/abstract/2\">",
"      Vakil N, van Zanten SV, Kahrilas P, et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006; 101:1900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22168/abstract/3\">",
"      Nebel OT, Fornes MF, Castell DO. Symptomatic gastroesophageal reflux: incidence and precipitating factors. Am J Dig Dis 1976; 21:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22168/abstract/4\">",
"      Dent J, El-Serag HB, Wallander MA, Johansson S. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2005; 54:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22168/abstract/5\">",
"      Camilleri M, Dubois D, Coulie B, et al. Prevalence and socioeconomic impact of upper gastrointestinal disorders in the United States: results of the US Upper Gastrointestinal Study. Clin Gastroenterol Hepatol 2005; 3:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22168/abstract/6\">",
"      Zagari RM, Fuccio L, Wallander MA, et al. Gastro-oesophageal reflux symptoms, oesophagitis and Barrett's oesophagus in the general population: the Loiano-Monghidoro study. Gut 2008; 57:1354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22168/abstract/7\">",
"      Vakil NB, Traxler B, Levine D. Dysphagia in patients with erosive esophagitis: prevalence, severity, and response to proton pump inhibitor treatment. Clin Gastroenterol Hepatol 2004; 2:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22168/abstract/8\">",
"      Kahrilas PJ, Hughes N, Howden CW. Response of unexplained chest pain to proton pump inhibitor treatment in patients with and without objective evidence of gastro-oesophageal reflux disease. Gut 2011; 60:1473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22168/abstract/9\">",
"      Corso MJ, Pursnani KG, Mohiuddin MA, et al. Globus sensation is associated with hypertensive upper esophageal sphincter but not with gastroesophageal reflux. Dig Dis Sci 1998; 43:1513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22168/abstract/10\">",
"      Brzana RJ, Koch KL. Gastroesophageal reflux disease presenting with intractable nausea. Ann Intern Med 1997; 126:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22168/abstract/11\">",
"      Dent J. Microscopic esophageal mucosal injury in nonerosive reflux disease. Clin Gastroenterol Hepatol 2007; 5:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22168/abstract/12\">",
"      Ismail-Beigi F, Horton PF, Pope CE 2nd. Histological consequences of gastroesophageal reflux in man. Gastroenterology 1970; 58:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22168/abstract/13\">",
"      Orlando RC. Esophageal epithelial defenses against acid injury. Am J Gastroenterol 1994; 89:S48.",
"     </a>",
"    </li>",
"    <li>",
"     Levine MS. Gastroesophageal reflux disease. In: Radiology of the Esophagus, Levine MS (Ed), WB Saunders, Philadelphia 1989. p.1147.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22168/abstract/15\">",
"      Bytzer P, Jones R, Vakil N, et al. Limited ability of the proton-pump inhibitor test to identify patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2012; 10:1360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22168/abstract/16\">",
"      Numans ME, Lau J, de Wit NJ, Bonis PA. Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostic test characteristics. Ann Intern Med 2004; 140:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22168/abstract/17\">",
"      Giannini EG, Zentilin P, Dulbecco P, et al. Management strategy for patients with gastroesophageal reflux disease: a comparison between empirical treatment with esomeprazole and endoscopy-oriented treatment. Am J Gastroenterol 2008; 103:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22168/abstract/18\">",
"      Moayyedi P, Talley NJ. Gastro-oesophageal reflux disease. Lancet 2006; 367:2086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22168/abstract/19\">",
"      Kahrilas PJ, Shaheen NJ, Vaezi MF, et al. American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease. Gastroenterology 2008; 135:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22168/abstract/20\">",
"      Howard PJ, Maher L, Pryde A, Heading RC. Symptomatic gastro-oesophageal reflux, abnormal oesophageal acid exposure, and mucosal acid sensitivity are three separate, though related, aspects of gastro-oesophageal reflux disease. Gut 1991; 32:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22168/abstract/21\">",
"      Hemmink GJ, Bredenoord AJ, Weusten BL, et al. Esophageal pH-impedance monitoring in patients with therapy-resistant reflux symptoms: 'on' or 'off' proton pump inhibitor? Am J Gastroenterol 2008; 103:2446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22168/abstract/22\">",
"      DeVault KR, Castell DO. Guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Practice Parameters Committee of the American College of Gastroenterology. Arch Intern Med 1995; 155:2165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22168/abstract/23\">",
"      Sellar RJ, De Caestecker JS, Heading RC. Barium radiology: a sensitive test for gastro-oesophageal reflux. Clin Radiol 1987; 38:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22168/abstract/24\">",
"      Gonsalves N, Policarpio-Nicolas M, Zhang Q, et al. Histopathologic variability and endoscopic correlates in adults with eosinophilic esophagitis. Gastrointest Endosc 2006; 64:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22168/abstract/25\">",
"      Monnier P, Savary M. Contribution of endoscopy to gastroesophageal reflux disease. Scand J Gastroenterol 1984; 19(Suppl 106):26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22168/abstract/26\">",
"      Pace F, Bianchi Porro G. Gastroesophageal reflux disease: a typical spectrum disease (a new conceptual framework is not needed). Am J Gastroenterol 2004; 99:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22168/abstract/27\">",
"      Hirano I, Richter JE, Practice Parameters Committee of the American College of Gastroenterology. ACG practice guidelines: esophageal reflux testing. Am J Gastroenterol 2007; 102:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22168/abstract/28\">",
"      Kahrilas PJ, Quigley EM. Clinical esophageal pH recording: a technical review for practice guideline development. Gastroenterology 1996; 110:1982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22168/abstract/29\">",
"      Pandolfino JE, Kahrilas PJ. Prolonged pH monitoring: Bravo capsule. Gastrointest Endosc Clin N Am 2005; 15:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22168/abstract/30\">",
"      Pandolfino JE, Schreiner MA, Lee TJ, et al. Comparison of the Bravo wireless and Digitrapper catheter-based pH monitoring systems for measuring esophageal acid exposure. Am J Gastroenterol 2005; 100:1466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22168/abstract/31\">",
"      Chander B, Hanley-Williams N, Deng Y, Sheth A. 24 Versus 48-hour bravo pH monitoring. J Clin Gastroenterol 2012; 46:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22168/abstract/32\">",
"      Pandolfino JE, Richter JE, Ours T, et al. Ambulatory esophageal pH monitoring using a wireless system. Am J Gastroenterol 2003; 98:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22168/abstract/33\">",
"      Garrean CP, Zhang Q, Gonsalves N, Hirano I. Acid reflux detection and symptom-reflux association using 4-day wireless pH recording combining 48-hour periods off and on PPI therapy. Am J Gastroenterol 2008; 103:1631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22168/abstract/34\">",
"      Galmiche P, Scarpignato C. Esophageal pH monitoring. In: Functional Evaluation in Esophageal Disease, Scarpignato C, Galmiche JP (Eds). Front Gastrointest Res 1994; 22:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22168/abstract/35\">",
"      Charbel S, Khandwala F, Vaezi MF. The role of esophageal pH monitoring in symptomatic patients on PPI therapy. Am J Gastroenterol 2005; 100:283.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2265 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.131.240.2-B63444C5D6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_41_22168=[""].join("\n");
var outline_f21_41_22168=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13576047\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13576054\">",
"      Upper gastrointestinal endoscopy findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13576062\">",
"      - Histology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13576252\">",
"      Radiographic findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13575781\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ADDITIONAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13576009\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Upper gastrointestinal endoscopy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H82189930\">",
"      - Esophagitis on esophagoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Los Angeles classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H575215834\">",
"      Savary-Miller classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Ambulatory esophageal pH monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Esophageal manometry",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2265\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2265|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?15/48/16142\" title=\"diagnostic image 1\">",
"      Esophageal stricture Ba swallow",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2265|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/44/20167\" title=\"picture 1\">",
"      Histologic findings in GERD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/30/32238\" title=\"picture 2\">",
"      Los Angeles grade A esophagitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/60/16335\" title=\"picture 3\">",
"      Los Angeles grade B esophagitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/1/16415\" title=\"picture 4\">",
"      Los Angeles grade C esophagitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/50/31535\" title=\"picture 5\">",
"      Los Angeles grade D esophagitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2265|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/7/26748\" title=\"table 1\">",
"      Indications for the clinical use of esophageal pH recording",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19253?source=related_link\">",
"      Complications of gastroesophageal reflux in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/8/1161?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of Barrett's esophagus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/19/21814?source=related_link\">",
"      Globus sensation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42840?source=related_link\">",
"      Medical management of gastroesophageal reflux disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/13/37078?source=related_link\">",
"      Medication-induced esophagitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/45/32474?source=related_link\">",
"      Pathogenesis, clinical manifestations, and diagnosis of eosinophilic esophagitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13928?source=related_link\">",
"      Pathophysiology of reflux esophagitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/30/38373?source=related_link\">",
"      Patient information: Acid reflux (gastroesophageal reflux disease) in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/2/24610?source=related_link\">",
"      Patient information: Acid reflux (gastroesophageal reflux disease) in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/0/21506?source=related_link\">",
"      Patient information: Upper endoscopy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/41/33426?source=related_link\">",
"      Patient information: Upper endoscopy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/57/42905?source=related_link\">",
"      Surgical management of gastroesophageal reflux in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17178?source=related_link\">",
"      Wireless video capsule endoscopy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_41_22169="Treatment of marginal zone (MALT) lymphoma";
var content_f21_41_22169=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of marginal zone (MALT) lymphoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/41/22169/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/41/22169/contributors\">",
"     Arnold S Freedman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/41/22169/contributors\">",
"     Jonathan W Friedberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/41/22169/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/41/22169/contributors\">",
"     Andrew Lister, MD, FRCP, FRCPath, FRCR",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/41/22169/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/41/22169/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/41/22169/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Marginal zone lymphoma (MZL) is a subtype of non-Hodgkin lymphoma (NHL) that includes three distinct diseases that have historically been classified together because they appear to arise from post-germinal center marginal zone B cells and share a similar immunophenotype:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Splenic marginal zone B cell lymphoma",
"     </li>",
"     <li>",
"      Extranodal marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) type (MALT-type lymphoma, MALT lymphoma)",
"     </li>",
"     <li>",
"      Nodal marginal zone B cell lymphoma",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic review will discuss the treatment of MZL. The pathogenesis, clinical manifestations, pathologic features, cytogenetics, diagnosis of these disorders is presented separately, as is their potential relationship to autoimmune disorders. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/9/19610?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of extranodal (MALT) and nodal marginal zone lymphomas\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/40/33416?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of splenic marginal zone lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EXTRANODAL MARGINAL ZONE LYMPHOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extranodal MZL, also called low grade B cell lymphoma of mucosa-associated lymphoid tissue (MALT), is an extranodal lymphoma that arises in a number of epithelial tissues, including the stomach, salivary gland, lung, small bowel, and elsewhere. For treatment purposes, extranodal MALT is separated into those developing in the stomach (gastric MALT) and those developing in non-gastric extranodal locations (non-gastric MALT). This distinction is primarily based upon the role of Helicobacter pylori (H pylori) in the development of gastric MALT and the efficacy of H pylori eradication in the treatment of gastric MALT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2634?source=see_link\">",
"     \"Association between Helicobacter pylori infection and gastrointestinal malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Gastric MALT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastric MALT (also called gastric MALToma) accounts for approximately 50 percent of all gastric lymphomas and its development is associated with infection with H pylori resulting in chronic gastritis. Localized disease often responds to therapy aimed at H pylori eradication while those with more advanced disease or those who progress after this initial treatment are often treated with involved field radiotherapy.",
"   </p>",
"   <p>",
"    The treatment of gastric MALT is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/53/3930?source=see_link&amp;anchor=H4#H4\">",
"     \"Management of gastrointestinal lymphomas\", section on 'Gastric MALT lymphoma'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23049?source=see_link\">",
"     \"Treatment regimens for Helicobacter pylori\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Non-gastric MALT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of non-gastric MALT depends principally upon the stage of disease at diagnosis. More than one-third of patients with non-gastric MALT will have advanced disease at the time of diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22169/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. As an example, a series of 140 consecutive patients with MALT lymphoma demonstrated multiorgan involvement in 25 and 46 percent of those patients with gastric and non-gastric MALT, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22169/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Limited stage MALT lymphoma (ie, stage I-II) is generally treated with local therapy or managed expectantly. In comparison, more advanced disease is treated with immunotherapy or chemoimmunotherapy in a similar fashion to the more common indolent lymphoma, follicular lymphoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/40/9865?source=see_link\">",
"     \"Initial treatment of limited stage (I/II) follicular lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Of importance, patients with MALT of any stage who demonstrate coexistent large cell lymphoma are treated as diffuse large B cell lymphoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/45/26330?source=see_link\">",
"     \"Initial treatment of advanced stage diffuse large B cell lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Pretreatment evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pretreatment evaluation of a patient with non-gastric MALT is focused on determining the extent of disease and co-morbidities that may have impact on choice of therapy. In general, we perform the following examinations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Physical examination with determination of the patient's performance status by the Eastern Cooperative Oncology Group (ECOG) or Karnofsky performance scales (",
"      <a class=\"graphic graphic_table graphicRef72901 \" href=\"UTD.htm?9/15/9467\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef58785 \" href=\"UTD.htm?2/11/2236\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Laboratory testing includes a complete blood count with differential and platelet count, chemistries with liver and renal function and electrolytes, and lactate dehydrogenase (LDH). Patients should also be tested for hepatitis B prior to the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      therapy. Women of childbearing age should undergo a pregnancy test if chemotherapy is planned.",
"     </li>",
"     <li>",
"      Imaging should include a contrast-enhanced computed tomography scan of the chest, abdomen, and pelvis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with multifocal disease should have a bone marrow aspiration and biopsy to evaluate for bone marrow involvement. Stage is determined by with the Ann Arbor staging system (",
"    <a class=\"graphic graphic_table graphicRef73699 \" href=\"UTD.htm?36/59/37819\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Limited (stage I-II) disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited stage extranodal MALT includes those patients with involvement of a single extralymphatic site (IE) or a lymph node extending into a contiguous extralymphatic organ or tissue (IIE). Locoregional radiation therapy is the main treatment option for limited stage disease. Surgery is typically used for diagnostic purposes only but may play a role in the treatment of tumors in areas not conducive to radiation therapy (eg, lung). The addition of adjuvant chemotherapy or antibiotic therapy has not demonstrated improved disease-free or overall survival rates. There are occasional patients with stage I disease who are not ideal candidates for radiation therapy and may be initially observed closely.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Radiotherapy &mdash; Locoregional radiotherapy (RT) with 25 to 30 Gy is the principal therapy for most cases of limited stage extranodal MALT. This lymphoma is very sensitive to radiation and doses should not exceed 30 Gy. Because of the risk of the ocular structures to radiation, doses of 25 to 30 Gy are used for ocular MALT with excellent results. With recurrent disease or advanced disease, lower doses may suffice and doses as low as 400 cGy given in two fractions can be effective for palliation.",
"      <br/>",
"      <br/>",
"      With this approach, rates of complete response and local control are in excess of 90 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?21/41/22169/abstract/3-10\">",
"       3-10",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A prospective, multicenter phase II study evaluated the use of RT (median tumor dose of 30.6 Gy) in 37 patients with previously untreated stage IEA non-gastric MALT lymphoma (24 orbital, 4 thyroid, 4 salivary gland, and 5 others) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/41/22169/abstract/3\">",
"       3",
"      </a>",
"      ]. After a median follow-up of 37 months, complete remission or complete",
"      <span class=\"nowrap\">",
"       remission/unconfirmed",
"      </span>",
"      was achieved in 34 patients (92 percent). Three-year overall survival, progression-free survival, and local control rates were 100, 92, and 97 percent, respectively. Therapy was well tolerated. Grade 3 cataract formation was seen in 8 percent.",
"     </li>",
"     <li>",
"      In a retrospective study of 70 patients with stage IE or IIE MALT lymphoma, including some patients with gastric MALT, mostly treated with involved-field RT alone at doses of 25 to 35 Gy reported five-year disease-free (DFS) and overall survival rates of 76 and 96 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?21/41/22169/abstract/4\">",
"       4",
"      </a>",
"      ]. Patients with stomach and thyroid disease had five-year DFS of 93 percent, while DFS for other sites of involvement was 69 percent. Of the five patients treated with surgery alone, two relapsed locally.",
"     </li>",
"     <li>",
"      Another retrospective analysis of 103 patients with stage IE and IIE extranodal MALT lymphoma treated at a single institution reported high complete response (CR) rates (99 percent) for those patients treated with radiation therapy alone at a median dose of 30 Gy [",
"      <a class=\"abstract\" href=\"UTD.htm?21/41/22169/abstract/5\">",
"       5",
"      </a>",
"      ]. Relapses were seen in 17 percent of those who achieved a CR and were most commonly seen in a contralateral paired organ or distant site with a local control rate of 95 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Surgery &mdash; Surgery may be used as initial therapy for early stage MALT in locations not amenable to radiation, although with the low doses of radiation required, nearly all sites can be treated [",
"      <a class=\"abstract\" href=\"UTD.htm?21/41/22169/abstract/4,5,11-16\">",
"       4,5,11-16",
"      </a>",
"      ]. While surgery is not the initial treatment of choice for extranodal MALT, the pathologic diagnosis of MALT may become apparent only after a resection has taken place. If extranodal MALT lymphoma is diagnosed with an excisional biopsy and there is no evidence of residual disease, patients may be followed with close observation. However, if an initial surgical specimen demonstrates positive margins, adjuvant involved field RT is administered to avoid local recurrence.",
"     </li>",
"     <li>",
"      Adjuvant chemotherapy &mdash; While MZL has a high response rate to chemotherapy, the benefit of adjuvant chemotherapy after radiotherapy has yet to be proven [",
"      <a class=\"abstract\" href=\"UTD.htm?21/41/22169/abstract/17,18\">",
"       17,18",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The addition of anthracycline-based chemotherapy to RT in one randomized study of 98 previously untreated patients with stage IE primary orbital MZL did not improve the results obtained following RT alone [",
"      <a class=\"abstract\" href=\"UTD.htm?21/41/22169/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A retrospective study of 38 patients with stage",
"      <span class=\"nowrap\">",
"       III/IV",
"      </span>",
"      nongastric MZL reported that the use of an anthracycline-containing chemotherapy regimen after RT improved the rate of complete remission but not progression-free survival [",
"      <a class=\"abstract\" href=\"UTD.htm?21/41/22169/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Antibiotics &mdash; Unlike in gastric MALT, the benefit of antibiotic therapy for non-gastric MALT is unproven. An association between psittacosis and ocular adnexal marginal zone lymphoma (OAL) has been described, suggesting that Chlamydophila psittaci may be a causative agent [",
"      <a class=\"abstract\" href=\"UTD.htm?21/41/22169/abstract/21,22\">",
"       21,22",
"      </a>",
"      ]. There are conflicting reports of this association across geographic regions and in studies from the same regions [",
"      <a class=\"abstract\" href=\"UTD.htm?21/41/22169/abstract/23,24\">",
"       23,24",
"      </a>",
"      ]. Antibiotics have shown variable efficacy against OAL [",
"      <a class=\"abstract\" href=\"UTD.htm?21/41/22169/abstract/21,25-29\">",
"       21,25-29",
"      </a>",
"      ]. The association between OAL and Chlamydophila psittaci is discussed in more detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/9/19610?source=see_link&amp;anchor=H10#H10\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of extranodal (MALT) and nodal marginal zone lymphomas\", section on 'Chlamydophila (Chlamydia) psittaci'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In a prospective study of 77 patients with non-gastric MALT, evidence for infection with H pylori was present in 45 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?21/41/22169/abstract/30\">",
"       30",
"      </a>",
"      ]. However, in the 16 H pylori-positive patients receiving antibiotic treatment before anti-lymphoma therapy, partial regression of the lymphoma was seen in only one patient (ie, regression of a colonic lesion in a patient with both parotid and colonic disease).",
"     </li>",
"     <li>",
"      In an international phase II trial of 47 patients with stage I ocular adnexal MALT, 39 (89 percent) had detectable Chlamydophila and were treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?21/41/22169/abstract/28\">",
"       28",
"      </a>",
"      ]. Twenty-two patients demonstrated an at least partial response (six complete). At a median follow-up of 37 months, the estimated rate of progression-free survival at five years was 55 percent.",
"     </li>",
"     <li>",
"      The long-term prognosis of these patients is not known, however, and patients considered for antibiotic therapy alone are best treated on specific protocols and require long and careful follow-up care by an experienced",
"      <span class=\"nowrap\">",
"       hematologist/oncologist.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Advanced (stage III-IV) disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Advanced stage extranodal marginal zone lymphoma (MZL) includes those patients with extranodal disease plus multiple sites of nodal involvement (stage III-IV).",
"   </p>",
"   <p>",
"    The treatment of patients with advanced stage non-gastric extranodal MZL is not clearly defined and most data in this population comes from retrospective series or extrapolation of data from other indolent NHL. Until more information is available on outcomes in this patient population, these patients are typically treated in a similar fashion to those with advanced stage follicular lymphoma. Management usually includes immunotherapy with monoclonal antibodies directed at CD20 (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    ) with or without chemotherapy. The treatment of advanced stage follicular lymphoma is presented in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/40/9865?source=see_link\">",
"     \"Initial treatment of limited stage (I/II) follicular lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Support for the use of immunotherapy in extranodal MZL is based upon the extrapolation of a benefit among patients with other lymphomas that express CD20. In addition, an international trial of 227 patients with extranodal MALT (63 percent non-gastric) not responding to or not suitable for local therapy randomly assigned treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    with or without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22169/abstract/31\">",
"     31",
"    </a>",
"    ]. At a median follow-up of 62 months, the addition of rituximab resulted in the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A higher rate of complete remission (78 versus 65 percent) and event-free survival at five years (68 versus 50 percent).",
"     </li>",
"     <li>",
"      A trend toward improved progression-free survival (71 versus 62 percent) that did not reach statistical significance.",
"     </li>",
"     <li>",
"      A similar estimated five-year survival rate (89 percent each).",
"     </li>",
"     <li>",
"      Infusion-related symptoms in 18 percent, the majority of which were mild (grade 1).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    After completion of the planned accrual, a third arm was incorporated to investigate the use of single-agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    ; an analysis of this arm is not yet available. These initial results suggest that the addition of immunotherapy deepens response and improves event-free survival without adding significant toxicity. Rituximab therapy carries a risk of hepatitis B reactivation among patients positive for HBsAg or anti-HBc. The risk of hepatitis B reactivation is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26009?source=see_link\">",
"     \"Hepatitis B virus reactivation associated with immunosuppression\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Response rates are comparable to those observed for extraintestinal NHLs, but the overall prognosis is poor, with five-year and 10-year overall survival rates of approximately 50 and 20 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22169/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Follow up",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long term treatment success with any therapy for MALT is limited. As an example, a study of patients with MALT lymphoma who had achieved complete remission after initial therapy described relapses in 32 of 86 at a median time of 47 months (range: 14 to 307 months), suggesting the need for long-term observation of these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22169/abstract/33\">",
"     33",
"    </a>",
"    ]. When planning the post-treatment surveillance strategy, care should be taken to limit the number of CT scans, particularly in younger individuals, given concerns about radiation exposure and the risk for second malignancies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21785?source=see_link\">",
"     \"Radiation-related risks of imaging studies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Following the completion of therapy, patients are seen at periodic intervals to monitor for treatment complications and assess for possible relapse or progression. The frequency and extent of these visits depend upon the comfort of both the patient and physician. There have been no prospective, randomized trials comparing various schedules of follow-up. We generally follow patients every three to six months for the first two years and then every six to twelve months out to five years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Primary cutaneous marginal zone lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary cutaneous marginal zone lymphoma refers to those cases of MZL that present in the skin when there is no evidence of extracutaneous disease after the completion of an initial staging evaluation. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/9/26776?source=see_link\">",
"     \"Primary cutaneous marginal zone lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SPLENIC MARGINAL ZONE LYMPHOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Splenic MZL is a unique entity that often involves the spleen, splenic hilar lymph nodes, bone marrow, and peripheral blood. Peripheral lymph nodes are not typically involved. The majority of patients with splenic MZL demonstrate an indolent course, with a median overall survival in excess of 10 years. Treatment is directed at those with splenomegaly. The epidemiology, pathogenesis, clinical manifestations, pathologic features, and diagnosis of splenic MZL are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/40/33416?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of splenic marginal zone lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Pretreatment testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pretreatment evaluation of a patient with splenic MZL is focused on determining the extent of disease and co-morbidities that may impact on choice of therapy. In general, we perform the following examinations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Physical examination with determination of the patient's performance status by the Eastern Cooperative Oncology Group (ECOG) or Karnofsky performance scales (",
"      <a class=\"graphic graphic_table graphicRef72901 \" href=\"UTD.htm?9/15/9467\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef58785 \" href=\"UTD.htm?2/11/2236\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Laboratory testing includes a complete blood count with differential and platelet count, chemistries with liver and renal function and electrolytes, lactate dehydrogenase (LDH), serum protein electrophoresis, quantitative immunoglobulin, and serology for hepatitis C. Patients should also be tested for hepatitis B prior to the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      therapy. Women of childbearing age should undergo a pregnancy test if chemotherapy is planned.",
"     </li>",
"     <li>",
"      Unilateral bone marrow biopsy and aspirate.",
"     </li>",
"     <li>",
"      Imaging should include a contrast-enhanced computed tomography scan of the chest, abdomen, and pelvis. The neck should be included if lymph nodes in the neck are palpable on physical examination.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with multifocal disease should have a bone marrow aspiration and biopsy to evaluate for bone marrow involvement. Stage is determined by with the Ann Arbor staging system (",
"    <a class=\"graphic graphic_table graphicRef73699 \" href=\"UTD.htm?36/59/37819\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Indications for therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Not all patients with splenic MZL require immediate treatment since MZL is generally associated with reasonably long survival, measured in years, even if initially untreated [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22169/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. Asymptomatic patients without splenomegaly, anemia, thrombocytopenia, or leukopenia are observed initially. However, a subset of patients with splenic MZL may have a more aggressive course with a five-year cause specific survival rate of approximately 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22169/abstract/36\">",
"     36",
"    </a>",
"    ]. Factors associated with a worse outcome include anemia, hypoalbuminemia, an elevated lactate dehydrogenase, older age, and a high International Prognostic Index (IPI) score.",
"   </p>",
"   <p>",
"    Patients with splenomegaly and one of the following signs, symptoms, or comorbidities are considered for therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Local symptoms related to splenomegaly (eg, a sense of fullness or discomfort in the left upper quadrant, pain referred to the left shoulder, or early satiety)",
"     </li>",
"     <li>",
"      Cytopenias due to extensive bone marrow infiltration, autoimmune hemolytic anemia or thrombocytopenia, or hypersplenism",
"     </li>",
"     <li>",
"      Patients with coexisting hepatitis C infection may benefit from treatment of hepatitis C",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Initial treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial treatment of patients with splenic MZL and splenomegaly is principally determined by whether or not the patient has a coexisting hepatitis C infection. Those with hepatitis C may be considered for anti-viral therapy while those without hepatitis C may benefit from treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    . Splenectomy may be considered for those patients with isolated splenic MZL or with minimal bone marrow involvement. There have been no prospective trials comparing these approaches in patients with splenic MZL. A choice for an individual patient is largely made based upon the anticipated side effects and risks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Splenectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Splenectomy may be offered to patients with isolated splenic MZL plus splenomegaly with localized symptoms such as abdominal pain, early satiety, or weight loss. Patients who otherwise meet these criteria but also demonstrate minimal bone marrow involvement are sometimes considered for splenectomy as well. Large retrospective studies have reported improvement of cytopenias and relief of localized symptoms sustained for more than five years with splenectomy alone [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22169/abstract/37-43\">",
"     37-43",
"    </a>",
"    ]. In addition, some but not all of these retrospective studies suggested improvements in overall survival for those treated with splenectomy when compared with those treated with non-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    containing chemotherapy. There have been a few case series reporting improvements in patient symptoms with splenic irradiation in those who are not candidates for splenectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22169/abstract/44-46\">",
"     44-46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Rituximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment with single agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    can result in a reduction of splenomegaly and normalization of absolute lymphocyte counts in more than 90 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22169/abstract/47-49\">",
"     47-49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A single institution retrospective analysis of 70 patients with splenic MZL, 43 of whom underwent treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    alone (26 patients), chemotherapy alone (11 patients), or rituximab plus chemotherapy (6 patients), reported excellent outcomes in patients treated with single agent rituximab [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22169/abstract/47\">",
"     47",
"    </a>",
"    ]. When compared with those who received chemotherapy alone, patients who received single agent rituximab had superior rates of overall response (88 versus 55 percent), three year survival (86 versus 45 percent), and three-year, failure-free survival (86 versus 45 percent). Outcomes in patients who received both rituximab and chemotherapy were similar to those seen for patients who received rituximab alone. Although this retrospective, uncontrolled study provides exciting initial data on the use of rituximab in this population, caution must be used in comparing treatment options based upon data generated in a nonrandomized fashion.",
"   </p>",
"   <p>",
"    In another retrospective analysis, 85 cases of symptomatic splenic MZL were followed for a median of three years [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22169/abstract/48\">",
"     48",
"    </a>",
"    ]. Of these, 58 patients were treated with single agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    (375",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per week for six weeks followed by 375",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    every two months for one to two years), while 27 patients underwent splenectomy alone. Rituximab was associated with an overall response rate of 95 percent (71 percent complete) with a median time to clinical response of three weeks. Estimated rates of overall and progression-free survival at five years were 92 and 73 percent, respectively. Splenectomy resulted in an overall response rate of 85 percent with estimated progression-free and overall survival at five years of 58 and 77 percent, respectively.",
"   </p>",
"   <p>",
"    The major toxicities of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    include infusion reactions (ie, fevers, rigors, and hypotension) and infections related to immunosuppression. Rituximab also imposes a risk of hepatitis B reactivation among patients positive for hepatitis B surface antigen (HBsAg) or antibodies against hepatitis B core antigen (anti-HBc). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/19/38202?source=see_link&amp;anchor=H19#H19\">",
"     \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\", section on 'Rituximab'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/0/29706?source=see_link&amp;anchor=H24#H24\">",
"     \"Secondary immune deficiency induced by drugs and biologics\", section on 'Rituximab'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26009?source=see_link\">",
"     \"Hepatitis B virus reactivation associated with immunosuppression\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Antiviral therapy for hepatitis C",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of reports, primarily from Europe, have indicated that treatment of a coexisting hepatitis C virus infection (HCV) with interferon and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    has resulted in complete clinical remissions in some patients with indolent lymphoma, including marginal zone lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22169/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One study evaluated the effect of treatment with interferon alpha, alone or in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    , in 18 patients with splenic MZL, coexisting hepatitis C virus (HCV) infection, and mixed cryoglobulinemia [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22169/abstract/51\">",
"     51",
"    </a>",
"    ]. Hematologic and virologic responses were correlated, in that all 14 patients (78 percent) who cleared HCV RNA had a sustained hematologic response. Monoclonal immunoglobulin gene rearrangement persisted after treatment regardless of response. Interferon was without effect in six patients with splenic MZL who were not infected with HCV [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22169/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar treatment results have been noted in other reviews [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22169/abstract/53\">",
"     53",
"    </a>",
"    ], and in a series of 13 patients with HCV infection and various forms of indolent lymphoma, including follicular, plasmacytoid, as well as marginal zone lymphomas of the splenic, nodal, and extranodal types [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22169/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An initial trial of treatment directed at the hepatitis C virus infection may be indicated for patients who are asymptomatic from their lymphoma and would otherwise not require the initiation of chemotherapy directed at their lymphoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15498?source=see_link&amp;anchor=H5#H5\">",
"     \"Extrahepatic manifestations of hepatitis C virus infection\", section on 'Lymphoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Monitoring for relapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following the completion of therapy, patients are seen at periodic intervals to monitor for treatment complications and assess for possible relapse. The frequency and extent of these visits depends upon the comfort of both the patient and physician. There have been no prospective, randomized trials comparing various schedules of follow-up. When planning the post-treatment surveillance strategy, care should be taken to limit the number of CT scans, particularly in younger individuals, given concerns about radiation exposure and the risk for second malignancies. We generally follow patients every three months for the first year and then every three to six months. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21785?source=see_link\">",
"     \"Radiation-related risks of imaging studies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with disease progression after initial therapy are candidates for therapy similar to that of follicular lymphoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/40/9865?source=see_link\">",
"     \"Initial treatment of limited stage (I/II) follicular lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/10/7338?source=see_link\">",
"     \"Treatment of relapsed or refractory follicular lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     NODAL MARGINAL ZONE LYMPHOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nodal MZL is a primary nodal lymphoma with features identical to lymph nodes involved by extranodal (MALT) lymphoma, but without evidence of extranodal disease. It accounts for approximately 10 percent of patients with MZL.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Initial evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pretreatment evaluation of a patient with nodal MZL is focused on determining the extent of disease and co-morbidities that may impact on choice of therapy. In addition, specific site-related evaluations are used to rule out an extranodal primary site that has spread to the lymph nodes. In general, we perform the following examinations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Physical examination with determination of the patient's performance status by the Eastern Cooperative Oncology Group (ECOG) or Karnofsky performance scales (",
"      <a class=\"graphic graphic_table graphicRef72901 \" href=\"UTD.htm?9/15/9467\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef58785 \" href=\"UTD.htm?2/11/2236\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Laboratory testing includes a complete blood count with differential and platelet count, chemistries with liver and renal function and electrolytes, lactate dehydrogenase (LDH), and hepatitis C serology. Patients should also be tested for hepatitis B prior to the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      therapy. Women of childbearing age should undergo a pregnancy test if chemotherapy is planned.",
"     </li>",
"     <li>",
"      Imaging should include a contrast-enhanced computed tomography scan of the chest, abdomen, and pelvis. The neck should be included if lymph nodes in the neck are palpable on physical examination.",
"     </li>",
"     <li>",
"      Stage is determined by with the Ann Arbor staging system (",
"      <a class=\"graphic graphic_table graphicRef73699 \" href=\"UTD.htm?36/59/37819\">",
"       table 3",
"      </a>",
"      ). If clinical stage I or II disease is suspected, a bone marrow aspiration and biopsy should be performed to confirm limited disease.",
"     </li>",
"     <li>",
"      A directed evaluation of extranodal sites based upon lymph node involvement should be performed to exclude extranodal disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no general consensus regarding the treatment of patients with nodal MZL and patients should be encouraged to participate in trials whenever possible. Most of the data on the treatment of nodal MZL comes from retrospective studies and extrapolation of data from other common indolent lymphomas, such as follicular lymphoma. Many of the initial trials that evaluated alkylator-based therapy for indolent lymphomas included some patients with MZL. Complete response rates with single agent or combination therapy with alkylating agents (eg, CHOP) have ranged from 30 to 60 percent. Despite combination chemotherapy, the median time to progression of nodal MZL is approximately one year [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22169/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A few studies have reporting the outcomes of patients with MZL:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A phase II trial of concurrent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      in 26 patients with previously untreated (81 percent) or relapsed MZL reported an overall response rate of 85 percent (54 percent complete), but an accompanying toxic death rate of 15 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?21/41/22169/abstract/55\">",
"       55",
"      </a>",
"      ]. The most common severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      toxicities included neutropenia (57 percent) and thrombocytopenia (27 percent). While febrile neutropenia occurred in only 8 percent of patients, a delayed neutropenia several months after completion of therapy was seen resulting in two infectious deaths.",
"     </li>",
"     <li>",
"      A retrospective study of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19815?source=see_link\">",
"       cladribine",
"      </a>",
"      (2CdA) with or without",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      in 89 patients with advanced stage MZL (28 nodal MZL) reported an overall response rate of 89 percent (54 percent complete) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/41/22169/abstract/56\">",
"       56",
"      </a>",
"      ]. Patients who received 2CdA plus rituximab had an overall response rate of 97 percent (60 percent complete). The most frequent side effects were infusion-related reactions to rituximab.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with MZL have also been included in studies of alkylating agent-based regimens such as R-CHOP (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    ), R-CVP (cyclophosphamide, vincristine, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    plus rituximab), and the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/20/32071?source=see_link\">",
"     bendamustine",
"    </a>",
"    plus rituximab. Until more data are available from trials limited to patients with MZL, patients with nodal MZL not on a clinical trial are often treated in a similar fashion to those with the more common indolent lymphoma follicular lymphoma. The treatment of follicular lymphomas is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/40/9865?source=see_link\">",
"     \"Initial treatment of limited stage (I/II) follicular lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/10/7338?source=see_link\">",
"     \"Treatment of relapsed or refractory follicular lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     HISTOLOGIC TRANSFORMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;An integral part of the natural history of all indolent NHL, including MZL, is progression to a higher grade histologic subtype, such as diffuse large B cell lymphoma. As is detailed separately, a subgroup of patients with MZL who transform to a more aggressive histology may attain complete remission following treatment with aggressive chemotherapy and some may be cured by high dose chemotherapy followed by autologous hematopoietic cell transplantation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/19/5433?source=see_link\">",
"     \"Pathobiology and treatment of histologic transformation in the indolent non-Hodgkin lymphomas\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/49/12058?source=see_link&amp;anchor=H179016843#H179016843\">",
"     \"Hematopoietic cell transplantation in follicular lymphoma\", section on 'Following histologic transformation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12764592\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Marginal zone lymphoma (MZL) is a subtype of non-Hodgkin lymphoma (NHL) that includes three distinct diseases that have historically been classified together because they appear to arise from post-germinal center marginal zone B cells and share a similar immunophenotype:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Extranodal MZL (also called MALT lymphoma) arises in a number of epithelial tissues, including the stomach, salivary gland, lung, small bowel, and elsewhere. For treatment purposes, extranodal MZL is separated into those developing in the stomach (gastric MALT) and those developing in non-gastric extranodal locations (non-gastric MALT). Of importance, patients with MALT of any stage who demonstrate coexistent large cell lymphoma are treated as diffuse large B cell lymphoma. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/45/26330?source=see_link\">",
"       \"Initial treatment of advanced stage diffuse large B cell lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Gastric MALT often responds to therapy aimed at H pylori eradication while those with more advanced disease or those who progress after this initial treatment are often treated with involved field radiotherapy (RT). H. pylori negative gastric MALT should be treated with radiation therapy without a trial of antibiotics. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/53/3930?source=see_link&amp;anchor=H4#H4\">",
"       \"Management of gastrointestinal lymphomas\", section on 'Gastric MALT lymphoma'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23049?source=see_link\">",
"       \"Treatment regimens for Helicobacter pylori\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For most patients with limited stage non-gastric MALT lymphoma (ie, stage I or II), we suggest treatment with locoregional RT rather than other treatment modalities (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Alternatively, a subset of patients with stage I disease may be observed initially with plans to initiate RT at the time of disease progression. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Limited (stage I-II) disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most patients with more advanced stage non-gastric MALT lymphoma, we suggest treatment with immunotherapy or chemoimmunotherapy in a similar fashion to that used for the more common indolent lymphoma, follicular lymphoma (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Advanced (stage III-IV) disease'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/40/9865?source=see_link\">",
"       \"Initial treatment of limited stage (I/II) follicular lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Splenic MZL is a unique entity that often involves the spleen, splenic hilar lymph nodes, bone marrow, and peripheral blood. Peripheral lymph nodes are not typically involved. The majority of patients with splenic MZL demonstrate an indolent course, with a median overall survival in excess of 10 years. Treatment is directed at those with splenomegaly and symptoms.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For asymptomatic patients with splenic MZL without splenomegaly, anemia, thrombocytopenia, or leukopenia, we suggest observation rather than initial treatment (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Therapy is considered for patients with splenomegaly who also demonstrate local symptoms related to the splenomegaly, concomitant cytopenias, or for those with coexisting hepatitis C infection. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Indications for therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with isolated splenic MZL and local symptoms related to the splenomegaly or those with minimal bone marrow involvement, treatment options include splenectomy or a trial of single agent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      . Either of these options is reasonable for the majority of patients and a choice for an individual patient is largely made based upon the anticipated side effects and risks. Rituximab may be preferred in patients without coexisting hepatitis who wish to avoid surgery. In contrast, splenectomy may be preferred in patients who desire more rapid relief of symptoms due to splenomegaly or those with coexisting hepatitis infection. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Splenectomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with splenic MZL and cytopenias who do not have concomitant hepatitis C, we suggest treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      rather than splenectomy or observation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Rituximab'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with splenic MZL and coexisting hepatitis C infection, we suggest treatment with anti-viral therapy rather than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      , splenectomy, or observation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Antiviral therapy for hepatitis C'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nodal MZL is a primary nodal lymphoma with features identical to lymph nodes involved by extranodal (MALT) lymphoma, but without evidence of extranodal disease. There is no general consensus regarding the treatment of patients with nodal MZL and patients should be encouraged to participate in trials whenever possible. Until more data are available from trials limited to patients with MZL, patients with nodal MZL not on a clinical trial are often treated in a similar fashion to those with the more common indolent lymphoma, follicular lymphoma. The treatment of follicular lymphoma is discussed in more detail separately. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Treatment'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/40/9865?source=see_link\">",
"       \"Initial treatment of limited stage (I/II) follicular lymphoma\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/10/7338?source=see_link\">",
"       \"Treatment of relapsed or refractory follicular lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22169/abstract/1\">",
"      Sretenovic M, Colovic M, Jankovic G, et al. More than a third of non-gastric malt lymphomas are disseminated at diagnosis: a single center survey. Eur J Haematol 2009; 82:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22169/abstract/2\">",
"      Raderer M, W&ouml;hrer S, Streubel B, et al. Assessment of disease dissemination in gastric compared with extragastric mucosa-associated lymphoid tissue lymphoma using extensive staging: a single-center experience. J Clin Oncol 2006; 24:3136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22169/abstract/3\">",
"      Isobe K, Kagami Y, Higuchi K, et al. A multicenter phase II study of local radiation therapy for stage IEA mucosa-associated lymphoid tissue lymphomas: a preliminary report from the Japan Radiation Oncology Group (JAROG). Int J Radiat Oncol Biol Phys 2007; 69:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22169/abstract/4\">",
"      Tsang RW, Gospodarowicz MK, Pintilie M, et al. Stage I and II MALT lymphoma: results of treatment with radiotherapy. Int J Radiat Oncol Biol Phys 2001; 50:1258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22169/abstract/5\">",
"      Tsang RW, Gospodarowicz MK, Pintilie M, et al. Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome. J Clin Oncol 2003; 21:4157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22169/abstract/6\">",
"      Son SH, Choi BO, Kim GW, et al. Primary radiation therapy in patients with localized orbital marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT Lymphoma). Int J Radiat Oncol Biol Phys 2010; 77:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22169/abstract/7\">",
"      Goda JS, Gospodarowicz M, Pintilie M, et al. Long-term outcome in localized extranodal mucosa-associated lymphoid tissue lymphomas treated with radiotherapy. Cancer 2010; 116:3815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22169/abstract/8\">",
"      Goda JS, Le LW, Lapperriere NJ, et al. Localized orbital mucosa-associated lymphoma tissue lymphoma managed with primary radiation therapy: efficacy and toxicity. Int J Radiat Oncol Biol Phys 2011; 81:e659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22169/abstract/9\">",
"      Anacak Y, Miller RC, Constantinou N, et al. Primary mucosa-associated lymphoid tissue lymphoma of the salivary glands: a multicenter Rare Cancer Network study. Int J Radiat Oncol Biol Phys 2012; 82:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22169/abstract/10\">",
"      Hashimoto N, Sasaki R, Nishimura H, et al. Long-term outcome and patterns of failure in primary ocular adnexal mucosa-associated lymphoid tissue lymphoma treated with radiotherapy. Int J Radiat Oncol Biol Phys 2012; 82:1509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22169/abstract/11\">",
"      Fung CY, Tarbell NJ, Lucarelli MJ, et al. Ocular adnexal lymphoma: clinical behavior of distinct World Health Organization classification subtypes. Int J Radiat Oncol Biol Phys 2003; 57:1382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22169/abstract/12\">",
"      Hitchcock S, Ng AK, Fisher DC, et al. Treatment outcome of mucosa-associated lymphoid tissue/marginal zone non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys 2002; 52:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22169/abstract/13\">",
"      Uno T, Isobe K, Shikama N, et al. Radiotherapy for extranodal, marginal zone, B-cell lymphoma of mucosa-associated lymphoid tissue originating in the ocular adnexa: a multiinstitutional, retrospective review of 50 patients. Cancer 2003; 98:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22169/abstract/14\">",
"      Hasegawa M, Kojima M, Shioya M, et al. Treatment results of radiotherapy for malignant lymphoma of the orbit and histopathologic review according to the WHO classification. Int J Radiat Oncol Biol Phys 2003; 57:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22169/abstract/15\">",
"      Suh CO, Shim SJ, Lee SW, et al. Orbital marginal zone B-cell lymphoma of MALT: radiotherapy results and clinical behavior. Int J Radiat Oncol Biol Phys 2006; 65:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22169/abstract/16\">",
"      Decaudin D, de Cremoux P, Vincent-Salomon A, et al. Ocular adnexal lymphoma: a review of clinicopathologic features and treatment options. Blood 2006; 108:1451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22169/abstract/17\">",
"      Thieblemont C, Berger F, Dumontet C, et al. Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. Blood 2000; 95:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22169/abstract/18\">",
"      Zinzani PL, Stefoni V, Musuraca G, et al. Fludarabine-containing chemotherapy as frontline treatment of nongastrointestinal mucosa-associated lymphoid tissue lymphoma. Cancer 2004; 100:2190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22169/abstract/19\">",
"      Avil&eacute;s A, Neri N, Calva A, et al. Addition of a short course of chemotherapy did not improve outcome in patients with localized marginal B-cell lymphoma of the orbit. Oncology 2006; 70:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22169/abstract/20\">",
"      Oh SY, Ryoo BY, Kim WS, et al. Nongastric marginal zone B-cell lymphoma: analysis of 247 cases. Am J Hematol 2007; 82:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22169/abstract/21\">",
"      Husain A, Roberts D, Pro B, et al. Meta-analyses of the association between Chlamydia psittaci and ocular adnexal lymphoma and the response of ocular adnexal lymphoma to antibiotics. Cancer 2007; 110:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22169/abstract/22\">",
"      Ferreri AJ, Dolcetti R, Dognini GP, et al. Chlamydophila psittaci is viable and infectious in the conjunctiva and peripheral blood of patients with ocular adnexal lymphoma: results of a single-center prospective case-control study. Int J Cancer 2008; 123:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22169/abstract/23\">",
"      Chanudet E, Adam P, Nicholson AG, et al. Chlamydiae and Mycoplasma infections in pulmonary MALT lymphoma. Br J Cancer 2007; 97:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22169/abstract/24\">",
"      Matthews JM, Moreno LI, Dennis J, et al. Ocular Adnexal Lymphoma: no evidence for bacterial DNA associated with lymphoma pathogenesis. Br J Haematol 2008; 142:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22169/abstract/25\">",
"      Ferreri AJ, Ponzoni M, Guidoboni M, et al. Regression of ocular adnexal lymphoma after Chlamydia psittaci-eradicating antibiotic therapy. J Clin Oncol 2005; 23:5067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22169/abstract/26\">",
"      Ferreri AJ, Ponzoni M, Guidoboni M, et al. Bacteria-eradicating therapy with doxycycline in ocular adnexal MALT lymphoma: a multicenter prospective trial. J Natl Cancer Inst 2006; 98:1375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22169/abstract/27\">",
"      Govi S, Dognini GP, Licata G, et al. Six-month oral clarithromycin regimen is safe and active in extranodal marginal zone B-cell lymphomas: final results of a single-centre phase II trial. Br J Haematol 2010; 150:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22169/abstract/28\">",
"      Ferreri AJ, Govi S, Pasini E, et al. Chlamydophila psittaci eradication with doxycycline as first-line targeted therapy for ocular adnexae lymphoma: final results of an international phase II trial. J Clin Oncol 2012; 30:2988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22169/abstract/29\">",
"      Ferreri AJ, Guidoboni M, Ponzoni M, et al. Evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas. J Natl Cancer Inst 2004; 96:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22169/abstract/30\">",
"      Gr&uuml;nberger B, W&ouml;hrer S, Streubel B, et al. Antibiotic treatment is not effective in patients infected with Helicobacter pylori suffering from extragastric MALT lymphoma. J Clin Oncol 2006; 24:1370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22169/abstract/31\">",
"      Zucca E, Conconi A, Laszlo D, et al. Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized Study. J Clin Oncol 2013; 31:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22169/abstract/32\">",
"      Fisher RI, Dahlberg S, Nathwani BN, et al. A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group study. Blood 1995; 85:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22169/abstract/33\">",
"      Raderer M, Streubel B, Woehrer S, et al. High relapse rate in patients with MALT lymphoma warrants lifelong follow-up. Clin Cancer Res 2005; 11:3349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22169/abstract/34\">",
"      Portlock CS, Rosenberg SA. No initial therapy for stage III and IV non-Hodgkin's lymphomas of favorable histologic types. Ann Intern Med 1979; 90:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22169/abstract/35\">",
"      Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med 1984; 311:1471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22169/abstract/36\">",
"      Arcaini L, Lazzarino M, Colombo N, et al. Splenic marginal zone lymphoma: a prognostic model for clinical use. Blood 2006; 107:4643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22169/abstract/37\">",
"      Berger F, Felman P, Thieblemont C, et al. Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients. Blood 2000; 95:1950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22169/abstract/38\">",
"      Catovsky D, Matutes E. Splenic lymphoma with circulating villous lymphocytes/splenic marginal-zone lymphoma. Semin Hematol 1999; 36:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22169/abstract/39\">",
"      Franco V, Florena AM, Iannitto E. Splenic marginal zone lymphoma. Blood 2003; 101:2464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22169/abstract/40\">",
"      Parry-Jones N, Matutes E, Gruszka-Westwood AM, et al. Prognostic features of splenic lymphoma with villous lymphocytes: a report on 129 patients. Br J Haematol 2003; 120:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22169/abstract/41\">",
"      Iannitto E, Ambrosetti A, Ammatuna E, et al. Splenic marginal zone lymphoma with or without villous lymphocytes. Hematologic findings and outcomes in a series of 57 patients. Cancer 2004; 101:2050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22169/abstract/42\">",
"      Thieblemont C, Felman P, Callet-Bauchu E, et al. Splenic marginal-zone lymphoma: a distinct clinical and pathological entity. Lancet Oncol 2003; 4:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22169/abstract/43\">",
"      Olszewski AJ. Survival outcomes with and without splenectomy in splenic marginal zone lymphoma. Am J Hematol 2012; 87:E119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22169/abstract/44\">",
"      El Weshi A, Ribrag V, Girinski T, et al. Low and medium dose spleen radiation therapy are able to induce long-term responses in splenic lymphoma with villous lymphocytes. Br J Haematol 1998; 103:1212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22169/abstract/45\">",
"      Mulligan SP, Matutes E, Dearden C, Catovsky D. Splenic lymphoma with villous lymphocytes: natural history and response to therapy in 50 cases. Br J Haematol 1991; 78:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22169/abstract/46\">",
"      Troussard X, Valensi F, Duchayne E, et al. Splenic lymphoma with villous lymphocytes: clinical presentation, biology and prognostic factors in a series of 100 patients. Groupe Francais d'H&eacute;matologie Cellulaire (GFHC). Br J Haematol 1996; 93:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22169/abstract/47\">",
"      Tsimberidou AM, Catovsky D, Schlette E, et al. Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone. Cancer 2006; 107:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22169/abstract/48\">",
"      Kalpadakis C, Pangalis GA, Angelopoulou MK, et al. Treatment of splenic marginal zone lymphoma with rituximab monotherapy: progress report and comparison with splenectomy. Oncologist 2013; 18:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22169/abstract/49\">",
"      Else M, Mar&iacute;n-Niebla A, de la Cruz F, et al. Rituximab, used alone or in combination, is superior to other treatment modalities in splenic marginal zone lymphoma. Br J Haematol 2012; 159:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22169/abstract/50\">",
"      Suarez F, Lortholary O, Hermine O, Lecuit M. Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation. Blood 2006; 107:3034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22169/abstract/51\">",
"      Saadoun D, Suarez F, Lefrere F, et al. Splenic lymphoma with villous lymphocytes, associated with type II cryoglobulinemia and HCV infection: a new entity? Blood 2005; 105:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22169/abstract/52\">",
"      Hermine O, Lefr&egrave;re F, Bronowicki JP, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 2002; 347:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22169/abstract/53\">",
"      Gisbert JP, Garc&iacute;a-Buey L, Pajares JM, Moreno-Otero R. Systematic review: regression of lymphoproliferative disorders after treatment for hepatitis C infection. Aliment Pharmacol Ther 2005; 21:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22169/abstract/54\">",
"      Vallisa D, Bernuzzi P, Arcaini L, et al. Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin's lymphoma: a multicenter Italian experience. J Clin Oncol 2005; 23:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22169/abstract/55\">",
"      Brown JR, Friedberg JW, Feng Y, et al. A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas. Br J Haematol 2009; 145:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22169/abstract/56\">",
"      Orciuolo E, Buda G, Sordi E, et al. 2CdA chemotherapy and rituximab in the treatment of marginal zone lymphoma. Leuk Res 2010; 34:184.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4710 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-FB51BAF4EE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_41_22169=[""].join("\n");
var outline_f21_41_22169=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12764592\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EXTRANODAL MARGINAL ZONE LYMPHOMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Gastric MALT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Non-gastric MALT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Pretreatment evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Limited (stage I-II) disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Advanced (stage III-IV) disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Follow up",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Primary cutaneous marginal zone lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SPLENIC MARGINAL ZONE LYMPHOMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Pretreatment testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Indications for therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Initial treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Splenectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Rituximab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Antiviral therapy for hepatitis C",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Monitoring for relapse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      NODAL MARGINAL ZONE LYMPHOMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Initial evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      HISTOLOGIC TRANSFORMATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12764592\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4710\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4710|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/15/9467\" title=\"table 1\">",
"      ECOG performance scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/11/2236\" title=\"table 2\">",
"      Karnofsky performance status scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/59/37819\" title=\"table 3\">",
"      Ann Arbor system in lymphoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2634?source=related_link\">",
"      Association between Helicobacter pylori infection and gastrointestinal malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/9/19610?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of extranodal (MALT) and nodal marginal zone lymphomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/40/33416?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of splenic marginal zone lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15498?source=related_link\">",
"      Extrahepatic manifestations of hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/49/12058?source=related_link\">",
"      Hematopoietic cell transplantation in follicular lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26009?source=related_link\">",
"      Hepatitis B virus reactivation associated with immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/19/38202?source=related_link\">",
"      Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/45/26330?source=related_link\">",
"      Initial treatment of advanced stage diffuse large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/40/9865?source=related_link\">",
"      Initial treatment of limited stage (I/II) follicular lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/53/3930?source=related_link\">",
"      Management of gastrointestinal lymphomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/19/5433?source=related_link\">",
"      Pathobiology and treatment of histologic transformation in the indolent non-Hodgkin lymphomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/9/26776?source=related_link\">",
"      Primary cutaneous marginal zone lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21785?source=related_link\">",
"      Radiation-related risks of imaging studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/0/29706?source=related_link\">",
"      Secondary immune deficiency induced by drugs and biologics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/10/7338?source=related_link\">",
"      Treatment of relapsed or refractory follicular lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23049?source=related_link\">",
"      Treatment regimens for Helicobacter pylori",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_41_22170="Sonographic findings associated with fetal aneuploidy";
var content_f21_41_22170=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Sonographic findings associated with fetal aneuploidy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/41/22170/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/41/22170/contributors\">",
"     Beryl R Benacerraf, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/41/22170/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/41/22170/contributors\">",
"     Louise Wilkins-Haug, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/41/22170/contributors\">",
"     Deborah Levine, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/41/22170/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/41/22170/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/41/22170/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 20, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two types of fetal chromosomal abnormalities identifiable by karyotype:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Aneuploidy, which is an abnormal number of chromosomes",
"     </li>",
"     <li>",
"      Aberrations of chromosome structure, such as deletions, rings, translocations, and duplications",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Aneuploidy is the most common genetic abnormality detected by prenatal diagnosis. Of the 6006 fetal karyotypes obtained at one center, 151 of the 207 abnormalities (73 percent) were aneuploidies (trisomy, triploidy, monosomy), and about 90 percent of these involved chromosomes 21, 18, 13, X, or Y",
"    <span class=\"nowrap\">",
"     (135/207",
"    </span>",
"    or 65 percent of all karyotypic abnormalities) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/1\">",
"     1",
"    </a>",
"    ]. Fetal chromosomal abnormalities are more common in the first and second trimesters than in live born infants, due to the high rate of spontaneous loss of these fetuses over the course of pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Termination of affected pregnancies also plays a role.",
"   </p>",
"   <p>",
"    The antepartum detection of fetal aneuploidy is one of the major goals of prenatal screening programs. Sonographic examination is useful because fetuses with abnormal karyotypes often have anatomic changes or anomalies. Sonographic findings, maternal serum analyte markers, and parental risk factors for genetic disease are all considered in determining the risk that the fetus is affected. However, invasive testing (amniocentesis or chorionic villus biopsy) is required to obtain a definitive karyotypic diagnosis.",
"   </p>",
"   <p>",
"    Sonographic findings associated with fetal aneuploidy will be discussed here. A detailed discussion of first and second trimester maternal screening for Down syndrome and trisomy 18, with and without sonography, are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/22/7529?source=see_link\">",
"     \"First trimester combined test and integrated tests for screening for Down syndrome and trisomy 18\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/29/1493?source=see_link\">",
"     \"Second trimester maternal serum screening for Down syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ULTRASOUND MARKERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Soft markers are ultrasound findings of uncertain significance [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. They are often associated with normal fetuses (ie, normal variants), usually have no clinical sequelae, and are transient, resolving with advancing gestation or after birth. They do carry an increased risk for fetal aneuploidy, however, and correlation with the patient's biochemical risk status should be done. These markers include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Increased nuchal translucency",
"     </li>",
"     <li>",
"      Absent nasal bone",
"     </li>",
"     <li>",
"      Echogenic bowel",
"     </li>",
"     <li>",
"      Pyelectasis",
"     </li>",
"     <li>",
"      Shortened long bones (humerus, femur)",
"     </li>",
"     <li>",
"      Echogenic intracardiac focus",
"     </li>",
"     <li>",
"      Choroid plexus cysts",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Isolated soft markers are identified in 11 to 17 percent of normal fetuses [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/6\">",
"     6",
"    </a>",
"    ]. The prevalence is higher in aneuploid fetuses and the likelihood of aneuploidy is significantly increased when more than one marker is present [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/6-9\">",
"     6-9",
"    </a>",
"    ]. Even in this setting, use of soft markers for screening for, or excluding, fetal aneuploidy is inefficient; however, a detailed evaluation of fetal anatomy should be performed whenever one or more soft markers has been identified.",
"   </p>",
"   <p>",
"    Screening for soft markers is not a component of a basic obstetrical ultrasound examination. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36824?source=see_link\">",
"     \"Ultrasound examination in obstetrics and gynecology\"",
"    </a>",
"    .) Detection and reporting of soft markers (ie, echogenic intracardiac focus and choroid plexus cysts) is controversial because this information is anxiety-provoking for patients, requires considerable time for counseling, and may lead to invasive prenatal testing. Such testing may result in procedure-related loss of a normal fetus, and is costly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Increased nuchal translucency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation of nuchal translucency is the most reliable and widely used sonographic marker of trisomy 21. Determination of fetal nuchal translucency between 10 and 14 weeks of gestation combined with maternal analyte testing is an excellent screening test for detecting trisomy 21. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/22/7529?source=see_link\">",
"     \"First trimester combined test and integrated tests for screening for Down syndrome and trisomy 18\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nuchal translucency is the translucent nuchal space at the posterior fetal neck observed sonographically in the midsagittal plane (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef62637 \" href=\"UTD.htm?4/11/4274\">",
"     image 1",
"    </a>",
"    ). An increase in the nuchal translucency measurement is associated with an increased risk of fetal aneuploidy, structural anomalies, genetic syndromes, and adverse outcome. The risk increases as nuchal translucency increases. A detailed discussion can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/50/2857?source=see_link\">",
"     \"First trimester cystic hygroma and increased nuchal translucency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Nuchal fold",
"    </span>",
"    &nbsp;&mdash;&nbsp;The nuchal fold, rather than nuchal translucency, is measured in the second trimester. The nuchal fold is the measurement between the outer edge of the occipital bone to the outer margin of the skin and is taken in the axial plane. An increase in this measurement is also associated with aneuploidy. An increased nuchal fold is detected in 20 to 33 percent of fetuses with Down syndrome and 0.5 to 2 percent of euploid fetuses [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Trisomy 21 (Down syndrome)'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Absent nasal bone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with trisomy 21 often have short nasal root depth [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/11\">",
"     11",
"    </a>",
"    ]. Based on this observation, absence of visualization of the fetal nasal bone ossification has been investigated as a possible fetal marker of Down syndrome (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef59173 graphicRef51069 \" href=\"UTD.htm?1/55/1911\">",
"     image 2A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/12-15\">",
"     12-15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When the fetal profile is viewed in the midsagittal plane, the nasal bone synostosis appears as a thin echogenic line within the bridge of the nose. The nasal bone is considered present if this line is more echogenic than the overlying skin, and absent if it is not visualized, or less echogenic, than the overlying skin [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/16\">",
"     16",
"    </a>",
"    ]. The optimum time for nasal bone assessment is at crown rump length of 65 to 74 mm (13 to 13.5 weeks of gestation) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/17\">",
"     17",
"    </a>",
"    ]. Absent nasal bone ossification earlier in gestation could reflect delayed maturation in a euploid fetus, rather than actual absence of the structure.",
"   </p>",
"   <p>",
"    The utility of this marker varies among studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A review of over 35,000 nasal bone examinations from nine studies including women at varying risk of Down syndrome noted successful examination was possible in 94.3 percent (range 76 to 100 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/18\">",
"       18",
"      </a>",
"      ]. An absent nasal bone was noted in 65 percent (range 0 to 80 percent) of fetuses with trisomy 21, but only 0.8 percent (range 0.3 to 2.5 percent) of chromosomally normal fetuses.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A number of factors could explain the wide range of results. The training and experience of the examiner are critical and varied among studies. Performance of 40 to 120 supervised scans is needed to achieve competence [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/19\">",
"     19",
"    </a>",
"    ]. There may have been greater attention to imaging the nasal bone in studies involving high risk patients, as some study populations were unselected while others were at high risk of Down syndrome. Some aneuploid fetuses could have been missed since pregnancy outcome was incompletely ascertained in most studies. In addition, the likelihood of trisomy 21 when the nasal bone is absent is affected by several factors. As an example, the likelihood ratio for trisomy 21 when the nasal bone is absent is considerably higher in Caucasians than in women of Afro-Caribbean origin (LR for trisomy 21: 31 versus 9), at 13 versus 11 weeks of gestation (LR for trisomy 21: 52 versus 18), and at NT 3.5-4.4 mm versus NT &ge;5.5 mm (LR for trisomy 21: 13 versus 5) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Combining multiple markers improves the detection of Down syndrome. This was illustrated in a study that screened over 20,000 women at 11 to 13 and",
"    <span class=\"nowrap\">",
"     6/7ths",
"    </span>",
"    weeks of gestation using maternal serum analytes, fetal nuchal translucency, and",
"    <span class=\"nowrap\">",
"     presence/absence",
"    </span>",
"    of nasal bone [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/20\">",
"     20",
"    </a>",
"    ]. Combined testing resulted in detection of 90 percent of fetuses with Down syndrome with a false positive rate of 2.5 percent (the detection rate was 95 percent if the false positive rate was 5 percent). The investigators published formulas utilizing these variables to predict Down syndrome risk.",
"   </p>",
"   <p>",
"    In summary, nonvisualization of the nasal bone ossification at around 13 weeks of gestation is a proven finding in fetuses with Down syndrome. However, accurate prenatal assessment is technically difficult and requires on-going clinical practice. At this time, the role for fetal nasal bone imaging is unclear. In experienced hands, it may be a useful adjunct to screening, especially when other studies show a borderline or high risk of Down syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/18,21\">",
"     18,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An absent nasal bone is less common in fetuses with trisomy 18 or 13 than in those with Down syndrome, but still more common with these aneuploidies than in euploid fetuses. In one review, the frequency of absent nasal bone in euploid, trisomy 13, trisomy 18, and trisomy 21 was 2.5, 45, 53, and 60 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Second trimester",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the second trimester, the reported sensitivity of absent nasal bone for Down syndrome varies widely, but is generally lower than in the first trimester [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. The nasal bone is absent in 30 to 43 percent of Down syndrome fetuses and 0.3 to 0.7 percent of euploid fetuses [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/10\">",
"     10",
"    </a>",
"    ]. Using either nasal hypoplasia or absence as a marker increases sensitivity; when either an absent or hypoplastic nasal bone is detected, sensitivity for Down syndrome is 60 percent and the false positive rate increases to 2 to 4 percent. However, the detection rate depends upon the threshold used. Options include the ratio of biparietal diameter-nasal bone length",
"    <span class=\"nowrap\">",
"     (BPD/NB",
"    </span>",
"    &gt;9) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/25\">",
"     25",
"    </a>",
"    ], a single pre-defined threshold for abnormal nasal bone length (&le;2.5 mm [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/26\">",
"     26",
"    </a>",
"    ]), a gestational age-based threshold (&lt;2.5th or 5th centile) based on the distribution of nasal bone length in normal fetuses [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/23\">",
"     23",
"    </a>",
"    ], or use of multiple of the median (MoM) of nasal bone length for gestational age (&lt;0.75 MoM) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. In a comparative study, the MoM method appeared to have the best combination of sensitivity and specificity (49 and 92 percent, respectively, compared with 61 and 84 percent, respectively, for",
"    <span class=\"nowrap\">",
"     BPD/NB",
"    </span>",
"    &gt;11) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Echogenic bowel",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fetal echogenic bowel refers to increased echogenicity (brightness) of the fetal bowel noted on second trimester sonographic examination (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef51551 graphicRef73631 \" href=\"UTD.htm?35/8/35972\">",
"     image 3A-B",
"    </a>",
"    ). It may be first identified in the first trimester but is more commonly identified in the second trimester. It has been found in 1 to 2 percent of normal fetuses and 13 to 21 percent of fetuses with Down syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/10\">",
"     10",
"    </a>",
"    ]. However, a variety of fetal and pregnancy complications have also been associated with this finding: chromosomal defects, fetal growth restriction, cystic fibrosis, congenital infection, intraamniotic bleeding, and gastrointestinal obstruction (",
"    <a class=\"graphic graphic_table graphicRef80484 \" href=\"UTD.htm?7/49/7963\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Aneuploidy has been associated with abnormal bowel function (decreased motility, increased water absorption) in newborns and it is possible that a similar process in the fetus could cause echogenic bowel. Fetal echogenic bowel is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/20/36166?source=see_link\">",
"     \"Fetal echogenic bowel\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Pyelectasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pyelectasis or mild hydronephrosis is a common finding in fetuses. Studies that defined pyelectasis as renal pelvic diameter of &ge;4 mm at 15 to 19 weeks of gestation demonstrated pyelectasis in 10 to 25 percent of fetuses with Down syndrome and 1 to 3 percent of euploid fetuses [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/29-34\">",
"     29-34",
"    </a>",
"    ]. Aneuploidy is present in 0.3 to 0.9 percent of fetuses with isolated pyelectasis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/31,32,35\">",
"     31,32,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In both euploid and aneuploid fetuses, pyelectasis is usually caused by vesicoureteral reflux, but may be related to obstruction. Mild dilation (ie, 4 to 7 mm in the second trimester) typically resolves over the course of gestation or in the postnatal period. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/52/42824?source=see_link\">",
"     \"Overview of antenatal hydronephrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Ventriculomegaly",
"    </span>",
"    &nbsp;&mdash;&nbsp;Isolated ventriculomegaly is a risk factor for Down syndrome, but most children with isolated, mild ventriculomegaly have a normal outcome. Mild ventriculomegaly is detected in 4 to13 percent of fetuses with Down syndrome and 0.1 to 0.4 percent of euploid fetuses [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/10\">",
"     10",
"    </a>",
"    ]. The risk of abnormal outcome, such as Down syndrome, increases with the degree of ventriculomegaly, progression of ventriculomegaly, and presence of other anomalies. Ventriculomegaly is discussed in detail separately. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Trisomy 21 (Down syndrome)'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/39/12920?source=see_link\">",
"     \"Fetal ventriculomegaly\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Shortened long bones",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fetuses with Down syndrome have slightly shorter long-bones than their normal counterparts. A shortened humerus appears to be a better predictor of Down syndrome than a shortened femur (positive likelihood ratio 4.8 and 3.7, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Various criteria have been published for determining whether a femur or humerus is too short [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/33,36\">",
"     33,36",
"    </a>",
"    ]. These criteria overlap the range observed in unaffected fetuses and vary widely among different populations; therefore, each laboratory should develop specific standards for its own population. We consider abnormal an observed-to-expected length ratio (based on biparietal diameter) of less than 0.9.",
"   </p>",
"   <p>",
"    In contrast, severely shortened (&lt;5th percentile) or abnormal appearing long bones may be a sign of a skeletal dysplasia or early onset fetal growth restriction [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/37/42585?source=see_link\">",
"     \"Prenatal diagnosis of the lethal skeletal dysplasias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Echogenic intracardiac focus",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sonographic criteria for echogenic intracardiac foci is brightness equivalent to that of bone (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef51859 \" href=\"UTD.htm?17/28/17856\">",
"     image 4",
"    </a>",
"    ). Echogenic intracardiac foci usually occur as a single focus in the left ventricle, but multiple foci, biventricular foci, or a right ventricular location can also occur. This entity is different from diffuse, extensive myocardial calcification, which is rare and associated with myocardial dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Echogenic intracardiac foci may be first identified in the first trimester, but identification this early in pregnancy is rare. In the second trimester, 21 to 28 percent of fetuses with Down syndrome have an echogenic intracardiac focus, while this is seen in 3 to 5 percent of normals [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/10\">",
"     10",
"    </a>",
"    ]. The incidence varies across",
"    <span class=\"nowrap\">",
"     races/ethnicities",
"    </span>",
"    (present in up to 30 percent of Asian fetuses), and decreases with advancing gestational age [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/40-43\">",
"     40-43",
"    </a>",
"    ]. It is thought to be related to microcalcification and fibrosis of the papillary muscle or chordae, often disappears later in pregnancy or postnatally, and is not associated with myocardial dysfunction or structural anomalies [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/44-46\">",
"     44-46",
"    </a>",
"    ]. In an autopsy study of abortuses, stillbirths, and perinatal deaths, discrete central papillary muscle calcification was more common in fetuses with trisomy 13 than trisomy 21 (39 and 16 percent, respectively, versus 2 percent of normal controls) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The best available evidence suggests that an isolated echogenic intracardiac focus in the fetus of an otherwise low risk woman does not confer an increased risk of fetal aneuploidy (",
"    <a class=\"graphic graphic_table graphicRef82498 \" href=\"UTD.htm?3/37/3677\">",
"     table 2",
"    </a>",
"    ) . Although some papers have reported that the number or location of echogenic foci affects the risk of fetal aneuploidy (higher risk with biventricular or right ventricular involvement), the general consensus is that these factors have not been proven to matter [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Choroid plexus cysts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Choroid plexus cysts are most common in the second trimester. They may be visualized during the late first trimester, but their prevalence has not been determined this early in pregnancy. They usually disappear by the third trimester; those that persist are usually asymptomatic and benign.",
"   </p>",
"   <p>",
"    They appear to result from filling of the neuroepithelial folds with cerebrospinal fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/49\">",
"     49",
"    </a>",
"    ]. The typical sonographic appearance is a small (usually less than 1 cm), sonolucent structure(s) with well delineated borders located within the choroid plexus. A wide range of appearances are possible from unilateral single cysts to bilateral septated and multiple cysts [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/50-56\">",
"     50-56",
"    </a>",
"    ]. A targeted scan for other fetal anomalies should follow imaging of these cysts.",
"   </p>",
"   <p>",
"    Choroid plexus cysts are present in 30 to 50 percent of fetuses with trisomy 18 compared with 1 to 3 percent of all second trimester fetuses [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/29,51\">",
"     29,51",
"    </a>",
"    ]. The majority of large studies suggest that choroid plexus cyst(s) with an otherwise completely normal detailed structural survey (including examination of the face, heart, great vessels, and extremities) is highly reassuring of a normal karyotype [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/29,57-59\">",
"     29,57-59",
"    </a>",
"    ]. In addition, if the fetus is able to unclench its hand and hold it open, trisomy 18 is not likely. In a meta-analysis including 748 fetuses with isolated choroid plexus cyst(s), the risk of trisomy 18 was",
"    <span class=\"nowrap\">",
"     1/374",
"    </span>",
"    and the positive predictive value was",
"    <span class=\"nowrap\">",
"     1/390",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/60\">",
"     60",
"    </a>",
"    ]. In another meta-analysis, there were no cases of trisomy 18 among 1016 fetuses with isolated choroid plexus cysts whose mothers were less than 35 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When isolated choroid plexus cyst(s) are detected in an otherwise low risk patient (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef74248 graphicRef50051 \" href=\"UTD.htm?34/17/35094\">",
"     image 5A-B",
"    </a>",
"    ), the risk of amniocentesis",
"    <span class=\"nowrap\">",
"     (1/250",
"    </span>",
"    chance of pregnancy loss) is higher than the risk that the fetus has trisomy 18 (less than",
"    <span class=\"nowrap\">",
"     1/374).",
"    </span>",
"    We suggested restricting amniocentesis to patients with additional sonographic abnormalities or high risk factors (ie, advanced maternal age [older than 32 years at delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/62\">",
"     62",
"    </a>",
"    ]], abnormal serum analyte screen) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/63\">",
"     63",
"    </a>",
"    ]. Some women may request amniocentesis after risk-benefit counseling.",
"   </p>",
"   <p>",
"    Isolated choroid plexus cysts detected prenatally are not associated with adverse long-term developmental outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/64-66\">",
"     64-66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although more prevalent in patients with Down syndrome, sandal gap toe, short ear length, and a hypoplastic wedge-shaped middle phalanx of the fifth digit that causes it to curve toward the fourth finger (clinodactyly), are also common normal variants [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/67-72\">",
"     67-72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An observed-to-expected iliac length measurement &ge;1.21 or a widened iliac angle (&gt;90 degrees) has a low positive predictive value for the detection of Down syndrome in low risk populations [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/73,74\">",
"     73,74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Micrognathia is one of the characteristics of a long list of chromosomal and nonchromosomal syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/75\">",
"     75",
"    </a>",
"    ]. The fetal mandible can be evaluated by ultrasound from the late first trimester until term, if the position of the fetal head is favorable. Prenatal diagnosis of micrognathia can be made subjectively or objectively by comparing mandible measurements against standard tables.",
"   </p>",
"   <p>",
"    An aberrant right subclavian artery appears to be a strong predictor of Down syndrome (positive likelihood ratio 21), but has only been evaluated in two small studies [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/10\">",
"     10",
"    </a>",
"    ]. It has been detected in 18 to 47 percent of Down syndrome fetuses and 1 to 2 percent of euploid fetuses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4927786\">",
"    <span class=\"h1\">",
"     DOPPLER MARKERS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Reversed end-diastolic flow",
"    </span>",
"    &nbsp;&mdash;&nbsp;Doppler velocimetry studies are not generally performed in the first trimester; safety of this technique at the earliest stage of pregnancy has not been established. However, the observation of persistent reversed end-diastolic umbilical artery flow (REDV) in the fetus with nuchal thickening appears highly predictive of aneuploidy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/76-79\">",
"     76-79",
"    </a>",
"    ]. A pilot study of 11 fetuses with persistent REDV at 10 to 14 weeks of gestation who underwent karyotyping found nine (82 percent) had aneuploidy and all died [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/76\">",
"     76",
"    </a>",
"    ]. Similar findings have been noted in case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/77-79\">",
"     77-79",
"    </a>",
"    ], suggesting this may become an ancillary test for evaluating fetuses with nuchal thickening, early onset growth restriction, or congenital anomalies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/30/10728?source=see_link\">",
"     \"Doppler ultrasound of the umbilical artery for fetal surveillance\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Abnormal flow in the ductus venosus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormal ductus venosus flow velocities have been observed in aneuploid fetuses, but have also been noted in euploid fetuses [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/80-83\">",
"     80-83",
"    </a>",
"    ] and those with cardiac defects [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/84\">",
"     84",
"    </a>",
"    ]. In one review, the frequency of a ductus venosus reversed a-wave by karyotype was: euploid fetuses (3 percent), trisomy 13 (55 percent), trisomy 18 (58 percent), and trisomy 21 (66 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/22\">",
"     22",
"    </a>",
"    ]. This measurement is difficult to obtain and has not been adequately evaluated to permit clinical use [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4927908\">",
"    <span class=\"h2\">",
"     Tricuspid regurgitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assessment of tricuspid flow in the first trimester can also be used to detect aneuploid fetuses. In one study, tricuspid regurgitation at 11 to 13 weeks was observed in 0.9 percent of euploid fetuses, 55.7 percent of fetuses with trisomy 21, 33.3 percent of fetuses with trisomy 18, 30 percent of fetuses with trisomies 13, and 37.5 percent of fetuses with Turner syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     STRUCTURAL ANOMALIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequency of chromosomal abnormalities is increased in fetuses with sonographic evidence of structural anomalies. This relationship was illustrated in a study of 386 fetuses with a structural defect: the frequency of an abnormal karyotype in these fetuses was 11 percent versus only 0.5 percent in normal liveborn infants [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The magnitude of risk for chromosomal abnormality is highly dependent upon the specific malformation. As an example, combined data from two series showed that 12 of 14 fetuses with an omphalocele not containing the liver had a chromosomal abnormality but only three of 34 had a chromosomal abnormality when the liver was contained in the omphalocele sac [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/88,89\">",
"     88,89",
"    </a>",
"    ]. (See individual topic reviews on specific congenital abnormalities for information on the risk of abnormal karyotype with each abnormality).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Cystic hygroma",
"    </span>",
"    &nbsp;&mdash;&nbsp;A cystic hygroma is a thin-walled, subcutaneous uni- or multilocular subcutaneous mass filled with lymphatic fluid and usually occurring in the posterior neck. It results from a localized area of lymphatic dysplasia with dilatation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    leakage of lymph from the lymphatic vessels. It may be accompanied by generalized lymphedema. A small, unilocular cystic hygroma without accompanying diffuse lymphedema may be difficult to distinguish from other causes of nuchal thickening. By comparison, septations are characteristic of multilocular cystic hygromas and readily differentiate cystic hygromas from simple increased nuchal translucency (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef53158 graphicRef64913 \" href=\"UTD.htm?41/15/42231\">",
"     image 6A-B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    First trimester cystic hygromas are often associated with trisomies, whereas second trimester cystic hygromas are often associated with monosomy X. These risks are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/50/2857?source=see_link\">",
"     \"First trimester cystic hygroma and increased nuchal translucency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     FETAL GROWTH RESTRICTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the most common etiologies for small fetal size are uteroplacental insufficiency and constitutional factors, aneuploidy has been detected in 20 percent of pregnancies referred for further evaluation of a small fetus [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/90\">",
"     90",
"    </a>",
"    ]. However, almost all small fetuses with karyotypic abnormalities also have structural defects: only 2 percent of fetuses with isolated growth restriction have abnormal chromosomes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/27/23994?source=see_link\">",
"     \"Fetal growth restriction: Evaluation and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fetal growth restriction associated with aneuploidy can occur as early as the first trimester [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/91\">",
"     91",
"    </a>",
"    ]. The severity of growth restriction correlates with the severity of the chromosomal abnormality. This was illustrated in a study that compared the crown-rump length (CRL) at 9 to 13 weeks of gestation of 144 aneuploid fetuses and 440 normal fetuses [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/92\">",
"     92",
"    </a>",
"    ]. When the crown-rump length was shorter than expected (ie,",
"    <span class=\"nowrap\">",
"     observed/expected",
"    </span>",
"    CRL &le;0.86) the risk of any aneuploidy was significantly increased, odds ratio 2.52. This effect was demonstrated for trisomy 18 and 13, but not for trisomy 21. In another series, the incidence of fetal growth restriction among fetuses with trisomy 21, 13, and 18 was 30, 50, and 90 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/93\">",
"     93",
"    </a>",
"    ]. First trimester growth restriction is also very common among fetuses with triploidy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SINGLE UMBILICAL ARTERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a well documented association between single umbilical artery (SUA) and an increased risk of aneuploidy when additional fetal malformations are detected. The rate of aneuploidy with isolated SUA is not known, but most experts do not recommend routine chromosomal analysis if there are no other malformations or other indications for genetic amniocentesis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/46/27370?source=see_link\">",
"     \"Histopathology of placental disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SONOGRAPHIC FEATURES OF SELECTED ANEUPLOIDIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Trisomy 21 (Down syndrome)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately one-third of fetuses with trisomy 21 have one or more sonographically detectable structural malformations (major or minor) in the following systems [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/27,95\">",
"     27,95",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cardiovascular, especially endocardial cushion defects and ventricular septal defects",
"     </li>",
"     <li>",
"      Central nervous system (eg, mild ventriculomegaly)",
"     </li>",
"     <li>",
"      Gastrointestinal system (eg, duodenal atresia [after 22 weeks] (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef62011 \" href=\"UTD.htm?39/32/40463\">",
"       image 7",
"      </a>",
"      ))",
"     </li>",
"     <li>",
"      Craniofacial (eg, cystic hygroma, thickened nuchal fold, brachycephaly)",
"     </li>",
"     <li>",
"      Hydrops fetalis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Forty to 50 percent of fetuses with Down syndrome have a thickened nuchal fold of &ge;6 mm between 15 and 20 weeks of gestation (with a &lt;1 percent false positive rate) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/96\">",
"     96",
"    </a>",
"    ]. Although the thickened nuchal fold can revert to normal later in pregnancy, the risk of Down syndrome remains high [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/97\">",
"     97",
"    </a>",
"    ]. We have found a thickened nuchal fold to be the most sensitive (40 to 50 percent) and specific (99 percent) single ultrasound marker for Down syndrome in the second trimester (15 to 20 weeks but not later) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56326 \" href=\"UTD.htm?11/48/12033\">",
"     image 8",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/96,98,99\">",
"     96,98,99",
"    </a>",
"    ]. However, the sensitivity of nuchal fold thickening for the detection of Down syndrome may vary between laboratories and is higher in the first trimester (70 to 80 percent at 10 to 14 weeks of gestation) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/100\">",
"     100",
"    </a>",
"    ]. Cardiac defects are also common, affecting 40 percent of infants with Down syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/15/26874?source=see_link\">",
"     \"Clinical features and diagnosis of Down syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other sonographic findings are considered soft markers for Down syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/4,5,28,33,36,67-69,73,74,101-110\">",
"     4,5,28,33,36,67-69,73,74,101-110",
"    </a>",
"    ]. These soft markers are frequently found among normal fetuses and should",
"    <strong>",
"     not",
"    </strong>",
"    <strong>",
"     be used in isolation",
"    </strong>",
"    for detecting fetuses with Down syndrome in the low risk population.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Slightly shortened humerus",
"     </li>",
"     <li>",
"      Slightly shortened femur",
"     </li>",
"     <li>",
"      Echogenic intracardiac foci",
"     </li>",
"     <li>",
"      Echogenic bowel",
"     </li>",
"     <li>",
"      Pyelectasis",
"     </li>",
"     <li>",
"      Hypoplastic or absent nasal bone",
"     </li>",
"     <li>",
"      Hypoplasia of the middle phalanx of the fifth digit",
"     </li>",
"     <li>",
"      Clinodactyly",
"     </li>",
"     <li>",
"      Separation of the great toe (sandal gap toe)",
"     </li>",
"     <li>",
"      Widened iliac angle",
"     </li>",
"     <li>",
"      Short ear length",
"     </li>",
"     <li>",
"      Short frontal lobe",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Genetic sonogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 'genetic sonogram' uses ultrasound to assess the fetus for both structural anomalies and soft markers suggestive of Down syndrome. It is typically performed in the second trimester, but may be useful in first trimester screening as well [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/111\">",
"     111",
"    </a>",
"    ]. Likelihood ratios have been determined for several soft markers (",
"    <a class=\"graphic graphic_table graphicRef82498 \" href=\"UTD.htm?3/37/3677\">",
"     table 2",
"    </a>",
"    ), but have not been determined for others because the association with Down syndrome has not been proven to be statistically significant [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/112\">",
"     112",
"    </a>",
"    ]. Online calculators are also available for determining Down syndrome risk using patient-specific information (eg,",
"    <a class=\"external\" href=\"file://www.perinatology.com/calculators/Down Syndromee Revised Risk.htm\">",
"     Perinatology.com",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Ideally, a completely normal fetus on ultrasound examination in the setting of abnormal biochemical screening would indicate the risk of Down syndrome was very low and diagnostic testing could be avoided, thus reducing morbidity resulting from invasive intervention for false positive screening tests. Conversely, diagnostic testing would be offered to women with normal biochemical screening tests if ultrasound examination detected soft markers, thereby lowering the rate of false negative biochemical screens and improving detection of affected fetuses.",
"   </p>",
"   <p>",
"    Some experts believe that the genetic sonogram is not sufficiently reliable to guide recommendations for or against fetal karyotype testing in women who undergo expanded biochemical screening [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/113,114\">",
"     113,114",
"    </a>",
"    ]. This viewpoint was supported by a study of over 9000 women with abnormal biochemical screening results that confirmed that a normal genetic sonogram was associated with a significantly reduced risk of Down syndrome (LR 0.55, 95% CI 0.49-0.62); however, if all women with normal ultrasound examinations and abnormal biochemical screens avoided amniocentesis, then 115 of 245 fetuses with Down syndrome would have been missed [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/114\">",
"     114",
"    </a>",
"    ]. Furthermore, in women with normal biochemical screening results, an abnormal genetic sonogram was not highly predictive of Down syndrome: 1200 amniocenteses would need to be performed in this setting to detect one affected fetus.",
"   </p>",
"   <p>",
"    In contrast to this study, others believe the genetic sonogram can be utilized successfully to better define the risk of Down syndrome if both the presence and the number of soft markers identified are taken into account when revising the individual woman's risk of carrying an affected fetus. Nyberg reported the positive likelihood ratio for Down syndrome with no soft markers, one marker, two markers, and three or more markers in the second trimester was 0.4, 2, 10, and 115, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/115,116\">",
"     115,116",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of the genetic sonogram, particularly for patients who have had prior first trimester serum screening, remains controversial. Second trimester genetic sonography after first trimester combined screening improves detection of trisomy 21, but at the expense of increasing screen-positive rates since most fetuses with Down syndrome will have already been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/112,117\">",
"     112,117",
"    </a>",
"    ]. One study of a mixed population of 14,934 patients, including 51 with Down syndrome, found that 41 of the 51 affected fetuses were identified in the first trimester, while an additional five Down syndrome fetuses were detected using the second trimester ultrasound: four had heart defects and one had a thickened nuchal fold [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/118\">",
"     118",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Using the genetic sonogram to modify the prior risk from maternal age or second trimester serum screen is currently accepted practice by most centers involved in Down syndrome screening [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/7,101,119\">",
"     7,101,119",
"    </a>",
"    ]. For detection of Down syndrome, the genetic sonogram alone has been reported to have sensitivity ranging from 59 to 87 percent, positive likelihood ratios ranging from 3 to 20, and negative likelihood ratios ranging from 0.1 to 0.4 in the second trimester; however, in some of these series, test performance included sonograms of fetuses with major structural anomalies [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/6\">",
"     6",
"    </a>",
"    ]. When the genetic sonogram is used to modify standard serum screening results, sensitivity has been estimated to be at least 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/112\">",
"     112",
"    </a>",
"    ]. Women who undergo the second trimester quadruple test as their serum test appear to benefit most from combining the results of serum screening and the genetic sonogram. The FASTER trial evaluated the impact of the genetic sonogram after first trimester screening in 7842 patients (including 59 fetuses with Down syndrome) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/112\">",
"     112",
"    </a>",
"    ]. Adding the genetic sonogram to the quadruple, integrated, stepwise, and contingent tests resulted in a rise in detection rate from 81, 93, 97, and 95 percent, respectively, to 90, 98, 98, and 97 percent, respectively.",
"   </p>",
"   <p>",
"    In the only report of use of a genetic sonogram in the first trimester, an echogenic intracardiac focus, pyelectasis (renal pelvis diameter &ge;1.5 mm), or echogenic bowel was observed in 73 of 228 fetuses (33 percent) with Down syndrome compared with only 66 of 797 (8 percent) euploid fetuses [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Trisomy 18",
"    </span>",
"    &nbsp;&mdash;&nbsp;After Down syndrome, trisomy 18 is the second most common autosomal trisomy detected in the second trimester; it is almost always lethal in early childhood. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/0/23562?source=see_link&amp;anchor=H11#H11\">",
"     \"Congenital cytogenetic abnormalities\", section on 'Trisomy 18 syndrome'",
"    </a>",
"    .) Sonographic abnormalities include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Limb abnormalities (eg, upper limb reduction, clenched hands with overlapping index finger, clubbed feet, rocker bottom feet)",
"     </li>",
"     <li>",
"      Nuchal thickening or cystic hygroma",
"     </li>",
"     <li>",
"      Choroid plexus cyst(s)",
"     </li>",
"     <li>",
"      Abnormal cisterna magna, absent corpus callosum,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      cerebellar hypoplasia",
"     </li>",
"     <li>",
"      Neural tube defects (NTDs)",
"     </li>",
"     <li>",
"      Ventriculomegaly",
"     </li>",
"     <li>",
"      Strawberry shaped calvarium (pointed front and a flat occiput)",
"     </li>",
"     <li>",
"      Facial defects (eg, clefts, micrognathia, low-set ears, microphthalmus)",
"     </li>",
"     <li>",
"      Cardiovascular defects (eg, septal and valvular defects)",
"     </li>",
"     <li>",
"      Gastrointestinal defects (eg, omphalocele, diaphragmatic hernia)",
"     </li>",
"     <li>",
"      Urogenital defects (eg, horseshoe kidney, hydronephrosis)",
"     </li>",
"     <li>",
"      Two-vessel umbilical cord, umbilical cord cysts",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The frequency of sonographically detected gross anomalies in fetuses with trisomy 18 varies with gestational age, and is approximately 53 percent up to and including 17.5 weeks of gestation and 67 percent from 17.5 to 24 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/120\">",
"     120",
"    </a>",
"    ]. The detection rate of trisomy 18 can be increased to approximately 90 percent (with a false positive rate of 2 to 3 percent) by combining findings on ultrasound examination with results of the maternal analyte screen (in the second trimester: low levels of alpha-fetoprotein, unconjugated estriol, and human chorionic gonadotropin; in the first trimester: very low beta-hCG and a very low PAPP-A levels).",
"   </p>",
"   <p>",
"    Some authors have opined that by 19 to 20 weeks of gestation, genetic ultrasounds done in a targeted prospective fashion by experienced sonographers should have 100 percent sensitivity (no false negatives) for detecting trisomy 18 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/57,121-123\">",
"     57,121-123",
"    </a>",
"    ]. For this reason, they recommend against genetic amniocentesis in pregnancies with second trimester maternal analyte changes suggestive of trisomy 18 if the genetic sonogram is normal and the pregnancy is &ge;19 weeks of gestation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/57/18329?source=see_link\">",
"     \"Pregnancy outcomes predicted by serum markers assayed in Down syndrome screening\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/22/7529?source=see_link\">",
"     \"First trimester combined test and integrated tests for screening for Down syndrome and trisomy 18\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cardiac defects are particularly common, affecting &gt;90 percent of fetuses. In the third trimester, fetuses with trisomy 18 often have both polyhydramnios and intrauterine growth restriction (IUGR), an unusual combination. In one series, 21 percent of trisomy 18 fetuses had IUGR (due to impaired cell growth in trisomic cells) and polyhydramnios (due to intestinal obstruction) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/124\">",
"     124",
"    </a>",
"    ]. Trisomy 18 is especially likely when both findings are observed and associated with abnormal hand positioning.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Trisomy 13",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trisomy 13 is rare (incidence",
"    <span class=\"nowrap\">",
"     1/5,000",
"    </span>",
"    to",
"    <span class=\"nowrap\">",
"     1/20,000",
"    </span>",
"    births) and associated with more severe structural malformations than trisomy 21 or 18. It is sonographically detectable in &gt;90 percent of cases due to the presence of multiple, severe structural malformations, including [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/125,126\">",
"     125,126",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Alobar holoprosencephaly",
"     </li>",
"     <li>",
"      Severe midline facial abnormalities (eg, cyclopia, midline facial clefts, anophthalmia, hypoplastic nose)",
"     </li>",
"     <li>",
"      Polycystic kidneys",
"     </li>",
"     <li>",
"      Posterior fossa anomalies",
"     </li>",
"     <li>",
"      Agenesis of the corpus callosum",
"     </li>",
"     <li>",
"      Ventriculomegaly",
"     </li>",
"     <li>",
"      Neural tube defects",
"     </li>",
"     <li>",
"      Cardiac defects (eg, septal defects, tetralogy of Fallot, hypoplastic left ventricle, echogenic intracardiac foci)",
"     </li>",
"     <li>",
"      Skeletal defects (eg, polydactyly)",
"     </li>",
"     <li>",
"      Nuchal thickening",
"     </li>",
"     <li>",
"      Urogenital defects (eg, enlarged echogenic kidneys, horseshoe kidney)",
"     </li>",
"     <li>",
"      Gastrointestinal defects (eg, omphalocele, diaphragmatic hernia)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Since several of these defects can be visualized at 11 to 14 weeks of gestation, first trimester detection of trisomy 13 is quite high [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/127\">",
"     127",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Trisomy 13 is the least common of the autosomal trisomies that can result in live birth because more than 75 percent of affected fetuses die in utero [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/128\">",
"     128",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Triploidy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe malformations and fetal loss are nearly universal in triploid fetuses because of the excess complement of chromosomes (three of each chromosome, 69 in all). Thus, this syndrome is highly detectable by prenatal ultrasound examination.",
"   </p>",
"   <p>",
"    When pregnancies extend beyond the first trimester, the most characteristic finding of triploidy is severe asymmetrical IUGR [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/94\">",
"     94",
"    </a>",
"    ]. When the extra set of chromosomes is maternal, IUGR is associated with a small calcified placenta and oligohydramnios. Alternatively, a large hydropic placenta may be present, suggesting a partial mole. The latter occurs when the extra set of chromosomes is paternal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/31/13816?source=see_link\">",
"     \"Gestational trophoblastic disease: Pathology\"",
"    </a>",
"    .) Fetal malformations associated with triploidy include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Major facial defects",
"     </li>",
"     <li>",
"      Central nervous system anomalies (eg, ventriculomegaly, holoprosencephaly, Dandy-Walker anomaly)",
"     </li>",
"     <li>",
"      Neural tube defects",
"     </li>",
"     <li>",
"      Renal anomalies",
"     </li>",
"     <li>",
"      Syndactyly of the third and fourth digits",
"     </li>",
"     <li>",
"      Clubbed feet",
"     </li>",
"     <li>",
"      Two vessel umbilical cord",
"     </li>",
"     <li>",
"      Nuchal thickening",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These are typically present in over 90 percent of fetuses [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Turner syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unlike the previously described trisomies, which occur as a result of nondisjunction, Turner syndrome (45X0) is",
"    <strong>",
"     NOT",
"    </strong>",
"    associated with advanced maternal age and is caused by several different mechanisms. Most Turner syndrome conceptuses end in first trimester miscarriage; Turner syndrome occurs in 1 in 2000 liveborn girls. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33449?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Turner syndrome (gonadal dysgenesis)\"",
"    </a>",
"    .) Sonographic findings include [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/129\">",
"     129",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Large septate cystic hygromata, usually noted in the second trimester",
"     </li>",
"     <li>",
"      Total body lymphangiectasia (fetal hydrops)",
"     </li>",
"     <li>",
"      Cardiac defects (eg, coarctation)",
"     </li>",
"     <li>",
"      Nuchal thickening",
"     </li>",
"     <li>",
"      Short femur",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In one study of 61 fetuses with cystic hygroma, the 45,X karyotype was found only in patients with septated hygromas and was present in 30 of 39 cases (77 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/130\">",
"     130",
"    </a>",
"    ]. In contrast, trisomy 21 was the most common abnormal karyotype in nonseptated lesions, noted in 5 of 16 cases (31 percent).",
"   </p>",
"   <p>",
"    Sixty percent of affected fetuses develop signs of hydrops (eg, ascites, pleural effusions, and edema) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/41/22170/abstract/130\">",
"     130",
"    </a>",
"    ]. Generalized hydrops associated with large septate cystic hygromata has a very poor prognosis, approximately 100 percent mortality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The antepartum detection of fetal aneuploidy is a major goal of prenatal screening programs. Sonographic examination is useful because fetuses with abnormal karyotypes often have anatomic changes or anomalies. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Soft markers are ultrasound findings that are usually associated with normal fetuses, have no clinical sequelae, and are transient. Isolated soft markers are identified in 11 to 17 percent of normal fetuses. The prevalence is higher in aneuploid fetuses and the likelihood of aneuploidy is significantly increased when more than one marker is present. However, even in this setting, use of soft markers for screening for or excluding fetal aneuploidy is inefficient. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Ultrasound markers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most useful marker is increased nuchal translucency. Determination of fetal nuchal translucency between 10 and 14 weeks of gestation combined with maternal analyte testing is an excellent screening test for detecting trisomy 21. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Increased nuchal translucency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fetuses with sonographic evidence of an structural anomaly are at increased risk of having a chromosomal abnormality. The magnitude of risk is highly dependent upon the specific malformation. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Structural anomalies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      First trimester cystic hygromas are often associated with trisomies, whereas second trimester cystic hygromas are often associated with monosomy X. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Cystic hygroma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Growth restricted fetuses and those with a single umbilical artery are at increased risk of having an abnormal karyotype if they also have structural defects. We offer genetic amniocentesis to patients with these findings. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Fetal growth restriction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The use of the genetic sonogram, particularly for patients who have had prior first trimester screening, is controversial, whereas modifying a prior risk of Down syndrome based on maternal age alone or second trimester serum screening is a common practice. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Trisomy 21 (Down syndrome)'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/1\">",
"      Evans MI, Ebrahim SA, Berry SM, et al. Fluorescent in situ hybridization utilization for high-risk prenatal diagnosis: a trade-off among speed, expense, and inherent limitations of chromosome-specific probes. Am J Obstet Gynecol 1994; 171:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/2\">",
"      Hook EB, Topol BB, Cross PK. The natural history of cytogenetically abnormal fetuses detected at midtrimester amniocentesis which are not terminated electively: new data and estimates of the excess and relative risk of late fetal death associated with 47,+21 and some other abnormal karyotypes. Am J Hum Genet 1989; 45:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/3\">",
"      Morris JK, Wald NJ, Watt HC. Fetal loss in Down syndrome pregnancies. Prenat Diagn 1999; 19:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/4\">",
"      Bethune M. Literature review and suggested protocol for managing ultrasound soft markers for Down syndrome: thickened nuchal fold, echogenic bowel, shortened femur, shortened humerus, pyelectasis and absent or hypoplastic nasal bone. Australas Radiol 2007; 51:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/5\">",
"      Bethune M. Management options for echogenic intracardiac focus and choroid plexus cysts: a review including Australian Association of Obstetrical and Gynaecological Ultrasonologists consensus statement. Australas Radiol 2007; 51:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/6\">",
"      Breathnach FM, Fleming A, Malone FD. The second trimester genetic sonogram. Am J Med Genet C Semin Med Genet 2007; 145C:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/7\">",
"      Bromley B, Lieberman E, Shipp TD, Benacerraf BR. The genetic sonogram: a method of risk assessment for Down syndrome in the second trimester. J Ultrasound Med 2002; 21:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/8\">",
"      DeVore GR. Second trimester ultrasonography may identify 77 to 97% of fetuses with trisomy 18. J Ultrasound Med 2000; 19:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/9\">",
"      Nicolaides KH, Snijders RJ, Gosden CM, et al. Ultrasonographically detectable markers of fetal chromosomal abnormalities. Lancet 1992; 340:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/10\">",
"      Agathokleous M, Chaveeva P, Poon LC, et al. Meta-analysis of second-trimester markers for trisomy 21. Ultrasound Obstet Gynecol 2013; 41:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/11\">",
"      Farkas LG, Katic MJ, Forrest CR, Litsas L. Surface anatomy of the face in Down's syndrome: linear and angular measurements in the craniofacial regions. J Craniofac Surg 2001; 12:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/12\">",
"      Cicero S, Curcio P, Papageorghiou A, et al. Absence of nasal bone in fetuses with trisomy 21 at 11-14 weeks of gestation: an observational study. Lancet 2001; 358:1665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/13\">",
"      Cicero S, Rembouskos G, Vandecruys H, et al. Likelihood ratio for trisomy 21 in fetuses with absent nasal bone at the 11-14-week scan. Ultrasound Obstet Gynecol 2004; 23:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/14\">",
"      Odibo AO, Sehdev HM, Dunn L, et al. The association between fetal nasal bone hypoplasia and aneuploidy. Obstet Gynecol 2004; 104:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/15\">",
"      Orlandi F, Rossi C, Orlandi E, et al. First-trimester screening for trisomy-21 using a simplified method to assess the presence or absence of the fetal nasal bone. Am J Obstet Gynecol 2005; 192:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/16\">",
"      Sonek JD. Nasal bone evaluation with ultrasonography: a marker for fetal aneuploidy. Ultrasound Obstet Gynecol 2003; 22:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/17\">",
"      Ville Y. What is the role of fetal nasal bone examination in the assessment of risk for trisomy 21 in clinical practice? Am J Obstet Gynecol 2006; 195:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/18\">",
"      Rosen T, D'Alton ME, Platt LD, et al. First-trimester ultrasound assessment of the nasal bone to screen for aneuploidy. Obstet Gynecol 2007; 110:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/19\">",
"      Cicero S, Dezerega V, Andrade E, et al. Learning curve for sonographic examination of the fetal nasal bone at 11-14 weeks. Ultrasound Obstet Gynecol 2003; 22:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/20\">",
"      Cicero S, Avgidou K, Rembouskos G, et al. Nasal bone in first-trimester screening for trisomy 21. Am J Obstet Gynecol 2006; 195:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/21\">",
"      Driscoll DA, Gross SJ, Professional Practice and Guidelines Committee. First trimester diagnosis and screening for fetal aneuploidy. Genet Med 2008; 10:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/22\">",
"      Nicolaides KH. Screening for fetal aneuploidies at 11 to 13 weeks. Prenat Diagn 2011; 31:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/23\">",
"      Sonek JD, Cicero S, Neiger R, Nicolaides KH. Nasal bone assessment in prenatal screening for trisomy 21. Am J Obstet Gynecol 2006; 195:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/24\">",
"      Shanks A, Odibo A. Nasal bone in prenatal trisomy 21 screening. Obstet Gynecol Surv 2010; 65:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/25\">",
"      Bromley B, Lieberman E, Shipp TD, Benacerraf BR. Fetal nose bone length: a marker for Down syndrome in the second trimester. J Ultrasound Med 2002; 21:1387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/26\">",
"      Cicero S, Sonek JD, McKenna DS, et al. Nasal bone hypoplasia in trisomy 21 at 15-22 weeks' gestation. Ultrasound Obstet Gynecol 2003; 21:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/27\">",
"      Papp C, Szigeti Z, T&oacute;th-P&aacute;l E, et al. Ultrasonographic findings of fetal aneuploidies in the second trimester--our experiences. Fetal Diagn Ther 2008; 23:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/28\">",
"      Odibo AO, Sehdev HM, Stamilio DM, et al. Defining nasal bone hypoplasia in second-trimester Down syndrome screening: does the use of multiples of the median improve screening efficacy? Am J Obstet Gynecol 2007; 197:361.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/29\">",
"      Dagklis T, Plasencia W, Maiz N, et al. Choroid plexus cyst, intracardiac echogenic focus, hyperechogenic bowel and hydronephrosis in screening for trisomy 21 at 11 + 0 to 13 + 6 weeks. Ultrasound Obstet Gynecol 2008; 31:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/30\">",
"      Havutcu AE, Nikolopoulos G, Adinkra P, Lamont RF. The association between fetal pyelectasis on second trimester ultrasound scan and aneuploidy among 25,586 low risk unselected women. Prenat Diagn 2002; 22:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/31\">",
"      Coco C, Jeanty P. Isolated fetal pyelectasis and chromosomal abnormalities. Am J Obstet Gynecol 2005; 193:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/32\">",
"      Corteville JE, Dicke JM, Crane JP. Fetal pyelectasis and Down syndrome: is genetic amniocentesis warranted? Obstet Gynecol 1992; 79:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/33\">",
"      Benacerraf BR, Neuberg D, Bromley B, Frigoletto FD Jr. Sonographic scoring index for prenatal detection of chromosomal abnormalities. J Ultrasound Med 1992; 11:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/34\">",
"      Carbone JF, Tuuli MG, Dicke JM, et al. Revisiting the risk for aneuploidy in fetuses with isolated pyelectasis. Prenat Diagn 2011; 31:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/35\">",
"      Chudleigh PM, Chitty LS, Pembrey M, Campbell S. The association of aneuploidy and mild fetal pyelectasis in an unselected population: the results of a multicenter study. Ultrasound Obstet Gynecol 2001; 17:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/36\">",
"      Lockwood C, Benacerraf B, Krinsky A, et al. A sonographic screening method for Down syndrome. Am J Obstet Gynecol 1987; 157:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/37\">",
"      Papageorghiou AT, Fratelli N, Leslie K, et al. Outcome of fetuses with antenatally diagnosed short femur. Ultrasound Obstet Gynecol 2008; 31:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/38\">",
"      Weisz B, David AL, Chitty L, et al. Association of isolated short femur in the mid-trimester fetus with perinatal outcome. Ultrasound Obstet Gynecol 2008; 31:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/39\">",
"      Simchen MJ, Toi A, Silver M, et al. Fetal cardiac calcifications: report of four prenatally diagnosed cases and review of the literature. Ultrasound Obstet Gynecol 2006; 27:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/40\">",
"      Shipp TD, Bromley B, Lieberman E, Benacerraf BR. The frequency of the detection of fetal echogenic intracardiac foci with respect to maternal race. Ultrasound Obstet Gynecol 2000; 15:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/41\">",
"      Achiron R, Lipitz S, Gabbay U, Yagel S. Prenatal ultrasonographic diagnosis of fetal heart echogenic foci: no correlation with Down syndrome. Obstet Gynecol 1997; 89:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/42\">",
"      Rebarber A, Levey KA, Funai E, et al. An ethnic predilection for fetal echogenic intracardiac focus identified during targeted midtrimester ultrasound examination: A retrospective review. BMC Pregnancy Childbirth 2004; 4:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/43\">",
"      Tran SH, Caughey AB, Norton ME. Ethnic variation in the prevalence of echogenic intracardiac foci and the association with Down syndrome. Ultrasound Obstet Gynecol 2005; 26:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/44\">",
"      Wax JR, Donnelly J, Carpenter M, et al. Childhood cardiac function after prenatal diagnosis of intracardiac echogenic foci. J Ultrasound Med 2003; 22:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/45\">",
"      Schechter AG, Fakhry J, Shapiro LR, Gewitz MH. In utero thickening of the chordae tendinae. A cause of intracardiac echogenic foci. J Ultrasound Med 1987; 6:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/46\">",
"      Tennstedt C, Chaoui R, Vogel M, et al. Pathologic correlation of sonographic echogenic foci in the fetal heart. Prenat Diagn 2000; 20:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/47\">",
"      Roberts DJ, Genest D. Cardiac histologic pathology characteristic of trisomies 13 and 21. Hum Pathol 1992; 23:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/48\">",
"      Simpson JM, Cook A, Sharland G. The significance of echogenic foci in the fetal heart: a prospective study of 228 cases. Ultrasound Obstet Gynecol 1996; 8:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/49\">",
"      Shuangshoti, S, Netsky, M. Neuroepithelial (colloid) cysts of the nervous system. Further observations on pathogenesis, incidence, and histochemistry. Neurology 1966; 16:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/50\">",
"      Chitkara U, Cogswell C, Norton K, et al. Choroid plexus cysts in the fetus: a benign anatomic variant or pathologic entity? Report of 41 cases and review of the literature. Obstet Gynecol 1988; 72:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/51\">",
"      Benacerraf BR, Harlow B, Frigoletto FD Jr. Are choroid plexus cysts an indication for second-trimester amniocentesis? Am J Obstet Gynecol 1990; 162:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/52\">",
"      Benacerraf BR, Laboda LA. Cyst of the fetal choroid plexus: a normal variant? Am J Obstet Gynecol 1989; 160:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/53\">",
"      Hertzberg BS, Kay HH, Bowie JD. Fetal choroid plexus lesions. Relationship of antenatal sonographic appearance to clinical outcome. J Ultrasound Med 1989; 8:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/54\">",
"      DeRoo TR, Harris RD, Sargent SK, et al. Fetal choroid plexus cysts: prevalence, clinical significance, and sonographic appearance. AJR Am J Roentgenol 1988; 151:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/55\">",
"      Benacerraf BR. Asymptomatic cysts of the fetal choroid plexus in the second trimester. J Ultrasound Med 1987; 6:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/56\">",
"      Chudleigh P, Pearce JM, Campbell S. The prenatal diagnosis of transient cysts of the fetal choroid plexus. Prenat Diagn 1984; 4:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/57\">",
"      Yeo L, Guzman ER, Day-Salvatore D, et al. Prenatal detection of fetal trisomy 18 through abnormal sonographic features. J Ultrasound Med 2003; 22:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/58\">",
"      Coco C, Jeanty P. Karyotyping of fetuses with isolated choroid plexus cysts is not justified in an unselected population. J Ultrasound Med 2004; 23:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/59\">",
"      Bronsteen R, Lee W, Vettraino IM, et al. Second-trimester sonography and trisomy 18: the significance of isolated choroid plexus cysts after an examination that includes the fetal hands. J Ultrasound Med 2004; 23:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/60\">",
"      Gross SJ, Shulman LP, Tolley EA, et al. Isolated fetal choroid plexus cysts and trisomy 18: a review and meta-analysis. Am J Obstet Gynecol 1995; 172:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/61\">",
"      Demasio K, Canterino J, Ananth C, et al. Isolated choroid plexus cyst in low-risk women less than 35 years old. Am J Obstet Gynecol 2002; 187:1246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/62\">",
"      Gupta JK, Khan KS, Thornton JG, Lilford RJ. Management of fetal choroid plexus cysts. Br J Obstet Gynaecol 1997; 104:881.",
"     </a>",
"    </li>",
"    <li>",
"     American College of Obstetricians and Gynecologists. Prenatal diagnosis of fetal chromosomal abnormalities. ACOG practice bulletin #27. American College of Obstetricians and Gynecologists, Washington, DC 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/64\">",
"      Bernier FP, Crawford SG, Dewey D. Developmental outcome of children who had choroid plexus cysts detected prenatally. Prenat Diagn 2005; 25:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/65\">",
"      Digiovanni LM, Quinlan MP, Verp MS. Choroid plexus cysts: infant and early childhood developmental outcome. Obstet Gynecol 1997; 90:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/66\">",
"      DiPietro JA, Cristofalo EA, Voegtline KM, Crino J. Isolated prenatal choroid plexus cysts do not affect child development. Prenat Diagn 2011; 31:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/67\">",
"      Benacerraf BR, Harlow BL, Frigoletto FD Jr. Hypoplasia of the middle phalanx of the fifth digit. A feature of the second trimester fetus with Down's syndrome. J Ultrasound Med 1990; 9:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/68\">",
"      Wilkins I. Separation of the great toe in fetuses with Down syndrome. J Ultrasound Med 1994; 13:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/69\">",
"      Chitkara U, Lee L, Oehlert JW, et al. Fetal ear length measurement: a useful predictor of aneuploidy? Ultrasound Obstet Gynecol 2002; 19:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/70\">",
"      Sacchini C, El-Sheikhah A, Cicero S, et al. Ear length in trisomy 21 fetuses at 11-14 weeks of gestation. Ultrasound Obstet Gynecol 2003; 22:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/71\">",
"      Bahado-Singh RO, Oz UA, Mendilcioglu I, Mahoney MJ. The mid-trimester genetic sonogram. Semin Perinatol 2005; 29:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/72\">",
"      Hobbins JC, Lezotte DC, Persutte WH, et al. An 8-center study to evaluate the utility of mid-term genetic sonograms among high-risk pregnancies. J Ultrasound Med 2003; 22:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/73\">",
"      Abuhamad AZ, Kolm P, Mari G, et al. Ultrasonographic fetal iliac length measurement in the screening for Down syndrome. Am J Obstet Gynecol 1994; 171:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/74\">",
"      Shipp TD, Bromley B, Lieberman E, Benacerraf BR. The second-trimester fetal iliac angle as a sign of Down's syndrome. Ultrasound Obstet Gynecol 1998; 12:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/75\">",
"      Paladini D. Fetal micrognathia: almost always an ominous finding. Ultrasound Obstet Gynecol 2010; 35:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/76\">",
"      Borrell A, Martinez JM, Farre MT, et al. Reversed end-diastolic flow in first-trimester umbilical artery: an ominous new sign for fetal outcome. Am J Obstet Gynecol 2001; 185:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/77\">",
"      Murta CG, Moron AF, Avila MA. Reversed diastolic umbilical artery flow in the first trimester associated with chromosomal fetal abnormalities or cardiac defects. Obstet Gynecol 2000; 95:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/78\">",
"      Comas C, Carrera M, Devesa R, et al. Early detection of reversed diastolic umbilical flow: should we offer karyotyping? Ultrasound Obstet Gynecol 1997; 10:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/79\">",
"      Huisman TW, Bilardo CM. Transient increase in nuchal translucency thickness and reversed end-diastolic ductus venosus flow in a fetus with trisomy 18. Ultrasound Obstet Gynecol 1997; 10:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/80\">",
"      Murta CG, Moron AF, Avila MA, Weiner CP. Application of ductus venosus Doppler velocimetry for the detection of fetal aneuploidy in the first trimester of pregnancy. Fetal Diagn Ther 2002; 17:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/81\">",
"      Mavrides E, Sairam S, Hollis B, Thilaganathan B. Screening for aneuploidy in the first trimester by assessment of blood flow in the ductus venosus. BJOG 2002; 109:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/82\">",
"      Oh C, Harman C, Baschat AA. Abnormal first-trimester ductus venosus blood flow: a risk factor for adverse outcome in fetuses with normal nuchal translucency. Ultrasound Obstet Gynecol 2007; 30:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/83\">",
"      Maiz N, Valencia C, Kagan KO, et al. Ductus venosus Doppler in screening for trisomies 21, 18 and 13 and Turner syndrome at 11-13 weeks of gestation. Ultrasound Obstet Gynecol 2009; 33:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/84\">",
"      Maiz N, Plasencia W, Dagklis T, et al. Ductus venosus Doppler in fetuses with cardiac defects and increased nuchal translucency thickness. Ultrasound Obstet Gynecol 2008; 31:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/85\">",
"      Malone FD, D'Alton ME, Society for Maternal-Fetal Medicine. First-trimester sonographic screening for Down syndrome. Obstet Gynecol 2003; 102:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/86\">",
"      Kagan KO, Valencia C, Livanos P, et al. Tricuspid regurgitation in screening for trisomies 21, 18 and 13 and Turner syndrome at 11+0 to 13+6 weeks of gestation. Ultrasound Obstet Gynecol 2009; 33:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/87\">",
"      Wladimiroff JW, Sachs ES, Reuss A, et al. Prenatal diagnosis of chromosome abnormalities in the presence of fetal structural defects. Am J Med Genet 1988; 29:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/88\">",
"      Getachew MM, Goldstein RB, Edge V, et al. Correlation between omphalocele contents and karyotypic abnormalities: sonographic study in 37 cases. AJR Am J Roentgenol 1992; 158:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/89\">",
"      Nyberg DA, Fitzsimmons J, Mack LA, et al. Chromosomal abnormalities in fetuses with omphalocele. Significance of omphalocele contents. J Ultrasound Med 1989; 8:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/90\">",
"      Snijders RJ, Sherrod C, Gosden CM, Nicolaides KH. Fetal growth retardation: associated malformations and chromosomal abnormalities. Am J Obstet Gynecol 1993; 168:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/91\">",
"      Schemmer G, Wapner RJ, Johnson A, et al. First-trimester growth patterns of aneuploid fetuses. Prenat Diagn 1997; 17:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/92\">",
"      Bahado-Singh RO, Lynch L, Deren O, et al. First-trimester growth restriction and fetal aneuploidy: the effect of type of aneuploidy and gestational age. Am J Obstet Gynecol 1997; 176:976.",
"     </a>",
"    </li>",
"    <li>",
"     Tyson, RW, Kalousek, DK. Chromosomal abnormalities in stillbirth and neonatal death. In: Developmental Pathology of the Embryo, Dimmick, JE, Kalousek, DK (Eds), JB Lippincott 1992.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/94\">",
"      Jauniaux E, Brown R, Rodeck C, Nicolaides KH. Prenatal diagnosis of triploidy during the second trimester of pregnancy. Obstet Gynecol 1996; 88:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/95\">",
"      Spicer RL. Cardiovascular disease in Down syndrome. Pediatr Clin North Am 1984; 31:1331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/96\">",
"      Benacerraf BR, Barss VA, Laboda LA. A sonographic sign for the detection in the second trimester of the fetus with Down's syndrome. Am J Obstet Gynecol 1985; 151:1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/97\">",
"      Bromley B, Benacerraf BR. The resolving nuchal fold in second trimester fetuses: not necessarily reassuring. J Ultrasound Med 1995; 14:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/98\">",
"      Benacerraf BR, Frigoletto FD Jr, Cramer DW. Down syndrome: sonographic sign for diagnosis in the second-trimester fetus. Radiology 1987; 163:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/99\">",
"      Benacerraf BR, Gelman R, Frigoletto FD Jr. Sonographic identification of second-trimester fetuses with Down's syndrome. N Engl J Med 1987; 317:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/100\">",
"      Smith-Bindman R, Hosmer W, Feldstein VA, et al. Second-trimester ultrasound to detect fetuses with Down syndrome: a meta-analysis. JAMA 2001; 285:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/101\">",
"      Nyberg DA, Luthy DA, Resta RG, et al. Age-adjusted ultrasound risk assessment for fetal Down's syndrome during the second trimester: description of the method and analysis of 142 cases. Ultrasound Obstet Gynecol 1998; 12:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/102\">",
"      Vintzileos AM, Campbell WA, Guzman ER, et al. Second-trimester ultrasound markers for detection of trisomy 21: which markers are best? Obstet Gynecol 1997; 89:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/103\">",
"      Kliewer MA, Hertzberg BS, Freed KS, et al. Dysmorphologic features of the fetal pelvis in Down syndrome: prenatal sonographic depiction and diagnostic implications of the iliac angle. Radiology 1996; 201:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/104\">",
"      Vintzileos AM, Guzman ER, Smulian JC, et al. Choice of second-trimester genetic sonogram for detection of trisomy 21. Obstet Gynecol 1997; 90:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/105\">",
"      Nyberg DA, Dubinsky T, Resta RG, et al. Echogenic fetal bowel during the second trimester: clinical importance. Radiology 1993; 188:527.",
"     </a>",
"    </li>",
"    <li>",
"     Snijders, RJ, Nicolaides, KH. Ultrasound Markers for Fetal Chromosomal Defects, The Parthenon Publishing Group, Inc, New York 1996. p.122.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/107\">",
"      Bahado-Singh RO, Deren O, Tan A, et al. Ultrasonographically adjusted midtrimester risk of trisomy 21 and significant chromosomal defects in advanced maternal age. Am J Obstet Gynecol 1996; 175:1563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/108\">",
"      Bahado-Singh RO, Oz AU, Kovanci E, et al. New Down syndrome screening algorithm: ultrasonographic biometry and multiple serum markers combined with maternal age. Am J Obstet Gynecol 1998; 179:1627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/109\">",
"      Bromley B, Lieberman E, Benacerraf BR. The incorporation of maternal age into the sonographic scoring index for the detection at 14-20 weeks of fetuses with Down's syndrome. Ultrasound Obstet Gynecol 1997; 10:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/110\">",
"      Simon-Bouy B, Muller F, French Collaborative Group. Hyperechogenic fetal bowel and Down syndrome. Results of a French collaborative study based on 680 prospective cases. Prenat Diagn 2002; 22:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/111\">",
"      Benacerraf B. Advancing further the sonographic estimation of Down syndrome risk--how early can we go? Ultrasound Obstet Gynecol 2008; 31:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/112\">",
"      Aagaard-Tillery KM, Malone FD, Nyberg DA, et al. Role of second-trimester genetic sonography after Down syndrome screening. Obstet Gynecol 2009; 114:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/113\">",
"      Weisz B, Pandya PP, David AL, et al. Ultrasound findings after screening for Down syndrome using the integrated test. Obstet Gynecol 2007; 109:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/114\">",
"      Smith-Bindman R, Chu P, Goldberg JD. Second trimester prenatal ultrasound for the detection of pregnancies at increased risk of Down syndrome. Prenat Diagn 2007; 27:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/115\">",
"      Nyberg DA, Souter VL, El-Bastawissi A, et al. Isolated sonographic markers for detection of fetal Down syndrome in the second trimester of pregnancy. J Ultrasound Med 2001; 20:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/116\">",
"      Nyberg DA, Souter VL. Sonographic markers of fetal trisomies: second trimester. J Ultrasound Med 2001; 20:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/117\">",
"      Wax JR, Pinette MG, Cartin A, Blackstone J. Second-trimester genetic sonography after first-trimester combined screening for trisomy 21. J Ultrasound Med 2009; 28:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/118\">",
"      Rozenberg P, Bussi&egrave;res L, Chevret S, et al. Screening for Down syndrome using first-trimester combined screening followed by second-trimester ultrasound examination in an unselected population. Am J Obstet Gynecol 2006; 195:1379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/119\">",
"      Vergani P, Ghidini A, Weiner S, et al. Risk assessment for Down syndrome with genetic sonogram in women at risk. Prenat Diagn 2008; 28:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/120\">",
"      Bahado-Singh RO, Choi SJ, Oz U, et al. Early second-trimester individualized estimation of trisomy 18 risk by ultrasound. Obstet Gynecol 2003; 101:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/121\">",
"      Bronsteen R, Lee W, Vettraino IM, et al. Second-trimester sonography and trisomy 18. J Ultrasound Med 2004; 23:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/122\">",
"      Oyelese Y, Vintzileos AM. Is second-trimester genetic amniocentesis for trisomy 18 ever indicated in the presence of a normal genetic sonogram? Ultrasound Obstet Gynecol 2005; 26:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/123\">",
"      Lai S, Lau WL, Leung WC, et al. Is ultrasound alone enough for prenatal screening of trisomy 18? A single centre experience in 69 cases over 10 years. Prenat Diagn 2010; 30:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/124\">",
"      Nyberg DA, Kramer D, Resta RG, et al. Prenatal sonographic findings of trisomy 18: review of 47 cases. J Ultrasound Med 1993; 12:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/125\">",
"      Lehman CD, Nyberg DA, Winter TC 3rd, et al. Trisomy 13 syndrome: prenatal US findings in a review of 33 cases. Radiology 1995; 194:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/126\">",
"      Watson WJ, Miller RC, Wax JR, et al. Sonographic detection of trisomy 13 in the first and second trimesters of pregnancy. J Ultrasound Med 2007; 26:1209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/127\">",
"      Papageorghiou AT, Avgidou K, Spencer K, et al. Sonographic screening for trisomy 13 at 11 to 13(+6) weeks of gestation. Am J Obstet Gynecol 2006; 194:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/128\">",
"      Snijders RJ, Holzgreve W, Cuckle H, Nicolaides KH. Maternal age-specific risks for trisomies at 9-14 weeks' gestation. Prenat Diagn 1994; 14:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/129\">",
"      Bronshtein M, Zimmer EZ, Blazer S. A characteristic cluster of fetal sonographic markers that are predictive of fetal Turner syndrome in early pregnancy. Am J Obstet Gynecol 2003; 188:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/41/22170/abstract/130\">",
"      Brumfield CG, Wenstrom KD, Davis RO, et al. Second-trimester cystic hygroma: prognosis of septated and nonseptated lesions. Obstet Gynecol 1996; 88:979.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 447 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-213.131.41.98-09444732DF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_41_22170=[""].join("\n");
var outline_f21_41_22170=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ULTRASOUND MARKERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Increased nuchal translucency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Nuchal fold",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Absent nasal bone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Second trimester",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Echogenic bowel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Pyelectasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Ventriculomegaly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Shortened long bones",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Echogenic intracardiac focus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Choroid plexus cysts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4927786\">",
"      DOPPLER MARKERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Reversed end-diastolic flow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Abnormal flow in the ductus venosus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4927908\">",
"      Tricuspid regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      STRUCTURAL ANOMALIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Cystic hygroma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      FETAL GROWTH RESTRICTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SINGLE UMBILICAL ARTERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SONOGRAPHIC FEATURES OF SELECTED ANEUPLOIDIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Trisomy 21 (Down syndrome)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Genetic sonogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Trisomy 18",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Trisomy 13",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Triploidy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Turner syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/447\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/447|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?4/11/4274\" title=\"diagnostic image 1\">",
"      First trimes nuchal lucency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?20/57/21394\" title=\"diagnostic image 2A\">",
"      Normal fetal nasal bone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?43/27/44464\" title=\"diagnostic image 2B\">",
"      Absent nasal bone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?0/52/832\" title=\"diagnostic image 3A\">",
"      Ultrasound image of normal bowel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?16/25/16784\" title=\"diagnostic image 3B\">",
"      Echogenic fetal bowel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?17/28/17856\" title=\"diagnostic image 4\">",
"      Echogenic fetal intracardiac focus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?33/32/34318\" title=\"diagnostic image 5A\">",
"      Choroid plexus cyst",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?33/38/34404\" title=\"diagnostic image 5B\">",
"      Choroid plexus cysts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?24/12/24769\" title=\"diagnostic image 6A\">",
"      Large septated fetal cystic hygroma with hydrops",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?40/15/41203\" title=\"diagnostic image 6B\">",
"      Very large septated fetal cystic hygroma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?39/32/40463\" title=\"diagnostic image 7\">",
"      Duodenal atresia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?11/48/12033\" title=\"diagnostic image 8\">",
"      Second trimester nuchal fold",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/447|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/49/7963\" title=\"table 1\">",
"      Fetal echogenic bowel outcome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/37/3677\" title=\"table 2\">",
"      LR of Down syndrome based on presence of an isolated soft marker",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/15/26874?source=related_link\">",
"      Clinical features and diagnosis of Down syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33449?source=related_link\">",
"      Clinical manifestations and diagnosis of Turner syndrome (gonadal dysgenesis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/0/23562?source=related_link\">",
"      Congenital cytogenetic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/30/10728?source=related_link\">",
"      Doppler ultrasound of the umbilical artery for fetal surveillance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/20/36166?source=related_link\">",
"      Fetal echogenic bowel",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/27/23994?source=related_link\">",
"      Fetal growth restriction: Evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/39/12920?source=related_link\">",
"      Fetal ventriculomegaly",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/22/7529?source=related_link\">",
"      First trimester combined test and integrated tests for screening for Down syndrome and trisomy 18",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/50/2857?source=related_link\">",
"      First trimester cystic hygroma and increased nuchal translucency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/31/13816?source=related_link\">",
"      Gestational trophoblastic disease: Pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/46/27370?source=related_link\">",
"      Histopathology of placental disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/52/42824?source=related_link\">",
"      Overview of antenatal hydronephrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/57/18329?source=related_link\">",
"      Pregnancy outcomes predicted by serum markers assayed in Down syndrome screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/37/42585?source=related_link\">",
"      Prenatal diagnosis of the lethal skeletal dysplasias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/29/1493?source=related_link\">",
"      Second trimester maternal serum screening for Down syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36824?source=related_link\">",
"      Ultrasound examination in obstetrics and gynecology",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_41_22171="DSM-IV-TR criteria for agoraphobia";
var content_f21_41_22171=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F60377&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F60377&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    DSM-IV-TR criteria for agoraphobia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Anxiety about being in places or situations from which escape might be difficult (or embarrassing) or in which help may not be available in the event of having an unexpected or situationally predisposed panic attack or panic-like symptoms. Agoraphobic fears typically involve characteristic clusters of situations that include being outside the home alone; being in a crowd or standing in a line; being on a bridge; and traveling in a bus, train, or automobile.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The situations are avoided (eg, travel is restricted) or else are endured with marked distress or with anxiety about having a panic attack or panic-like symptoms, or require the presence of a companion.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The anxiety or phobic avoidance is not better accounted for by another mental disorder such as social phobia (eg, avoidance limited to social situations because of fear of embarrassment), specific phobia (eg, avoidance limited to a single situation like elevators), obsessive-compulsive disorder (eg, avoidance of dirt in someone with an obsession about contamination), posttraumatic stress disorder (eg, avoidance of stimuli associated with a severe stressor), or separation anxiety disorder (eg, avoidance of leaving home or relatives).",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from: the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, (Copyright 2000). American Psychiatric Association.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_41_22171=[""].join("\n");
var outline_f21_41_22171=null;
var title_f21_41_22172="TR knockout phenotype";
var content_f21_41_22172=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F54862&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F54862&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Summary of TR knockout phenotype",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        TR",
"        <sub>",
"         &alpha;",
"        </sub>",
"        1/",
"        <sub>",
"         &alpha;",
"        </sub>",
"        2",
"       </td>",
"       <td class=\"subtitle1\">",
"        TR",
"        <sub>",
"         &alpha;",
"        </sub>",
"        1",
"       </td>",
"       <td class=\"subtitle1\">",
"        TR",
"        <sub>",
"         &beta;",
"        </sub>",
"        1/",
"        <sub>",
"         &beta;",
"        </sub>",
"        2",
"       </td>",
"       <td class=\"subtitle1\">",
"        TR",
"        <sub>",
"         &alpha;",
"        </sub>",
"        1/",
"        <sub>",
"         &alpha;",
"        </sub>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thyroid",
"       </td>",
"       <td>",
"        Hypoplastic",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Enlarged 2.5-fold",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Serum T4",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"       <td>",
"        Elevated",
"       </td>",
"       <td>",
"        Markedly elevated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        TSH (serum/mRNA)",
"       </td>",
"       <td>",
"        Reduced",
"       </td>",
"       <td>",
"        Reduced",
"       </td>",
"       <td>",
"        Nonsuppressed",
"       </td>",
"       <td>",
"        Increased x 10-fold",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Survival",
"       </td>",
"       <td>",
"        Neonatal lethal at 4-6 weeks",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Lethal at 5 weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bone",
"       </td>",
"       <td>",
"        Reduced longitudinal area, demineralized",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Abnormal growth, defective mineralization",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Brain",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other",
"       </td>",
"       <td>",
"        Arrested maturation of small intestine",
"       </td>",
"       <td>",
"        Reduced HR, prolonged QT reduced body temperature",
"       </td>",
"       <td colspan=\"1\">",
"        Functional cochlear defect",
"       </td>",
"       <td>",
"        Defective maturation of small intestine",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Brent, GA. Tissue-specific actions of thyroid hormone: Insights from animal models. Reviews in Endocrine &amp; Metabolic Disorders 2000; 1:27. Copyright &copy; 2000 Kluwer Academic Publishers.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_41_22172=[""].join("\n");
var outline_f21_41_22172=null;
var title_f21_41_22173="OSA scoring system";
var content_f21_41_22173=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F70982&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F70982&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Obstructive sleep apnea (OSA) severity scoring system: American Society of Anesthesiologists example",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Points",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        A. Severity of sleep apnea based on sleep study (or clinical indicators if sleep study not available).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"2\">",
"        <strong>",
"         Severity of OSA",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        None (apnea hypopnea index [AHI]) 0 to 5 adults; 0 children)",
"       </td>",
"       <td>",
"        0 points",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        Mild (AHI 6 to 20 adults; 1 to 5 children)",
"       </td>",
"       <td>",
"        1 points",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        Moderate (AHI 21 to 40 adults; 6 to 10 children)",
"       </td>",
"       <td>",
"        2 points",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        Severe (AHI greater than 40 adults; greater than 10 children)",
"       </td>",
"       <td>",
"        3 points",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        <strong>",
"         Point score ____ (0 to 3)",
"        </strong>",
"        *",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        B. Invasiveness of surgery and anesthesia.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"2\">",
"        <strong>",
"         Type of surgery and anesthesia",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        Superficial surgery under local or peripheral nerve block anesthesia without sedation",
"       </td>",
"       <td>",
"        0 points",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        Superficial surgery with moderate sedation or general anesthesia",
"       </td>",
"       <td>",
"        1 points",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        Peripheral surgery with spinal or epidural anesthesia (with no more than moderate sedation)",
"       </td>",
"       <td>",
"        1 points",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        Peripheral surgery with general anesthesia",
"       </td>",
"       <td>",
"        2 points",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        Airway surgery with moderate sedation",
"       </td>",
"       <td>",
"        2 points",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        Major surgery, general anesthesia",
"       </td>",
"       <td>",
"        3 points",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        Airway surgery, general anesthesia",
"       </td>",
"       <td>",
"        3 points",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        <strong>",
"         Point score ____ (0 to 3)",
"        </strong>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        C. Requirement for postoperative opioids.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"2\">",
"        <strong>",
"         Opioid requirement",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        None",
"       </td>",
"       <td>",
"        0 points",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        Low-dose oral opioids",
"       </td>",
"       <td>",
"        1 points",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        High-dose oral opioids, parenteral or neuraxial opioids",
"       </td>",
"       <td>",
"        3 points",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        <strong>",
"         Point score ____ (0 to 3)",
"        </strong>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        D. Estimation of perioperative risk. Overall score = the score for A plus the greater of the score for either B or C.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        <strong>",
"         Total point score ____ (0 to 6)",
"        </strong>",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * One point may be subtracted if a patient has been on continuous positive airway pressure or noninvasive positive pressure ventilation before surgery and will be using his or her appliance consistently during the postoperative period.",
"     <br>",
"      <font class=\"bullet\">",
"       &bull;",
"      </font>",
"      One point should be added if a patient with mild or moderate obstructive sleep apnea (OSA) also has a resting arterial carbon dioxide tension (PaCO",
"      <sub>",
"       2",
"      </sub>",
"      greater than 50 mmHg).",
"      <br>",
"       &Delta; Patients with a score of 4 may be at increased perioperative risk from OSA; patients with a score of 5 or 6 may be at significantly increased perioperative risk from OSA.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: American Society of Anesthesiologists Task Force on Perioperative Management of Patients with Obstructive Sleep Apnea. Practice guidelines for the perioperative management of patients with obstructive sleep apnea: a report by the American Society of Anesthesiologists Task Force on Perioperative Management of Patients with Obstructive Sleep Apnea. Anesthesiology 2006; 104:1081. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_41_22173=[""].join("\n");
var outline_f21_41_22173=null;
var title_f21_41_22174="Contents: Postpartum issues";
var content_f21_41_22174=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?6/40/6798\">",
"       Obstetrics, Gynecology and Women's Health",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Postpartum issues",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Postpartum issues",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Breastfeeding",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/39/42616\">",
"           Breastfeeding: Parental education and support",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/15/17658\">",
"           Common problems of breastfeeding and weaning",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/47/32505\">",
"           Infant benefits of breastfeeding",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/53/43864\">",
"           Maternal nutrition during lactation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/36/6727\">",
"           Nutritional composition of human milk for full-term infants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/1/32794\">",
"           Principles of medication use during lactation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/53/38745\">",
"           Use of psychotropic medications in breastfeeding women",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Endocrine disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/38/9833\">",
"           Causes of hypopituitarism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/47/14073\">",
"           Hypothyroidism during pregnancy: Clinical manifestations, diagnosis, and treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/62/37866\">",
"           Medical management and follow-up of gestational diabetes mellitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/51/16186\">",
"           Overview of thyroid disease in pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/15/248\">",
"           Postpartum thyroiditis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         General issues",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/5/28761\">",
"           Approaches to reduction of maternal mortality in resource-limited settings",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/59/40888\">",
"           Overview of maternal mortality",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/30/39402\">",
"           Overview of postpartum care",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/8/24713\">",
"           Postpartum and postabortion contraception",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Heart disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/62/18410\">",
"           Peripartum cardiomyopathy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hemorrhage",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/4/16455\">",
"           Management of hematomas incurred as a result of obstetrical delivery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/44/27336\">",
"           Management of postpartum hemorrhage at cesarean delivery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/60/41929\">",
"           Management of postpartum hemorrhage at vaginal delivery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/38/42600\">",
"           Overview of postpartum hemorrhage",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/43/29367\">",
"           Peripartum hysterectomy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Infection",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/16/18698\">",
"           Group B streptococcal infection in neonates and young infants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/35/31290\">",
"           Overview of control measures to prevent surgical site infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/11/39097\">",
"           Postpartum endometritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/41/6807\">",
"           Septic pelvic thrombophlebitis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Newborn issues",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/16/18698\">",
"           Group B streptococcal infection in neonates and young infants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/46/41705\">",
"           Neonatal circumcision: Risks and benefits",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/46/26346\">",
"           Neonatal resuscitation in the delivery room",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/57/15256\">",
"           Techniques for neonatal circumcision",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Psychiatric issues",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/11/20666\">",
"           Postpartum blues and depression",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/53/38745\">",
"           Use of psychotropic medications in breastfeeding women",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Renal disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/44/33479\">",
"           Acute kidney injury (acute renal failure) in pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/61/36826\">",
"           Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/31/42490\">",
"           Treatment and prognosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndromes in adults",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-4C5A267023-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f21_41_22174=[""].join("\n");
var outline_f21_41_22174=null;
var title_f21_41_22175="AGA Nasoenteric routes";
var content_f21_41_22175=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F68626&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F68626&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Possible routes for feeding",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 402px; height: 445px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PEG: percutaneous endoscopic gastrostomy; PEJ: percutaneous endoscopic jejunostomy.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: American Gastroenterological Association Medical Position Statement: guidelines for the use of enteral nutrition. Gastroenterology 1995; 108:1282.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_41_22175=[""].join("\n");
var outline_f21_41_22175=null;
